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Abstract 
 
 
Exsanguination following severe injury remains the most common preventable cause of 
traumatic death. One third of these patients exhibit trauma-induced coagulopathy (TIC) 
with an associated significant morbidity and mortality. A key feature of damage control 
resuscitation (DCR) is early diagnosis and direct targeting of TIC with blood component 
therapy combined in major haemorrhage protocols (MHPs). The impact and efficacy of 
high-dose blood component therapy on TIC is currently unknown. The overall aim of this 
thesis is to address these specific areas of uncertainty. 
 
A prospective observational cohort study of 106 severely injured, bleeding trauma patients 
was performed over a three-year period. Blood samples for coagulation testing and clotting 
factor analysis were drawn on arrival and during the acute bleeding (resuscitative) phase 
after administration of every 4 U of PRBCs, up to 12 U. The quantity of blood products 
administered within each interval was recorded. 
 
Following implementation of MHP significantly higher ratios of blood component therapy 
were observed. FFP:PRBC transfusion improved from 1:3 to 1:2 (p<0.01) and 
CRYO:PRBCs from 1:10 to 1:7 (p<0.05). There was a six-fold reduction in platelets 
wastage (14% to 2%, p<0.01). On admission, 43% of patients were coagulopathic and 
increased to 49% by PRBC 4, 62% by PRBC 8 and 68% by PRBC 12, despite adherence to 
DCR strategies.  In shock, lactate clearance did not occur until haemorrhage control was 
achieved with no further PRBC requirement.  Only the combination of high-dose FFP, 
CRYO and platelet therapy with a high total fibrinogen load produced a consistent 
improvement in ROTEM parameters.  
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The body of work within this thesis supports the need for larger studies to determine the 
clinical benefits of early fibrinogen supplementation in treating severely injured trauma 
patients suffering from life threatening haemorrhage.	  
 
 
 
 
 
  
	   5	  
Declaration 
 
I, Sirat Khan, confirm that the research included within this thesis is my own work or that 
where it has been carried out in collaboration with, or supported by others, that this is duly 
acknowledged below and my contribution indicated. Previously published material is also 
acknowledged below. 
 
I attest that I have exercised reasonable care to ensure that the work is original, and does 
not to the best of my knowledge break any UK law, infringe any third party’s copyright or 
other Intellectual Property Right, or contain any confidential material. 
 
I accept that the College has the right to use plagiarism detection software to check the 
electronic version of the thesis. 
 
I confirm that this thesis has not been previously submitted for the award of a degree by 
this or any other university. 
 
The copyright of this thesis rests with the author and no quotation from it or information 
derived from it may be published without the prior written consent of the author. 
 
Signature:  
 
Date: 17th March 2015 
 
. 
 
 
	   6	  
Publications  
 
 
Davenport R, Khan S. Management of major trauma haemorrhage: treatment priorities and 
controversies. Br J Haematol. 2011 Dec; 155(5): 537–48.  
 
Khan S, Allard S, Weaver A, Barber C, Davenport R, Brohi K. A major haemorrhage 
protocol improves the delivery of blood component therapy and reduces waste in trauma 
massive transfusion. Injury. 2013 May; 44(5): 587–92.  
 
 
Khan S, Brohi K, Chana M, Raza I, Stanworth S, Gaarder C, Davenport R; International 
Trauma Research Network (INTRN). Hemostatic resuscitation is neither hemostatic nor 
resuscitative in trauma haemorrhage. J Trauma Acute Care Surg. 2014 Mar; 76(3): 561–67. 
 
 
Khan S, Davenport R, Raza I, Glasgow S, De’Ath HD, Johansson PI, Curry N, Stanworth 
S, Gaarder C, Brohi K. Damage control resuscitation using blood component therapy in 
standard doses has a limited effect on coagulopathy during trauma haemorrhage. Intensive 
Care Med. 2015 Feb (1–9). 
  
	   7	  
Acknowledgements 
First and foremost I want to thank my supervisor Professor Karim Brohi. It has been an 
honour and a privilege to be to be his Ph.D. student. I would like to express my sincere 
gratitude for all his contributions of time and ideas, all which served to make my 
experience productive, stimulating and, above all, fun. One simply cannot wish for a better 
or friendlier supervisor.  
I am grateful to Dr. Dan Hart for agreeing to be my second supervisor, and to Simon 
Eaglestone for all his helpful advice and support over the years.  
I am forever indebted to my friends and colleagues in the TCAU who provided the perfect 
work environment. They have all supported me immensely during my studies on a personal 
and a professional level: Anita, Ross, Elaine, Henry, Zane, Imran, Simon, Claire, Karen and 
Veena. 
Royal London Hospital for their tireless assistance day and night. Without their dedication, 
this research would simply not have been possible. 
I owe my deepest gratitude to all the patients and their families that have consented to be a 
part of the studies presented here in this thesis.  They have selflessly bestowed upon me a 
great privilege, despite the physical and mental trauma they have suffered. The magnitude 
of these gestures is not lost on me 
Lastly, I am forever indebted to my family - especially my parents - for all their love and 
encouragement.  They have raised me with a passion for knowledge and supported me in 
every single one of my pursuits in life. Words cannot accurately capture the immense 
appreciation and admiration I have for all that they have done for me throughout this 
process.  This thesis is as much a product of their support and sacrifice, as it is of my 
efforts.  This thesis is dedicated to them. 
	   8	  
Table of Contents 
 
Declaration ................................................................................................................ 5 
Publications ............................................................................................................... 6 
Acknowledgements ................................................................................................... 7 
Table of Contents ..................................................................................................... 8 
List of Figures ......................................................................................................... 11 
List of Tables .......................................................................................................... 13 
List of Abbreviations .............................................................................................. 14 
CHAPTER ONE ..................................................................................................... 17 
1.1 The significance of trauma ...................................................................................... 18 
1.2 Classification and characteristics of trauma ......................................................... 20 
1.3 Mechanism of injury ............................................................................................... 21 
1.4 Mortality following trauma .................................................................................... 22 
1.5 Trauma and research .............................................................................................. 25 
1.6 The cost of major trauma ....................................................................................... 26 
1.7 Trauma and haemorrhage ...................................................................................... 27 
1.8 Trauma-induced coagulopathy .............................................................................. 28 
1.9 Acute traumatic coagulopathy ............................................................................... 30 
1.10 Coagulation tests for the diagnosis of ATC ......................................................... 33 
1.11 ROTEM .................................................................................................................. 36 
1.12 Advantages of ROTEM ......................................................................................... 41 
1.13 Limitations of ROTEM ......................................................................................... 41 
1.14 Alternatives to ROTEM ........................................................................................ 43 
1.15 Historic haemorrhage control strategies in trauma ........................................... 44 
1.16 Fluid therapy .......................................................................................................... 45 
1.17 Permissive hypotension ......................................................................................... 46 
1.18 Damage control resuscitation ............................................................................... 47 
1.19 Massive transfusion ............................................................................................... 49 
1.20 Transfusion strategies for trauma haemorrhage ................................................ 50 
1.21 Full whole blood ..................................................................................................... 51 
1.22 Fresh frozen plasma .............................................................................................. 52 
1.23 Platelets ................................................................................................................... 55 
1.24 Fibrinogen .............................................................................................................. 57 
1.25 Transfusion practice in trauma ............................................................................ 58 
1.26 Summary ................................................................................................................ 62 
1.27 Hypotheses and aims ............................................................................................. 62 
CHAPTER TWO ................................................................................................... 64 
2.1 Study design ............................................................................................................. 65 
2.2 Study participants .................................................................................................... 65 
2.2.1 Inclusion criteria ................................................................................................. 66 
2.2.2 Exclusion criteria ................................................................................................ 67 
2.2.3 Code Red ............................................................................................................ 68 
2.3 Consent process ........................................................................................................ 68 
2.4 Blood collection ........................................................................................................ 70 
2.4.1 Samplings materials ........................................................................................... 74 
2.4.2 Coagulation biomarkers ..................................................................................... 75 
	   9	  
2.5 Blood sample analysis .............................................................................................. 76 
2.5.1 ROTEM analysis ................................................................................................ 76 
2.5.2 Definition of coagulopathy ................................................................................. 78 
2.5.3 Sysmex – an automated coagulation analyser .................................................... 78 
2.5.4 Procedure for vW:Ag assay ................................................................................ 79 
2.5.5 Procedure for coagulation factors ...................................................................... 81 
2.6 Data collection .......................................................................................................... 82 
2.7 Statistical analysis .................................................................................................... 83 
CHAPTER THREE ............................................................................................... 84 
3.1 Introduction ............................................................................................................. 85 
3.2 Aims .......................................................................................................................... 86 
3.3 Methods .................................................................................................................... 87 
3.3.1 Study design ....................................................................................................... 87 
3.3.2 Participants ......................................................................................................... 90 
3.3.3 Data collection .................................................................................................... 90 
3.3.4 Data analysis ...................................................................................................... 91 
3.4 Results ....................................................................................................................... 91 
3.5 Discussion ................................................................................................................. 99 
3.6 Limitations ............................................................................................................. 102 
3.7 Conclusion .............................................................................................................. 102 
CHAPTER FOUR ................................................................................................ 104 
4.1 Introduction ........................................................................................................... 105 
4.2 Aims ........................................................................................................................ 105 
4.3 Methods .................................................................................................................. 106 
4.3.1 Study design ..................................................................................................... 106 
4.3.2 Patient selection ................................................................................................ 107 
4.3.3 MHPs ................................................................................................................ 108 
4.3.4 Sampling technique .......................................................................................... 109 
4.3.5 Sample analysis ................................................................................................ 109 
4.3.6 Fibrinogen level analysis .................................................................................. 110 
4.3.7 Definitions ........................................................................................................ 110 
4.3.8 Data collection .................................................................................................. 111 
4.3.9 Statistical analysis ............................................................................................ 111 
4.4 Results ..................................................................................................................... 111 
4.5 Discussion ............................................................................................................... 127 
4.6 Limitations ............................................................................................................. 129 
4.7 Conclusions ............................................................................................................. 129 
CHAPTER FIVE .................................................................................................. 131 
5.1 Introduction ........................................................................................................... 132 
5.2 Aims ........................................................................................................................ 133 
5.3 Methods .................................................................................................................. 133 
5.3.1 Study design ..................................................................................................... 134 
5.3.2 Patient selection ................................................................................................ 134 
5.3.3 Sampling technique .......................................................................................... 134 
5.3.4 Definitions ........................................................................................................ 134 
5.3.5 Data collection and analysis ............................................................................. 134 
5.4 Results ..................................................................................................................... 135 
5.5 Discussion ............................................................................................................... 147 
5.6 Limitations ............................................................................................................. 148 
5.7 Conclusion .............................................................................................................. 149 
CHAPTER SIX ..................................................................................................... 150 
6.1 Introduction ........................................................................................................... 151 
6.2 Aims ........................................................................................................................ 152 
	   10	  
6.3 Methods .................................................................................................................. 153 
6.3.1 Study design ..................................................................................................... 153 
6.3.2 Patient selection ................................................................................................ 153 
6.3.3 Sampling technique .......................................................................................... 154 
6.3.4 Sample analysis ................................................................................................ 154 
6.3.5 Automated one-stage factor assays .................................................................. 155 
6.3.6 ROTEM analysis .............................................................................................. 155 
6.3.7 Data collection .................................................................................................. 156 
6.3.8 Outcome measures ........................................................................................... 156 
6.3.9 Statistical analysis ............................................................................................ 157 
6.4 Results ..................................................................................................................... 157 
6.5 Discussion ............................................................................................................... 173 
6.6 Limitations ............................................................................................................. 176 
6.7 Conclusions ............................................................................................................. 176 
CHAPTER SEVEN .............................................................................................. 177 
7.1 Summary of the findings ....................................................................................... 178 
7.2 Strengths and limitations of this thesis ................................................................ 184 
7.3 Clinical importance and future work .................................................................. 189 
References ............................................................................................................. 192 
APPENDICES ...................................................................................................... 210 
Appendix 1. ACIT II patient information sheet ....................................................... 211 
Appendix 2. Personal Consultee (PC) information sheet ......................................... 216 
Appendix 3. Subject consent form ............................................................................. 222 
Appendix 4. Consultee declaration form ................................................................... 223 
Appendix 5. Consent to donation and storage of blood samples ............................. 225 
 
	   11	  
List of Figures 
 
 
Figure 1.1. Civilian trauma patients by age and gender. .................................................. 19 
Figure 1.2. Abbreviated injury scale scoring system. ....................................................... 20 
Figure 1.3. A summary of trauma in England and Wales from 2002 to 2011. ................. 22 
Figure 1.4. Cumulative number of non-survivors for the first 48 h after  
hospital admission. ............................................................................................................. 24 
Figure 1.5. The current patient pathway for major trauma in the UK. ............................. 24 
Figure 1.6. The multifactorial drivers of trauma-induced coagulopathy, showing some of 
the mechanisms that give rise to TIC. ................................................................................ 30 
Figure 1.7. Incidence of coagulopathy. ............................................................................. 31 
Figure 1.8. Prevalence of coagulopathy by injury severity and base deficit in patients 
requiring a blood transfusion. ........................................................................................... 33 
Figure 1.9. Relative time to PTr result. ............................................................................. 34 
Figure 1.10. Relationships between ATC and clinical outcomes. ..................................... 36 
Figure 1.11. ROTEM (delta). ............................................................................................ 37 
Figure 1.12. ROTEM Trace. .............................................................................................. 38 
Figure 1.13. A computer-simulated signature ROTEM ATC Trace and  
Non-ATC Trace. ................................................................................................................. 40 
Figure 2.1. The ACIT II ED sample SOP. Located within the ED. ................................... 71 
Figure 2.2. Summary of patient experience through the ACIT II study process. .............. 72 
Figure 2.3. TCAU blood sample processing facilities at the Trauma Sciences Group 
laboratory. .......................................................................................................................... 74 
Figure 2.4. ACIT II sample processing SOP chart. ........................................................... 76 
Figure 2.5. ROTEM detection. .......................................................................................... 77 
Figure 3.1. The Royal London Hospital’s massive transfusion protocol. ......................... 88 
Figure 3.2. The Royal London Hospital’s major haemorrhage protocol ......................... 89 
	   12	  
Figure 3.3. The effect of a major haemorrhage protocol on blood component delivery. . 94 
Figure 3.4. Effect of a major haemorrhage protocol on FFP delivery. ............................ 95 
Figure 3.5. Effect of a major haemorrhage protocol on blood component waste. ........... 96 
Figure 3.6. Effect of a major haemorrhage protocol on blood component waste  
per person. ......................................................................................................................... 97 
Figure 4.1A–F. The evolution of trauma-induced coagulopathy during  
haemorrhage. ........................................................................................................... 115–117 
Figure 4.2A–D. Change in CA5 (mm) during bleeding episode in coagulopathic  
patients (CA5 < 35 mm) stratified by transfusion requirements. ............................ 119–120 
Figure 4.3A–D. Change in MCF (mm) during bleeding episode in coagulopathic  
patients (MCF < 54 mm) stratified by transfusion requirements ............................ 121–122 
Figure 4.4A–D. Change in CT (secs) during bleeding episode in coagulopathic  
patients (CT > 94 secs) stratified by transfusion requirements. .............................. 123–124 
Figure 4.5A–C. Lactate clearance during haemorrhage. ....................................... 125–126 
Figure 5.1A–D. Effect of blood component therapy on coagulopathy when 
 administered during damage control resuscitation.. .............................................. 138–139 
Figure 5.2A–F. The effect of increasing doses of FFP on trauma-induced  
coagulopathy. ........................................................................................................... 141–143 
Figure 5.3A–F. The effect of increasing interval fibrinogen doses on trauma-induced 
coagulopathy. ........................................................................................................... 144–146  
Figure 6.1A–J. The effect of damage control resuscitation on coagulation factor 
concentration in actively bleeding trauma patients. ................................................ 160–164 
Figure 6.2. Coagulation factor concentration in those patients who had their  
trauma-induced coagulopathy corrected compared to those patients who worsened during 
the bleeding phase. ........................................................................................................... 165 
Figure 6.3A–J. The effect of a FFP transfusion on coagulation factor concentration  
in bleeding patients. ................................................................................................. 168–172 
Figure 7.1. The RLH’s revised major haemorrhage protocol ......................................... 190 
	   13	  
List of Tables 
 
Table 1.1. Injury severity score group and mortality ........................................................ 21 
Table 1.2. Standard nomenclature ROTEM parameters. .................................................. 39  
Table 2.1. Blood sample collection tubes. ......................................................................... 73 
Table 2.2. ROTEM repeatability and reproducibility ....................................................... 78 
Table 2.3. Method of coagulation assays and coagulation laboratory reference  
ranges. ................................................................................................................................ 79 
Table 3.1. Clinical characteristics of all trauma patients. ................................................ 92 
Table 3.2. Sensitivity and specificity of major haemorrhage protocols. ........................... 93 
Table 3.3 TTL’s ability to correctly initiate major haemorrhage protocol ....................... 93 
Table 3.4. Demographics, injury characteristics and 24-h transfusion requirements in 
patients receiving >10 PRBCs ........................................................................................... 98 
Table 4.1. Patient demographics and clinical characteristics. ....................................... 113 
Table 5.1. Clinical characteristics of patients. ............................................................... 136 
Table 5.2. Blood components administered during damage control resuscitation. ........ 137 
Table 6.1. Patient demographics and clinical characteristics. ....................................... 158 
Table 6.2. Effect of blood component therapy on coagulation factor concentration  
when administered during damage control resuscitation (mean). .................................. 167 
 
	   14	  
List of Abbreviations 
 
 
ACIT II activation of coagulation and inflammation in trauma II 
AIS  abbreviated injury scale 
ANOVA analysis of variance 
aPTT  activated partial thromboplastin time 
ARDS  acute respiratory distress syndrome 
ATC  acute traumatic coagulopathy 
ATLS  advanced trauma and life support 
BP  blood pressure 
BD  base deficit 
Ca2+  ionised calcium 
cc/kg  cubic centimetres per kilogram   
CI  confidence interval 
cm  centimetre 
CO2  carbon dioxide 
CRYO  cryoprecipitate 
DALY  disability adjusted life years 
DIC  disseminated intravascular coagulopathy 
DCR  damage control resuscitation  
DCS  damage control surgery 
ED  emergency department 
ELISA  enzyme-linked immunosorbent assay 
FBC  full blood count 
FFP  fresh frozen plasma 
FWB  full whole blood 
g  gram 
g/dl  gram per decilitre 
g/l  gram per litre 
GCS  Glasgow coma score 
GPIb  glycoprotein 1b 
h  hours 
hr   heart rate 
HR  haemostatic resuscitation 
ICU  intensive care unit 
INR  international normalised ratio 
	   15	  
IQR  interquartile range 
ISI  international sensitivity index 
ISS  injury severity score 
i.v.  intravenous 
kg  kilogram 
kPa  kilo Pascal 
l  litres 
M  molar 
MABP  mean arterial blood pressure 
mEq/l  molar equivalent per litre 
mg  milligram 
MHP  major haemorrhage protocol  
min  minute 
ml  millilitre 
mm  millimetre 
mmHg  millimetres mercury 
MOF  multiple organ failure 
mol/l  mole per litre 
mmol/l  millimole per litre 
MT  massive transfusion 
MTP  massive transfusion protocol 
NaCl  sodium chloride 
n  number 
NAO  national audit office 
NCEPOD national confidential enquiry into patient outcome and death 
NIH  national institute of health 
O2  oxygen 
OD  oxygen debt 
OR  odds ratio 
PL  phospholipid 
PLT  platelet 
PRBCs  packed red blood cells 
PT  prothrombin time 
PeLAR  personal, legally appointed representative  
PrLAR  professional, legally appointed representative  
PTSD  post-traumatic stress disorder 
PTr  prothrombin time ratio  
	   16	  
RLH  Royal London Hospital 
rpm  revolutions per minute 
rr  respiratory rate 
RR  relative risk 
RTC  road traffic collision 
s  second 
SBP  systolic blood pressure 
TARN  the trauma audit and research network 
TCAU  trauma clinical academic unit 
TF  tissue factor 
TIC  trauma-induced coagulopathy 
TNFα   tumour necrosis factor alpha 
tPA  tissue type plasminogen activator 
TRALI  transfusion-related acute lung injury 
TTL  trauma team leader 
TXA2  thromboxane A2 
U&E  urea and electrolytes  
vWF  Von Willebrand factor 
°C  degrees Celsius 
µ   micro 
χ2  Chi-squared test 
 
 
 
  
	   17	  
 
 
 
 
 
 
CHAPTER ONE 
 
Introduction  
	   18	  
1.1 The significance of trauma 
 
 
The body of work presented in this thesis reports the management of severe, and often life-
threatening, haemorrhage in trauma. 
 
The definition of trauma encompasses any injury resulting from penetrating or blunt 
physical force such as stabbings, falls or road traffic accidents (RTCs). It is undoubtedly 
one of the major healthcare issues faced by modern society, resulting in the annual death of 
more than five million people worldwide; this number is expected to increase to more than 
eight million by 2020 (1). In 2013 in the US, injuries accounted for 59% of all deaths 
among persons from one to 44 years of age, which is more deaths than non-communicable 
diseases and infectious diseases combined (2). 
 
In the UK, traumatic injury accounts for over 17,000 deaths annually (3). Approximately 
half of the patients who die from severe injuries do so prior to reaching hospital, either 
before the arrival of pre-hospital medical services, or due to rapid deterioration despite 
initial resuscitative attempts to stabilise them. 
 
Trauma is a disease and it is a condition that predominantly affects young adults. It kills 
more people between the ages of 15 and 44 than any other disease (Figure 1.1), with an 
average of 36 life years lost per trauma death (4). Not only does traumatic injury carry a 
high mortality rate, but it also is estimated that for every death due to injury, there are two 
patients left with permanent serious disabilities (5). In 2004, a report from the World 
Health Organisation stated that the average global burden of disease was 237 DALYs per 
1,000 population (6). RTCs alone were the ninth leading cause, accounting for 2.7% of the 
total. Comparatively, the principal source of disease burden was lower respiratory tract 
infections, which constituted only a slightly higher 6.2% of all DALYs (6). In addition to 
	   19	  
the personal and emotional effects, trauma inflicts a massive financial burden in terms of 
direct healthcare costs, as well as loss of productivity to society. 
 
 
  
 
Figure 1.1. Civilian trauma patients by age and gender. A 2007 UK study of 795 major 
trauma patients carried out by the NCEPOD found that 75% of major trauma patients were 
male, with a high concentration of those between the ages of 16 to 20 (5). 
 
 
The severity of the health impact associated with trauma is multifactorial. Following the 
initial injury, the trauma patient may not only be affected with severe physical impairments 
but may also suffer from equally disabling psychological disorders such as PTSD (7). 
Injured individuals may experience dramatic changes in their social circumstances, with an 
inability to return to work, thereby incurring financial hardship not only for them but also 
for their dependents. Others may have problems integrating back into society, either from a 
physical or a cognitive impairment. These damaging aftermaths of injury are not solely 
limited to the trauma patient but are far reaching. Family and friends may become 
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permanent caregivers for those with physical and cognitive disabilities and may have to 
dramatically alter their own lifestyles. 
 
1.2 Classification and characteristics of trauma 
 
Trauma is classified using an injury severity score (ISS) (8). The ISS is an anatomical 
scoring system that retrospectively assigns a measure of severity ranging from zero to 75, 
with a score of 16 or greater signifying major trauma. To calculate ISS, each injury is 
initially assigned an abbreviated injury score (AIS). The AIS is an anatomical scoring 
system first introduced in 1976 (9). It has subsequently undergone numerous revisions and 
has been updated against survival so that it now provides accurate ranking of the severity of 
injury. Injuries are ranked on a scale of 1 to 6, with 1 being minor, 5 severe, and 6 
representing a non-survivable injury (Figure 1.2). However, AIS represents the ‘threat to 
life’ associated with an injury and is not meant to represent a comprehensive measure of 
severity.  
 
Injury AIS Score 
1 Minor 
2 Moderate 
3 Serious 
4 Severe 
5 Critical 
6 Non-survivable 
 
Figure 1.2. AIS scoring system. (Adapted from Copes WS, Sacco WJ, Champion HR, Bain 
LW, “Progress in Characterising Anatomic Injury”. In Proceedings of the 33rd Annual 
Meeting of the Association for the Advancement of Automotive Medicine, Baltimore, MA, 
US, 205–218.) 
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To calculate ISS, the AIS from the three most severely injured body regions are squared 
and added together. Mortality increases with ISS (Table 1.1), and a score of 75 signifies 
injuries that are unlikely to be survived (5).  
 
ISS Percentage of major 
trauma patients 
Percentage mortality of this 
injury severity score group 
16–25 62.6 10.5 
26–40 28.9 22.1 
41–74 7.7 44.3 
75 0.8 76.6 
 
Table 1.1. ISS group and mortality. (Data courtesy of TARN (5).) 
 
The trauma population itself can be further broadly divided into either military or civilian 
cohorts that exhibit both comparable and contrasting characteristics. In the military setting, 
casualties are almost exclusively young males in their 20s. Data that has been collected 
from Operation Iraqi Freedom (10) reported that over 80% of those that were killed or 
injured were a direct result of penetrating missile explosions. The origin of such a missile 
(e.g. explosion, gunshot) depends largely upon the nature of the battle, enemy tactics and 
the geographical location of the combat theatre. When examining civilian trauma, while 
there is also a higher prevalence of male subjects, the gender ratio is rather more balanced 
and the average age of victims tend to be higher than that of the military population.  
 
1.3 Mechanism of injury 
 
Among the UK civilian population, a blunt mechanism of injury predominates, with fall 
from a height and RTCs representing the most common causes (11, 12). Naturally, specific 
characteristics vary between each country. In the UK itself, 98% of trauma is caused by 
blunt force and the most common mechanisms of injury are falls and RTCs. Major blunt 
	   22	  
trauma can also be caused by assault, burns, blasts, crushes and self-inflicted injuries, such 
as hanging. Penetrating injuries such as knife or gunshot wounds and impalements account 
for only 2% of major trauma, but this figure is predicted to increase (13) (Figure 1.3).  
 
 
Figure 1.3. A summary of trauma in England and Wales from 2002 to 2011. The 
category ‘Blow’ includes blunt assaults, while ‘Others’ relate to injuries sustained 
following industrial and farming accidents, for example. (Data courtesy of the Trauma 
Audit and Research Network.) 
 
 
1.4 Mortality following trauma 
 
Regardless of the mechanism of injury, the temporal distribution and modes of mortality in 
both cohorts bear similarities. Historically, there has been a trimodal description of trauma 
deaths (14). The first peak is immediate deaths that occur within one hour of the injury. 
About 50–70% of all trauma deaths are said to belong to this group; however, the data vary 
based on various factors, such as type of injury, region, or type of emergency medical 
 22 
1.2 Characteristics of Trauma  
In civilian trauma, young males are most often affected and a blunt 
mechanism of injury predominates.  In the UK, falls are the commonest 
cause of trauma (Figure 1.1).  Naturally, specific characteristics vary 
between each country.  
  
Figure 1.1.  A summary of trauma in England nd Wales from 2002 to 
2011 
Blow includes blunt assaults, Others relate to injuries sustained following 
industrial and farming accidents, for example.  (Data courtesy of the Trauma 
Audit & Research Network). 
1.2.1 Measuring Injury Severity 
The extent of overall injury is classified by the injury severity score (ISS), 
an anatomical scoring system.  The body is divided into six regions (head 
and neck, face, chest, abdomen, extremity and external) and each area is 
ascribed an abbreviated injury score, the AIS, from 0 to 6 (Table 1.1).   
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system. It is reported that up to 60% of trauma deaths occur immediately after injury or 
before hospital arrival (11, 15, 16). The majority of these patients die due to exsanguination 
(massive blood loss), from major vessel disruption or a catastrophic head injury and, for the 
most part, are unresponsive to any current medical intervention.  
 
The second distribution is within one to four hours after the injury and the third distribution 
around one to two weeks later. Datasets from two large European trauma registries showed 
that about 50% of all in-hospital trauma deaths occur within the first 24 h after admission 
((17, 18) Figure 1.4) and, within those initial 24 h, in excess of 70% deaths occur in the 
first six h after admission. These represent the greatest potential for salvage but are also the 
most difficult group of trauma patients to investigate (19, 20).  
 
The mode of death of these patients is divided equally between central nervous system 
injury and severe haemorrhage. Lefering et al., concluded that injury severity and massive 
haemorrhage were the most prevalent among very early hospital deaths (up to six h after 
admission to the ED), while the highest rates of severe head injury were found in patients 
who died in the first week (17, 18). Late deaths are frequently associated with 
complications such as organ failure or sepsis and increasing age (17, 18). With timely 
diagnosis and intervention, haemorrhage is reversible and is the leading cause of 
preventable death after trauma. Studies from the military and civilian community suggest 
that up to one third of haemorrhage-related deaths could be avoided by expedient control of 
bleeding (21-23). 
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Figure 1.4. Cumulative number of non-survivors for the first 48 h after hospital 
admission. Only patients from the Trauma Audit and Research Network (TARN) database 
with available time of admission and time of death are considered (n = 3,584) (Modified 
from Lefering et al., 2012 (18)) 
 
The overview for the current pathway for major trauma in the UK is detailed below in 
Figure 1.5. 
 
Figure 1.5. The current patient pathway for major trauma in the UK. (Ordered by the 
House of Commons, Report by the Controller and Auditor General, 2010 (24).) 
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1.5 Trauma and research 
 
Traumatic injuries are a public health problem of vast proportions. In the past, the National 
Academy of Sciences characterised accidental death and disability as the “neglected disease 
of modern society” (25). Yet, in spite of the global impact of trauma, it remains a field 
characterised by the lack of evidence-based practice. This lack of knowledge is due to a 
relative paucity of research. The RAND report in the UK (24) and the National Trauma 
Institute in the US (26) have both recently highlighted that trauma remains a poorly 
recognised public health problem with disproportionately low investments in research. 
Despite repeated reports identifying poor trauma practice, the Department of Health and the 
NHS have taken little action to improve major trauma care (13). Furthermore, deficiencies 
in major trauma care were identified by the Royal College of Surgeons as early as 1988, but 
there has been little progress since. In 2007, a report by the NCEPOD concluded that 60% 
of major trauma patients received a standard of care that was ‘less than good practice’ (27). 
A number of reports, including one by the National Audit Office (NAO) in 1992, have 
made recommendations about the information and actions required to improve the delivery 
of major trauma care, but there remains significant data gaps and a lack of formalised 
systems. 
 
In December 2010, the UK Department of Health (DH) requested RAND Europe to provide 
a strategic, rapid review of the funding landscape for complex trauma research in the UK. 
In this review, they were asked to focus on those areas of research that target the early 
phase of injury and can improve the effectiveness of therapies and interventions at the pre-
hospital and early in-hospital phase. The RAND report concluded that “complex trauma is 
an orphan and niche area of research that is disproportionately resourced in comparison to 
the burden of the disease” (24). However, less than 1% of the total UK public expenditure 
on health research is allotted to trauma research. In the US, in terms of potential life years 
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lost (defined by the millions of dollars per years of potential life lost per 100,000 
population), the National Trauma Institute (NTI) support ratio for trauma is only 10 cents, 
as compared to the US $3.51 for HIV and US $1.65 for cancer (26) .  
 
There are other specific challenges associated within trauma research besides poor funding. 
Trauma remains a challenging field for clinical research given the difficulty of enrolling 
patients who may present in physiological extremis, and outside traditional working hours. 
This is further compounded by the problems associated in obtaining consent in patients 
who may be unconscious on arrival to the hospital, distressed or lacking capacity. 
Consequently, not only is the overall volume of research in trauma limited, but the specific 
clinical fields investigated within the specialty are narrow. 
 
1.6 The cost of major trauma 
 
The cost of treating major trauma within the UK is not known with any real clarity. It is 
estimated, however, that major trauma costs the NHS a minimum of somewhere in the 
region of £0.3 billion and £0.4 billion a year. This estimate is calculated on the basis of the 
average costs of treating blunt and penetrating trauma, collected through academic research 
(28), and the estimate of the number of cases of major trauma. It includes the cost of 
ambulance transportation, the immediate hospital stay, and the cost of all procedures 
performed during the entire hospital admission. The costs of long-term hospital treatments, 
rehabilitation, home-care support, or informal carer costs after discharge remain unknown, 
but research suggests that, for major trauma, the majority of the costs are incurred 
following the initial period of hospitalisation. Furthermore, the NAO estimates that the 
annual lost economic output as a result of major trauma is between £3.3 billion and £3.7 
billion (13). 
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1.7 Trauma and haemorrhage 
 
Uncontrolled haemorrhage or exsanguination is responsible for over 40% of early in-
hospital trauma mortality (19) and is a leading cause of preventable death (29, 30). 
Furthermore, massive haemorrhage in most trauma patients is multifactorial and presents as 
a combination of both diffuse bleeding as a result of coagulopathy and bleeding from the 
vasculature that needs to be addressed surgically. Even though surgical bleeding can, in 
most instances, be controlled by the intervention of a trauma surgeon, control of 
coagulopathic bleeding is often difficult, and sometimes impossible (31). Moreover, it is 
estimated that 25–33% of severely injured, bleeding patients arrive at hospital with 
significant derangements in blood coagulation (32). It is this specific subset of patients that 
represent potentially reversible deaths if identified and treated early and aggressively (33). 
 
This derangement in coagulation function is known as the Acute Traumatic Coagulopathy 
(ATC) and patients presenting with this phenomenon have a mortality rate approaching 
50%. They have significantly greater transfusion requirements, organ injury, septic 
complications and critical care stay (34) (35) (36). Furthermore, transfusion of allogeneic 
blood replacement products during resuscitation inflicts a dose-dependent increase in the 
extent of these outcomes independent of shock severity (37). It is for this paramount reason 
that minimising blood loss is an absolute clinical priority after traumatic injury. Specific 
management strategies targeting ATC may allow significant improvement in outcomes (38) 
(39, 40) (41). These “damage control” resuscitation (DCR) (39) approaches require early 
identification of ATC to allow rapid activation of major haemorrhage protocols (MHPs).  
 
However, prediction of ATC from admission clinical parameters is unreliable, and 
traditional laboratory-based clotting tests have logistical issues that limit their utility in the 
acute trauma setting (42-44). In the absence of a diagnostic tool, current ATC management 
relies on empiric transfusion strategies activated on the basis of clinical surrogates of 
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haemorrhage or a physician’s “best guess” approach (45) (46) (23, 39). This results in 
delayed correction of ATC and is associated with suboptimal blood product usage (47) 
(48). Inadequate or sub-therapeutic transfusion has been proven to be associated with poor 
outcomes (46), but over-transfusion of blood components may result in dangerous 
additional donor exposures, such as Hepatitis and HIV, and furthermore is wasteful of a 
precious resource. In addition, PRBCs and other blood products are independently 
associated with reduced survival, excess morbidity, sepsis, and organ failure (49-51). 
Moreover, targeted transfusion therapy for severe traumatic haemorrhage based on 
comprehensive and rapid measures of coagulation may lead to improved outcomes while 
optimising blood utilisation, but there remains a lack of high-level evidence to support this 
(52-56). 
 
1.8 Trauma-induced coagulopathy  
 
Coagulopathy is a disease or condition affecting the blood’s ability to form a clot (57). 
Major injury and uncontrolled blood loss is often associated with trauma-induced 
coagulopathy (TIC) (Figure 1.6). Therefore, the most acute threat to an exsanguinating 
trauma patient is a bleeding diathesis. Impairments of normal haemostatic function after 
trauma results in difficult haemorrhage control, increased transfusion requirements and 
increased mortality (58).  
 
Different factors influence the severity of TIC. On the one hand, the coagulopathy can be 
influenced by environmental and therapeutic factors that may contribute, in part, to 
acidaemia, hypothermia, dilution, hypoperfusion and coagulation factor consumption (59). 
On the other hand, TIC can also be affected by individual patient-related factors, including 
genetic background, co-morbidities, inflammation and medications, especially 
anticoagulants, and pre-hospital fluid administration (59). 
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TIC has been recognised for decades and historically described in the literature as a 
sequelae of the “lethal triad” of coagulopathy, hypothermia and acidosis and associated 
dysfunction or consumption of coagulation proteases (60). Historically, loss of coagulation 
factors is explained by haemorrhage (loss) or consumption, dilution from crystalloid or 
colloid administration and massive whole blood transfusion. Abnormality in the function of 
proteases was thought to be a cause of hypothermia and the effect of acidosis on enzyme 
function. However, in severely injured trauma patients, such variables frequently occur in 
tandem; hence, determining the independent detrimental effect of each is often difficult.  
 
Clinically, TIC has many drivers and involves all aspects of haemostasis. The principle 
driver of TIC was previously considered to be haemodilution, but this is now thought to be 
an unlikely cause for the early coagulopathy seen following trauma, especially in the 
context of permissive hypotension and restrictive volume resuscitation. Furthermore, there 
is only weak evidence to suggest that direct tissue trauma in isolation consumes clotting 
factors akin to DIC, and there appears to be a decrease in fibrinogen utilisation during early 
coagulopathy (61). Coagulation is initiated by tissue damage (direct trauma) following 
exposure of procoagulant substances in the endothelium but coagulopathy is rare in 
severely injured patients without concomitant profound tissue hypoperfusion (shock) (61). 
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Figure 1.6. The multifactorial drivers of TIC, showing some of the mechanisms that 
give rise to TIC. (Adapted from Davenport, Khan 2011 (62).) 
 
1.9 Acute traumatic coagulopathy  
 
The landmark report of the existence of ATC was from a retrospective study of the 
admission coagulation results of 1,088 trauma patients transferred to the Royal London 
Hospital (RLH) by air ambulance (63). More recent studies have shown that shock and 
tissue trauma appear to act as primary drivers of coagulopathy in the immediate phase 
following injury (32) (64, 65) (66). ATC has been identified in up to 25% of trauma 
patients on admission to the hospital ED (35) (34, 67) (68). Trauma patients that were 
diagnosed with ATC on admission were observed to have a four-fold increase in mortality, 
greater transfusion requirements, required longer time within the intensive care unit (ICU), 
and face a significantly higher incidence of sepsis, organ injury and MOF (68).  
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These initial studies showed that ATC is closely correlated with the severity of tissue 
trauma (34, 36) and tissue hypoperfusion (67). Brohi et al. showed that, as the level of 
tissue trauma increased (rising ISS), the incidence of coagulopathy increased, such that 
nearly two thirds of patients with an ISS greater than 45 arrive with significant 
derangement of their haemostatic mechanisms. These authors also reported that trauma 
patients with coagulopathy were more likely to die than those without for any given ISS. 
Furthermore, trauma patients with coagulation abnormalities are known to develop organ 
dysfunction and spend longer in the critical care unit (69). Thus, injury severity is closely 
associated with the degree of acute coagulopathy seen after trauma. This London study 
reported only 10.8% of patients with an ISS of 15 or below had a coagulopathy, compared 
with 33.1% of those with an ISS over 15 (63) (Figure 1.7). This figure increased to 61.7% 
for those with an ISS over 45. However, tissue injury on its own is not sufficient to cause 
ATC. Shock with tissue hypoperfusion is a strong independent risk factor for poor 
outcomes in trauma (70, 71) and has been implicated in the pathogenesis of ATC (72). 
 
 
Figure 1.7. Incidence of coagulopathy. (Adapted from (63).) 
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In these studies, resuscitation with crystalloid fluid was minimal and no patients were 
sufficiently hypothermic (<33 ̊C) to impair coagulation protease activity, thrombin 
generation or reduce platelet function (73) (74). Hence, an alternative mechanism 
responsible for early coagulopathy was suggested. ATC is characterised by systemic 
anticoagulation and hyperfibrinolysis through endothelial activation of Protein C (62, 67, 
75). Uncontrolled exsanguination with associated physiological disturbances (e.g. 
hypothermia and acidosis complicated by the dilutional effects of intravenous fluid 
resuscitation) exacerbate ATC and give rise to TIC (Figure 1.6). Previous work from our 
group on the study of acute coagulopathy found that no patient with a normal BD had 
prolonged PT or aPTT, regardless of injury severity or the amount of thrombin generated 
(76). In contrast, there was a dose-dependent prolongation of clotting times with increasing 
systemic hypoperfusion. Only 2% of patients with a BD under six mmol/l had prolonged 
clotting times, compared with 20% of patients with a BD over six mmol/l. Another study of 
391 combat casualties in the Iraq War found that, for a given injury severity, patients who 
were shocked had a higher prevalence of ATC (77) (Figure 1.8). Nonetheless, the precise 
effects of acidaemia on coagulation remain unknown as it is clinically difficult to ascertain 
the precise inhibitory effects of pH vs tissue hypoperfusion and shock. 
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Figure 1.8. Prevalence of coagulopathy by ISS and BD in patients requiring a blood 
transfusion. (Adapted from *p<0.05 (78).) 
 
1.10 Coagulation tests for the diagnosis of ATC 
 
A knowledge gap exists with regard to the most appropriate tests for coagulation in trauma 
as there are no widely used validated and rapidly available investigations that can reliably 
guide transfusion therapy in an actively bleeding trauma patient (42, 79). Quantitatively 
measuring excess blood loss attributable to clinical coagulopathy is fraught with difficulty. 
Historic coagulation screening tests such as PT, aPTT, platelet count and fibrinogen levels 
are of limited value in acute exsanguination.  
 
The PT and aPTT are screening tests that measure the ‘extrinsic’ and ‘intrinsic’ pathways 
of coagulation respectively. They report the time taken for initial fibrin polymerisation of 
platelet poor plasma, at 37°C, in response to exogenous stimulation of coagulation. As 
such, they neglect the pivotal role of platelets, do not measure clot strength, and may not 
reflect haemostasis in vivo (42, 79). Laboratory-based assays in platelet-poor plasma (PT, 
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aPTT, fibrinogen) require standard processing with results that are often not available to the 
treating clinician for upwards of 30 minutes (Figure 1.9) (42). As previously mentioned, 
PT and aPTT provide only partial information on clot initiation (80). These tests were 
originally designed for monitoring patients prescribed oral anticoagulants or suffering from 
congenital defects of haemostasis. Their widespread use in medicine means clinicians are 
familiar with them, and they have become the most frequently used method for assessing 
coagulation status in a vast number of medical disciplines, including trauma care.  
 
  
Figure 1.9. Relative time to PTr result.  
 
A platelet count and fibrinogen concentration assay usually supplement routine tests of 
coagulation. However, platelet counts are often normal in trauma patients and fail to 
provide any measure of platelet dysfunction secondary to the physiologic derangement 
evident in TIC (32). Furthermore, using the platelet count to guide therapy is difficult due 
to the lack of evidence for the clinical relevance of abnormal results. The Clauss fibrinogen 
assay is a non-functional test and is unable to assess the cross-linking of polymerised fibrin 
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by factor XIII. Moreover, none of the assays are able to evaluate the rate of clot 
propagation vs clot lysis or overall clot strength. In summary, the limitations of these tests 
are: they are not available within useful timeframes and they are unable to measure the full 
pattern of clotting dysfunction and therefore cannot effectively guide treatment in patients 
suffering from massive haemorrhage.  
 
In modern-day practice, the vast majority of guidelines for diagnosis and management of 
major haemorrhage are based on arbitrary laboratory triggers, e.g. PT>1.5 x normal (81) 
(82). More recent work from our group showed that a PTr of 1.2 is a clinically significant 
threshold for the definition of ATC (65). A PTr>1.2 was associated with a stepwise 
increase in mortality and blood product requirements, and the group was able to 
demonstrate that the often-cited threshold for coagulopathy of PTr/IN  >1.5 failed to detect 
16% of patients with worse outcomes (Figure 1.10). Blood loss in severely injured trauma 
patients occurs at an alarming rate and these coagulation screens have questionable 
diagnostic sensitivity (83) and predictive power (84) to guide massive transfusions (MT). 
The “gold standard” test of coagulation in trauma should be robust in an emergency 
environment and should be able to rapidly evaluate all stages of whole blood clot formation 
and breakdown, while detailing the contribution of platelets and fibrinogen to clot function. 
One such diagnostic tool is rotational thromboelastometry (ROTEM). 
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Figure 1.10. Relationships between ATC and clinical outcomes. (A) Increasing 
mortality with increasing prolongations of the PT (*p<0.001) compared with PTr = 1. 
(B) Increasing 24-h administration of transfusion products with increasing prolongations 
of the PT (*p<0.001) compared with PTr = 1. (+p<0.001) compared with PTr = 1. 
(64)  
 
 1.11 ROTEM 
 
In the past decade, viscoelastic methods that assess the speed of clotting and the quality of 
the clot, such as ROTEM®—Tem International GmbH, Munich, Germany (Figure 1.11)—
have been successfully used to guide haemostatic therapy. The use of viscoelastic screens 
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have been evaluated in cardiothoracic surgery (85), obstetric practice (86), inherited 
bleeding disorders (87), monitoring of haemostatic agents such as activated recombinant 
factor VIIa (rFVIIa; NovoSeven, Novo Nordisk) (88) and bleeding trauma patients (88-91).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11. ROTEM (delta). 
 
ROTEM assesses the viscoelastic properties of blood, also known as “modulus of 
elasticity” or “clot firmness”, and provides graphical representation of clot formation and 
breakdown (fibrinolysis). This measurement occurs during the transition of blood from a 
fluid to semi-solid state and exhibits good correlation with thrombin generation assays (62, 
92). Blood is incubated at 37ºC in a series of cups with activators of coagulation (such as 
tissue factor, ellagic acid, and kaolin). The relative contribution of fibrinogen and platelets 
to clot strength can be evaluated through the inhibition of thrombocytes in ROTEM 
(FIBTEM). 
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Measurement of coagulation in ROTEM is performed after the vertical immersion of a 
plastic pin into the whole blood sample. The pin rotates slowly backwards and forwards at 
an angle of 4.75°. The oscillating pin is attached to an optical detector. After the generation 
of the first fibrin filaments between the pin and the wall of the test cup, the rotational range 
of the pin is reduced. The increasing restriction of the pin’s movement is transferred to a 
graphical display, a plot that shows changes in the viscoelastic properties of the clot over 
time (Figure 1.12). The device has four channels, allowing four tests to be performed 
simultaneously. Two basic ROTEM tests that use intrinsic activation (INTEM) and 
extrinsic activation (EXTEM) provide information on the general coagulation status. 
 
 
 
 
Figure 1.12. ROTEM Trace. (Adapted from ROTEM®, Tem International GmbH, Munich, 
Germany.) 
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Table 1.2. Standard nomenclature ROTEM parameters. (Modified from Tem 
International GmbH, Martin-Kollar-Strasse 13–15, 81829 München, Germany, 2014.) 
 
ROTEM Description of Parameter Interpretation of Parameter Main Factors 
CT (seconds) 
Clotting Time 
The CT is the time from the 
beginning of the test, once the 
clotting 
activator is added, until the 
time when an amplitude of 
two mm is achieved. 
Initiation phase 
 
The CT describes how fast the 
formation of fibrin begins. This 
parameter is analogical to the 
clotting time in a classical 
clotting test in a laboratory. It is 
the lag-phase of thrombin 
generation (dependent on the 
activity of coagulation factors) 
clot (amplitude of two mm) 
 
Clotting factors 
 
Anticoagulants 
CFT (seconds) 
Clot Formation 
Rate 
The CFT is the time between 
a two mm amplitude and a 20 
mm amplitude 
of the clotting signal. 
Amplification phase 
 
The CFT describes the next 
phase of the clotting: the kinetics 
of the formation of a stable clot 
through both activated 
thrombocytes and fibrin. 
 
Clot firmness as 
influenced by 
thrombocytes. 
 
Fibrinogen level and 
its ability to 
polymerise. 
α-angle 
(degrees) 
The angle between the middle 
axis and the 
tangent to the clotting curve 
through the two mm 
amplitude point. It 
describes the kinetics of 
clotting. 
Thrombin burst 
 
Maximum velocity of clot 
formation (dependent on platelet 
function and fibrin 
polymerisation). 
 
The diagnostic 
information of this 
parameter is similar to 
CFT. 
CAx (mm) 
Clot Amplitude 
Mechanical clot quality at 
fixed time point, e.g. 10 
minutes (CA10). 
 
Propagation phase 
 
Clot strength at a fixed time 
point. 
Thrombocytes 
 
Fibrinogen 
concentration and 
ability to polymerise. 
 
Factor XIII. 
 
MCF (mm) 
Maximum Clot 
Firmness 
MCF is the measure for the 
firmness of the clot and 
therefore 
the clot quality. It is the 
maximum amplitude that is 
reached 
before the clot is dissolved by 
fibrinolysis and the clot 
firmness 
falls again. 
 
Maximal clot strength 
 
Determined by platelets, 
fibrinogen and factor XIII. 
 
Thrombocytes 
 
Fibrinogen 
concentration and 
ability to polymerise. 
 
F XIII. 
 
The status of 
fibrinolysis. 
LIx (%) LIx is ratio of the amplitude 
to MCF at a given time point 
after CT. 
 
Clot termination 
 
Percentage clot lysis at a fixed 
time e.g. 30 minutes (LI30). 
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Compared to laboratory-based clotting assays, ROTEM is a rapid measure of coagulation. 
Laboratory clotting screens are of limited value in the management of trauma haemorrhage 
due to delayed availability of results, poor predictive power for MTs, and inability to 
quantify clot propagation vs clot lysis or overall clot strength (62).  
 
Recent work in ROTEM within our unit has shown that a threshold of clot amplitude at five 
minutes of <35  mm can diagnose ATC and predict the need for MT with reasonable 
accuracy—i.e. with a detection rate of 71% versus 43% for PTr  >1.2 (62). We have also 
shown that trauma patients with ATC (defined as PTr  >1.2) have a “signature” 
thromboelastogram (Figure 1.13).  
 
 
 
Figure 1.13. A computer-simulated signature ROTEM ATC Trace and Non-ATC 
Trace (62). 
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1.12 Advantages of ROTEM 
 
ROTEM can be operated by non-laboratory staff and is able to deliver a dynamic display of 
clot initiation, quality and lysis. The graphs generated show the degree of clot firmness as 
amplitude of the signal. The dynamics of clot formation and lysis are displayed as a change 
in this amplitude over time, providing a graphical representation of all stages of 
haemostasis, from clot initiation, clot formation to fibrinolysis. Unlike PT and aPTT, 
ROTEM is able to graphically evaluate the rate of clot propagation vs clot lysis or overall 
clot strength. Therefore, the speed of detection, whole blood assay and evaluation of clot 
dynamics make ROTEM an attractive option for the rapid identification of ATC.  
 
Educational programmes with training certifications and telephone support from 
transfusion experts have been shown to assist physicians in the interpretation of ROTEM 
traces and the clinical implications of abnormal results. Some hospitals have adopted a 
remote system, utilising trained technicians in the laboratory to perform ROTEM with 
results transmitted in real time to monitors in the clinical environment for correlation. 
 
A further advantage of using ROTEM is that it requires a relatively small blood sample. It 
only uses 300 micro l per test and a pre-set automated pipetting system that ensures 
accuracy. The ROTEM itself uses simple procedures, and hence is an easy test to learn. 
Consequently, intra-operator variability is low.  
 
1.13 Limitations of ROTEM  
 
ROTEM has been developed by clinicians independent of haematologists and haemostasis 
laboratories. Thus, they have yet to be fully scrutinised to provide any large-scale 
validation and hence clinicians are unable to make decisions based on the metrics created.. 
Comparison with previous studies is inherently difficult, given the large variation in 
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sampling protocols and device configuration used to evaluate ROTEM, such as fresh vs 
citrated blood, activated vs non-activated samples and so on. Commercially available 
assays are different with varying sensitivities, specificities, accuracies and reproducibility 
depending on the type and concentration of activator used. Furthermore, massive activation 
of the coagulation system with tissue factor may mask subtle changes that may occur.  
 
Factors for consideration regarding any near-patient testing are clinical staff training, 
frequency of maintenance and the need for robust quality assurance. ROTEM users need to 
fully engage with external quality assessment (EQA) providers to enable a monitoring or 
the performance of the devices. High staff turnovers and a relatively low incidence of TIC 
in some centres may limit clinician competency in the timely analysis of ROTEM graphs 
for bleeding trauma patients. Only major trauma centres that treat a high number of 
severely injured patients are likely to develop expertise in the ROTEM-guided management 
and diagnosis of TIC.  
 
Furthermore, the high costs of running a four-channel ROTEM machine are significant 
when compared to laboratory tests such as PT and aPTT. There is not only the cost of the 
machine itself to consider, but the also the consumables involved in the sample analysis. A 
solution to this is to only analyse EXTEM and FIBTEM channels, thus reducing the cost, 
however this has obvious implications for broader analysis. 
 
Finally, in 2014 NICE evaluated three viscoelastometric point-of-care testing devices 
(ROTEM, TEG and Sonoclot systems), to aid the NHS to decide whether to implement 
these tools.  The published recommendations in 2014 reported that both ROTEM and TEG 
were used to help detect, manage and monitor haemostasis during and after cardiac surgery 
(93).  However in regards to the emergency control of bleeding, NICE concluded there was 
“currently insufficient evidence to recommend the routine adoption of viscoelastometric 
point‑of‑care testing in the NHS to help detect, manage and monitor haemostasis in 
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bleeding after trauma” (93). Furthermore they recommended specific focused research into 
the clinical benefits and cost effectiveness of using viscoelastic point‑of‑care testing to help 
with the emergency control of bleeding after major trauma.  In particular NICE 
recommended that future trials should include longer‑term follow‑up beyond the initial 
hospital episode,  and further research to understand the characteristics of patients at high 
risk of haemostatic instability in whom viscoelastic testing may be most effective  (93) . 
 
1.14 Alternatives to ROTEM 
 
Another viscoelastic coagulation test that could be a possible alternative to ROTEM is 
thromboelastography (TEG). TEG works on a similar principle to ROTEM, however in 
TEG, a stationary pin attached to a wire (that can monitor movements) is immersed into the 
sample. The clot strength will influence the oscillation of the pin and these dynamic 
changes are converted to a curve.  
 
A major limitation of TEG in an emergency setting has been the sensitivity of the torsion 
pin to vibration and shock. The oscillating pin in ROTEM is believed to offer greater 
stability to the device, such that the military have been able to use the system with good 
effect. The Multiplate analyser is another possible alternative. The Multiplate is a 
functional analyser of coagulation based on whole blood impedance aggregometry. An 
advantage of Multiplate is that it shows a high sensitivity towards the effects of platelet 
inhibitors, such as ASA, clopidogrel and GPIIb/IIIa receptor inhibitors, unlike ROTEM. 
Since the Multiplate analyser is a fairly new device, only limited data exist regarding its 
diagnostic power.  
 
Fast, reliable diagnosis, as well as characterisation of TIC, is important and there is 
increasing evidence that these coagulation monitoring devices are helpful in guiding 
coagulation therapy for heavily bleeding trauma patients according to their actual needs 
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(94). In severely injured, bleeding trauma patients, it is crucial to receive rapid information 
on the patient’s current coagulation status. Low MCF in EXTEM, INTEM and FIBTEM 
has been identified as important determinants of RBC transfusions (95) (62, 75) (96) (97). 
In one study, Schochl et al. showed that MCF—but not standard coagulation tests (INR, 
PT, aPTT)—was predictive for blood product transfusions. Leemann et al. showed that low 
INTEM MCF and low haemoglobin levels were independent risk factors for a MT (>10 U 
PRBCs). Doran et al., in 2010, demonstrated (in a small cohort of severely injured combat 
casualties) that admission samples analysed by ROTEM are more sensitive than aPTT and 
PT in detecting coagulopathy. In patients who received a MT, the PT or aPTT was 
abnormal in 21% of cases compared to 64% for ROTEM (98). 
 
1.15 Historic haemorrhage control strategies in trauma 
 
Once a patient has arrived in the trauma room, the initial management of multiple trauma 
patients should always adhere to ATLS® principles and undergo the primary survey of 
airway (A), breathing (B), circulation (C), neurologic status (D: disability) and core 
temperature (E: environment) (99). However, patients suffering from severe trauma often 
arrive in the ED in hypovolemic shock and need large volumes of packed red blood cells 
(PRBCs) and blood component transfusion to minimise further loss, restore tissue perfusion 
and achieve haemodynamic stability (100).  
 
Historically, resuscitation strategies in trauma have involved large volumes of crystalloid 
followed by PRBC infusion. Other blood components such as fresh frozen plasma (FFP), 
cryoprecipitate (CRYO) and platelets (PLT) were supplemented based on routine 
laboratory values and at the discretion of ED physicians. The goal of this mode of treatment 
strategy was to address coagulopathy after the trauma patient has been initially stabilised 
and the acute resuscitation has been completed. This approach to resuscitation was, until 
very recently, endorsed by the American College of Surgeons Committee on Trauma and 
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the ATLS course. The guidelines suggest resuscitating all trauma patients with signs of 
shock with two or more litres of crystalloid in order to restore normal blood pressure. The 
pitfall of this methodology is its reactionary treatment of coagulopathy in that it tends to be 
too late in the clinical course, as dilution, consumption and fibrinolysis is now already 
deeply rooted (101). 
 
1.16 Fluid therapy  
 
Haemorrhagic shock can be defined as “a condition produced by rapid and significant loss 
of intravascular volume, which may lead sequentially to hemodynamic instability, 
decreases in oxygen delivery, decreased tissue perfusion, cellular hypoxia, organ damage, 
and death” (102). Haemorrhagic shock can be rapidly fatal. Patients presenting with 
hypotension (systolic blood pressure less than 90 mmHg), tachycardia (heart rate greater 
than 100 beats per minute), and obvious blood loss are readily identified as being in a state 
of haemorrhagic shock. In the case of haemorrhagic shock, fluid infusion represents the 
main treatment to improve perfusion, but aggressive replacement increases dilution 
coagulopathy and interstitial oedema and impairs microcirculation, thus worsening 
oxygenation (103). Furthermore, pre-hospital administration of high volumes (>3 L) of 
crystalloid or colloid fluids has been shown to be independently associated with a worse 
coagulation profile at ED admission (104). In 1985, a retrospective review by Hewson et al. 
of 68 massively transfused patients found that coagulopathy was common after crystalloid 
administration and that PTT correlated with the volume of crystalloids given (105). Thus, 
vigorous fluid resuscitation not only increases blood pressure, the effect of which increases 
hydrostatic forces on newly formed clots, but also dilutes clotting factors and haemoglobin 
and reduces body temperature. All of these effects could promote further bleeding and 
impair end organ perfusion (106). 
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1.17 Permissive hypotension 
 
Approximately one third of trauma deaths occur because the victims bleed to death within 
the first hours of their injury (107). For almost half a century, high-volume fluid 
resuscitation strategies have typically been used by trauma surgeons and emergency 
medical personnel in an attempt to reverse haemorrhagic shock by replacing lost blood with 
intravenous (IV) fluids or transfusions. Hypotensive resuscitation, also known as 
permissive hypotension (PH), has been proposed as an alternative to the current standard of 
care. Although PH is only now evolving into an integral part of DCR, the practice itself is 
not a new concept. Walter Cannon and John Fraser remarked on it as early as 1918, when 
serving with the Harvard Medical Unit in France during World War I (108). The main 
feature of PH, in contrast to standard fluid resuscitation, is that it uses less IV fluids and 
blood products during the early stages of treatment for haemorrhagic shock. In essence, PH 
resuscitation describes a process that minimises administration of fluid resuscitation until 
haemorrhage control has been achieved.  
 
Scientific attempts to examine outcomes for PH after serious traumatic injury have been 
mixed. A well-known randomised control study of trauma patients with truncal injuries, 
published by Bickell et al. in 1994, concluded that there was a benefit to delaying 
aggressive fluid resuscitation until after operative intervention and surgical haemorrhagic 
control had been established (109). This group compared mortality rates of patients who 
received immediate vs delayed administration of IV fluids and discovered improved 
survival, fewer complications, and shorter hospital stays in the delayed group. They 
demonstrated that, regardless of the victim’s blood pressure, survival was better in their 
urban “scoop and run” rapid transport system when no attempt at pre-hospital resuscitation 
was made (109). A study produced in 2006 by Hirshberg et al. utilised computer modelling 
to demonstrate the effect that the timing of resuscitation has on bleeding. It showed that an 
early bolus delayed haemostasis and increasing blood loss, while a late bolus triggered 
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rebleeding (110). Moreover, the limited use of fluids during resuscitation efforts is in direct 
opposition to guidelines recommended by the American College of Surgeons Committee on 
Trauma and the ATLS protocol (108). 
 
There have been theoretical concerns regarding the safety of hypotensive resuscitation. 
These are largely based on the possible harmful effects of decreased oxygen delivery to the 
various tissues of the body, a by-product of haemorrhagic shock. On the one hand, 
maintaining a MABP that is too low could result in inadequate perfusion, acidosis and 
subsequent organ failure, with potentially catastrophic outcomes. On the other hand, critics 
of aggressive fluid resuscitation argue that maintaining a raised or “normal” blood pressure 
in the face of exsanguination can result in equally catastrophic outcomes secondary to 
exsanguination and perpetuate the lethal triad of hypothermia, acidosis, and coagulopathy 
(111) in addition to breakdown of the newly developed fibrin clot. Morrison et al. (2011) 
prospectively examined the 30-day morbidity and mortality rates for the first 90 patients 
enrolled in a randomised controlled trial of hypotensive resuscitation, with the primary aim 
of assessing the effects of a limited transfusion and IV fluid strategy (107). These 
researchers showed that the PH group had significantly lower mortality in the early 
postoperative period and a non-significant trend for lower mortality at 30 days. When 
examining coagulopathy, they report that, among the PH group, there was a significantly 
lower international normalised ratio as compared to those in the higher mean arterial blood 
pressure (MABP) group, indicating a less severe coagulopathy. These preliminary results 
provide convincing evidence that supports the continued investigation and use of 
hypotensive resuscitation in a trauma setting. 
 
1.18 Damage control resuscitation  
 
The most important aim when treating an exsanguinating patient is the recognition and 
immediate control of bleeding. It is also possible to rapidly identify patients who are highly 
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likely to develop ATC at admission and promptly, aggressively and simultaneously treat 
hypothermia and acidosis. The technique to achieve this, developed by clinicians, is known 
as Damage Control Resuscitation (DCR) (39) and is a treatment strategy that targets the 
conditions that exacerbate haemorrhage in trauma patients. 
 
The term was originally coined by the US Navy in reference to techniques that maintained 
a battleship’s functional integrity after it had sustained serious or critical damage, and refers 
to the guidelines developed for combat casualties suffering substantial bleeding in Iraq and 
Afghanistan (112). Since then, “damage control” has been adapted to truncating initial 
surgical procedures on severely injured trauma patients, thus providing only those 
interventions necessary to establish haemostatic control and to focus on re-establishing a 
survivable physiologic status.  
 
DCR, a concept that has been popularised by the military, is now being studied in a civilian 
setting. In recent times, traditional methods of resuscitation of severely injured patients 
with exsanguinating haemorrhage have come under increasing scrutiny for their inadequacy 
in correcting the acidosis, hypothermia, and coagulopathy seen in this population of 
patients. Direct treatment of coagulopathy has been relatively neglected, unfortunately 
viewed as a by-product of resuscitation, haemodilution, and hypothermia, and delayed by 
blood banking logistics (113-116). Conventional resuscitation practices for damage control 
mainly focus on rapid reversal of worsening acidosis and prevention of hypothermia, and 
surgical techniques focus on controlling haemorrhage and contamination from perforated 
viscera. The concept of DCR has its foundations in the assumption that a coagulopathy is 
present very early in the clinical course after injury, and hence, earlier interventions to 
correct it in severely injured patients may lead to improved outcomes (108). The 
temporarily stabilised trauma patient then undergo continued resuscitation and aggressive 
correction of their physiology in the intensive care unit (ICU) before returning to the 
operating room (OR) for the definitive repair of their injuries. DCR is therefore a structured 
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intervention that begins immediately after initial assessment in a pre-hospital setting and 
ED and progresses through the OR into the ICU. It comprises two main components, the 
first being that resuscitation is limited to keep blood pressure at approximately 90 mmHg, 
preventing renewed bleeding from recently clotted vessels due to increased hydrostatic 
force. Second, intravascular volume restoration is accomplished by using thawed plasma as 
a primary resuscitation fluid in a high ratio to PRBCs, usually provided in packs known as 
MTPs (39).  
 
1.19 Massive transfusion 
 
It is estimated that 10% of military trauma patients and 3% to 5% of civilian trauma 
patients receive a massive transfusion (MT), which are generally defined as more than 10 U 
of PRBCs within 24 h of the start of treatment (101). Although this represents a small 
cohort of patients in real terms, it accounts for 75% of blood utilisation in busy Level 1 
trauma centres (62). Furthermore, this direct focus on the sole replenishment of PRBCs 
over 24 h does not address a significant subset of patients who would likely benefit from 
additional blood component therapy (i.e. over a shorter interval). In separate studies, both 
Moore et al. and Holcomb et al. have demonstrated that patients receiving 10 U of PRBCs 
in the first six hours after injury had a higher rate of mortality than those receiving the same 
quantity of PRBCs over a 24-hour period (117).  
 
Historically, massive transfusion protocols (MTPs) have been reactive to the problem of 
traumatic coagulopathy. Until recently, most published guidelines advocated the sequential 
replacement of PRBCs with crystalloids prior to clotting products and platelets and only 
after a laboratory confirmed derangement, i.e. PT>1.5 (118). However, as mentioned 
previously, laboratory-guided component therapy has a limited use in guiding treatment in 
exsanguinating patients. Furthermore, there can be a significant interval between when the 
blood is drawn to when the result is available to the trauma team. In addition, once the 
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decision has been made by the treating clinical team to transfuse plasma or platelets, more 
time (30–60 min) is lost while waiting for these products to thaw. In the severely injured, 
exsanguinating patient, this is a missed opportunity to treat or prevent TIC. 
 
Many institutions have embraced the concept of “proactive” resuscitation and the early use 
of PRBCs and blood components. This evolution stems from DCR: to expeditiously 
address the specific issues of rapid exsanguination and ATC, a targeted delivery of blood 
components in predefined ratios has been proposed and has given rise to the nomenclature 
of major haemorrhage protocols (MHPs) (39, 113). These MHPs are a formulaic protocol 
which are activated on the basis of clinical need and hence, not dependent on laboratory 
triggers such as PT results.  
 
1.20 Transfusion strategies for trauma haemorrhage 
 
Almost 80% of all trauma deaths that occur in the operating theatre are a result of 
haemorrhagic shock and exsanguination (29). Large volume blood and blood product 
replacement is required to maintain oxygen-carrying capacity and augment clot formation 
(82). Rates of MT in civilian trauma practice are less than 5%, but transfusion medicine has 
undergone a paradigm shift in recent years, following numerous reports of improved 
outcomes with early high-dose plasma therapy (119). Traditionally, MTPs have been 
reactive to the problem of traumatic coagulopathy. Until recently, most published 
guidelines advocated the sequential replacement of PRBCs with crystalloids prior to 
clotting products and platelets, and only after a laboratory confirmed derangement, e.g. 
PT>1.5 x normal, platelets<50 x 109/L (81, 82, 120). Computer modelling of major 
haemorrhage and MTPs offered reason to question the rationale and efficacy of restrictive 
transfusion practice. In 2005, Ho et al. demonstrated excessive coagulation factor dilution 
with delayed low-dose FFP that required at least 1:1 therapy to reverse the coagulopathy 
(121). Using an alternative simulation, Hirshberg et al. (2003) reported optimal replacement 
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ratios of 2:3 and proposed the concurrent use of plasma with an initial PRBC transfusion to 
prevent prolongation of clotting times (122). A large number of retrospective clinical 
studies have supported the results of these theoretical models, and several survival benefits 
have been seen following the adoption of aggressive transfusion strategies (119). Borgman 
et al. were the first to draw an association between the ratio of FFP:PRBCs and mortality 
(123). Casualties who received ratios of <1:4 had a 65% mortality rate, compared to a 
mortality rate of 19% in those who received >2:3 FFP:PRBCs. Similar analyses have been 
conducted using both military and civilian trauma registries, the majority of which have 
advocated ratios approaching 1:1 (82). Survivor bias is a major confounding factor in these 
retrospective studies as patients have to live long enough to receive a high ratio. 
Interestingly, recent work within our group has shown that the haemostatic effects of 
FFP:PRBCs may be maximal at red cell ratios of 1:2, again with 1:1 not conferring any 
additional benefit (124). 
 
1.21 Full whole blood 
 
As part of DCR, severely injured trauma patients were historically transfused with full 
whole blood (FWB), the resuscitative fluid of choice. Full whole blood was historically 
used in transfusion until it fell out of favour in the middle of the twentieth century due to its 
side effects and the convenience of component therapy for treating other non-traumatic 
diseases (108). Resuscitation strategies in the 1980s replaced the use of whole blood 
therapy with component therapy. In theory, whole blood replaces all the blood components 
lost to trauma haemorrhage, including platelets and fully functional coagulation proteases. 
Furthermore, the components of FWB are more functional than their stored counterparts. 
Separating blood into components results in dilution and the loss of about half of the viable 
platelets (108). Moreover, logistically, FWB provides the advantage of being readily 
available and requires no delay to account for thawing. However, it does require the 
presence of a ready and willing donor pool. It should be noted that transfusion with FWB, 
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as well as with component therapy, does carry its associated risks. Mortality in transfused 
trauma patients, even when controlled for other risk factors, has been well documented 
(39). Specifically, this relates to transfusion related acute lung injury (TRALI), which 
occurs in one in every 100,000 transfusions and is now the leading cause of mortality after 
blood product administration. TRALI is a life-threatening antibody-mediated event, most 
often seen during the administration of FFP. Other complications include multi organ 
failure (MOF) due to immunogenic transfused cells or infection. Infections are a common 
and significant sequelae of major traumatic injury and transfusion. In 2002, Claridge et al. 
prospectively evaluated the relationship between infections in 1,953 trauma patients and the 
transfusion of PRBCs within the first 48 hours of admission. They demonstrated that 
infection rates were four times more likely in transfused patients than in those who did not 
receive transfusion. Although transfusions are frequently required in the trauma setting, 
they should be administered appropriately and with no more PRBCs than absolutely 
necessary (125). 
 
Formula-driven MHPs are becoming commonplace in trauma haemorrhage management 
(126), although little is known regarding the effect MHPs have when compared directly 
with MTPS. A knowledge gap exists on the effects MHPs’ blood components have on TIC 
and in vivo coagulation factor concentration.  
 
1.22 Fresh frozen plasma 
 
Damage control resuscitation aims to directly address TIC through the early and aggressive 
administration of blood products to severely injured trauma victims. It is proposed that 
early and sustained administration of FFP can help correct the state of depleted coagulation 
factors common in a bleeding patient. However, the evidence for its efficacy in managing 
massive haemorrhage is limited (127). There are also inherent logistical obstacles to 
providing FFP to a trauma patient in a timely fashion. As the name suggests, a FFP is 
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plasma that is frozen at -18°C within eight h of being drawn from the donor pool. Using 
this method of freezing and storing plasma has the advantage of preserving all coagulation 
factors at their in vivo activity levels. These factors therefore remain stable during storage. 
Unfortunately, the disadvantage of this method is that the emergency transfusion is 
complicated by a 10–20 min delay while the units are thawed. Thus, it cannot always be 
available to a massively haemorrhaging patient during the crucial first minutes of DCR. 
 
Some centres have moved towards using alternative plasma products, such as thawed 
plasma and liquid plasma. These units are stored in liquid form and can be provided to an 
exsanguinating trauma patient immediately, without the need for thawing. Some loss of 
clotting factors has been reported when plasma is stored in liquid form, particularly loss of 
the “labile” factors V and VIII. Alternatively, thawed plasma can be considered equivalent 
to FFP. It is stored in liquid form for a maximum of five days after it is thawed. At the end 
of five days, coagulation factors other than factors V and VIII maintain 70% to 80% of 
their original activity levels, and fibrinogen levels are unchanged. The levels of factors V 
and VIII are reduced to 65% activity, but still within the haemostatic range (108). Thawed 
plasma has an average five-day shelf life; therefore it can be difficult to keep an adequate 
supply of thawed plasma on hand in the ED, in particular for the scarce “universal donor” 
type, AB. One possible option is liquid plasma, which has a shelf life of between 26 to 40 
days, depending on the preservative used. 
 
FFP is thought to contain all the coagulation proteases, fibrinogen (0.9g/unit) (128), and 
physiological anticoagulants (e.g. protein C, protein S and plasma proteins (129)), but the 
precise quantities of each vary from unit to unit, as there is no standardisation of individual 
FFP units. Within the trauma setting, larger quantities of FFP are recommended (greater 
than 10–20mg/kg) for a beneficial effect on the exsanguinating patient, but there are no 
published evidence-based guidelines as yet.  
 
	   54	  
There is much controversy over the ideal FFP:PRBC ratio in the trauma setting. In 2002, 
while describing the effect of fluids on coagulation, Hirshberg et al. concluded that to avoid 
coagulopathy, RBCs and FFP must be given in a 3:2 ratio (122). This concept further 
evolved to the use of a higher 1:1 FFP:PRBC ratio, although this is based largely on the 
evidence acquired from the military data regarding the management of combat casualties. 
Borgman et al. compared mortality rates associated with varying ratios of FFP to PRBCs in 
the management of trauma seen in the Iraq conflict (123). They performed a retrospective 
review of 246 patients at a US Army combat support hospital, each of whom received a 
MT. Three groups of patients were created according to the plasma to RBC ratio transfused 
during MT, and the mortality rates and the cause of death were then compared among 
groups. The researchers concluded that, in patients with combat-related trauma requiring 
MT, a high 1:1.4 plasma to PRBC ratio is independently associated with improved survival 
and hospital discharge, primarily by decreasing death from haemorrhage (123).  
 
There have also been numerous civilian observational studies that report good outcomes 
across a range of different blood product ratios (40, 108, 117). The largest observational 
transfusion study was of 905 bleeding trauma patients and was conducted in 10 Level I 
trauma centres in the US: it is known as the prospective observational multicentre major 
trauma transfusion (PROMMTT) study. In this PROMMTT study, investigators conducted 
a prospective group study documenting when FFP and PRBC transfusions were 
administered during active resuscitation and patient outcomes. Clinicians generally 
delivered transfusion ratios that cumulated in the range of 1:1 or 1:2, which shows a 
clinical equipoise for these two ratios (130).   
 
Transfusion of higher ratios of FFP:PRBCs is not without risk (51, 131). In 2008, Sperry et 
al. conducted a multicentre prospective cohort study evaluating clinical outcomes in 415 
blunt injured adults with haemorrhagic shock. They concluded that there was a higher risk 
of acute respiratory distress syndrome in those patients who required >FFP:PRBCs of 
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1:1.5. Furthermore, aside from the transmission of viral or bacterial pathogens, which 
should be effectively screened out prior to transfusion, blood products are independently 
associated with numerous adverse effects (131). Various groups have reported that 
immunomodulation and the risks of noscomial infection are more prevalent in transfused 
trauma patients (132, 133), and FFP itself is an independent risk factor for acute lung injury 
(ALI) and MOF (51). However, certain groups have questioned whether a more liberal 
transfusion policy actually controls bleeding earlier and therefore reduces exposure to 
blood and blood products (134). Blood components are a limited resource. Increased 
demands both on the availability and quantity of FFP are likely to impact heavily on 
transfusion services. Although there is a rapid uptake of newer transfusion strategies that 
promote a higher ratio component delivery, there is a lack of high-level evidence on the 
effect of these strategies on the coagulation profile in vivo.  
 
1.23 Platelets 
 
There is a widely accepted consensus that, in severe haemorrhage, the platelet count should 
be maintained above 50–100 x 109/L in polytrauma or central nervous system injury (68, 
76, 135). A dilutional thrombocytopenia (platelet counts<50–100 x 109/L), which is thought 
to be the major cause of microvascular bleeding, tends to develop only after MT patients 
received 18–20 units of stored whole blood (40). Further to the thrombocytopenia, intrinsic 
platelet function is impaired by both acidosis and hypothermia, which can develop in 
severely injured patients who require MT.  
 
Historically, it has long been thought that a declining platelet count usually requires 
intervention much later than a plasma deficit (136). Although the platelet count can be 
easily determined, there are no validated practical methods to rapidly assess the function of 
native platelets. Several military retrospective studies have reported improved outcomes 
after earlier transfusion of increased amounts of blood products (123, 137). In 2008, 
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Johansson et al. reported that increased amounts of plasma and platelets transfused in the 
OR in fixed ratios for patients with ruptured aortic aneurysms improved chances of survival 
(44% vs 66%, p<0.05). Furthermore, a platelet count of >100 x 109 upon arrival in the ICU 
was associated with improved survival. However, it remains to be seen if similar results can 
be achieved in a civilian trauma population, with different injury patterns, increased 
comorbidities, and without fresh whole blood transfusions.  
 
In 2008, Holcomb et al. hypothesised that higher PLT:PRBC and FFP:PRBC ratios would 
result in decreased early haemorrhagic death and this benefit would be sustained throughout 
the ensuing hospital stay (40). Over a one year period, this civilian study examined records 
of 467 MT trauma patients transported from the scene to 16 level 1 trauma centres. Using 
multivariate logistic models, their results showed that plasma and platelet to PRBC ratios 
and ISS were predictors of death at six hours, 24 hours, and 30 days. Specifically, patients 
with high PLT:PRBC ratios (≥1:2) had an increased 30-day survival compared to those 
with low PLT:PRBC ratios (59.9% vs 40.1%, p<0.01) (40). More recently, the same group 
published results from Pragmatic, Randomized Optimal Platelet and Plasma Ratios 
(PROPPR) trial, a pragmatic randomised controlled trial of 680 severely injured patients, 
where half were randomised into 1:1:1 blood product ratios and compared to a those 
receiving 1:1:2 blood product ratios (138). In contrast with earlier reports, for patients with 
major haemorrhage, early administration of plasma, platelets, and RBCs with either ratio 
did not result in significant differences in 24-h mortality rate (1:1:1: 12.7% vs 1:1:2: 17.0% 
p=0.12) or 30-day mortality rates (1:1:1: 22.4% vs 1:1:2: 26.1% p=0.26). However, more 
patients in the 1:1:1 cohort achieved haemostasis and fewer died due to early 
exsanguination. 
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1.24 Fibrinogen 
 
Fibrinogen is the primary substrate of the coagulation system and is fundamental to 
haemostasis. Profound acidosis, severe hypothermia (<32 ̊C) and haemodilution have been 
shown to lower fibrinogen (139, 140). In 2006, Martini et al. reported that acidosis 
compromised the clotting process, while accelerated fibrinogen consumption reduced 
fibrinogen levels in experiments conducted on swine with ATC (141). There have also been 
small, retrospective clinical studies that suggested a deterioration in fibrinogen levels (88, 
142); however, these levels have not reached values that would trigger fibrinogen 
replacement. To maintain the integrity of the coagulation function, it is recommended that 
fibrinogen is replaced when it falls below 0.8–1.0g/L (81). 
 
Although fibrinogen replacement has been used as first-line treatment for trauma-induced 
coagulopathy, and recent MT guidelines suggest maintaining higher levels of fibrinogen 
(above 1.5g/L), supporting evidence is weak (82, 143, 144) and not without limitations. 
Early clinical studies have pointed towards fibrinogen supplementation as a means to 
improve outcomes for trauma haemorrhage by improving clot strength (145), reducing 
blood loss (146) and increasing survival (88, 147). Likewise, two observational cohort 
studies (148, 149) have also reported a reduction in mortality for those patients who receive 
higher fibrinogen content during trauma haemorrhage therapy. To add weight to these 
findings, it is known that hypofibrinogenaemia is a key component of ATC (75) and occurs 
early during major blood loss (150). Furthermore, the CRASH-2 randomised controlled 
trial has not only confirmed the importance of tranexamic acid (TXA) and antifibrinolytics 
as a means to improve clinical outcomes (151), but, more importantly, has also shown that 
it is vital to deliver haemostatic therapy early (i.e. within three h of injury) (152).  
  
Fibrinogen supplementation with either Cryoprecipitate (CRYO in the UK or US) or 
fibrinogen concentrate (in Europe) is often delayed or considered second-line treatment in 
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the empiric delivery of haemostatic coagulation therapy (153). The estimated expected 
fibrinogen doses transfused in each blood component are PLT – 0.4g; FFP/ – 0.9g; and 
CRYO – 2g for each pool/unit transfused (128). Our group has shown that a low-admission 
fibrinogen level was independently associated with ISS (p<0.01), shock (p<0.001) and pre-
hospital fluid volume (p<0.001) (154). This prospective study showed that fibrinogen 
supplementation during transfusion maintained, but did not augment, fibrinogen levels. 
Furthermore, our group reported that administration of CRYO was associated with 
improved survival. In addition to this, ROTEM parameters correlated with fibrinogen levels 
and ex vivo fibrinogen administration reversed coagulopathic ROTEM parameters. Our 
group also showed that the fibrinogen level was an independent predictor of mortality at 24 
h and 28 days (p<0.001) (154). Further work is required to ascertain the true effect of 
fibrinogen replacement on the coagulation profile during DCR.  
 
1.25 Transfusion practice in trauma 
 
In recent years, there has been a shift in trauma haemorrhage management practices. Older 
Massive Transfusion Protocols (MTPs) that treated the coagulopathy associated with MT 
have been replaced by new Major Haemorrhage Protocols (MHPs) that predict those 
patients who will go on to receive a MT and thus protect haemostatic potential.  
 
Unsurprisingly, the demand for blood products when managing bleeding trauma patients 
depends a great deal on adequate and timely blood transfusion support (155). Transfusion 
requirements in the acute resuscitative trauma setting can be extremely challenging and 
demanding on the resources of a blood bank. Blood and its components are a scarce and 
costly resource and demand is anticipated to increase with an ageing populations (156, 157) 
(158). Transfusion laboratories try to maximise delivering the correct blood component 
from the blood bank to the right patients in a timely manner. The easiest way to assure the 
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timely availability of blood is to have an appropriate inventory on the shelf at all times; 
however, this is impossible due to the shortage of blood products across the NHS. 
 
In the trauma setting, there is a need for large volumes of blood components for those with 
known or suspected haemorrhage. Indeed, the most severely injured and actively bleeding 
patients can go on to require a massive blood transfusion (i.e. receiving more than 10 units 
of PRBCs) (159). Therefore the blood transfusion laboratory must provide large amounts of 
blood products promptly, but avoid excessive waste or over provision, which would expose 
the recipient to the unnecessary risks of immediate, early and late transfusion 
complications. This threshold identifies a group of patients with severe injury and large 
resource requirements, and much recent research has been directed at this population. It is 
this subset of trauma patients that creates the greatest burden on blood transfusion resources 
(159).  
 
In 2004, Como et al. conducted a retrospective study of over five thousand trauma patients 
at a US Level 1 Trauma centre in order to describe categorical associations between 
demographic data, ISS, transfused products, and patient outcomes. In this study, special 
attention was paid to the groups receiving greater than 10 U of PRBCs. These researchers 
concluded that although 5,219 PRBCs were transfused and only 3% of patients received 
more than 10 U, this group of 3% went on to receive 71% of all PRBCs issued by the 
transfusion laboratory (159). Furthermore, this subgroup of patients also had a high 
mortality rate of 39% (159). Therefore, the blood transfusion laboratory must promptly 
provide large amounts of appropriate blood products and communicate effectively with the 
trauma team. This allows for the early recognition of patients with MT needs and ensures 
their blood product requirements are met without excessive waste or over provision.  
 
Over the past decade, there has been extensive research into the optimum blood transfusion 
strategy for exsanguinating trauma patients (68, 124, 130, 146, 160, 161). However, little 
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information has been gathered on the logistical issues posed by these trauma patients on 
transfusion services (155). Specific challenges present themselves to the all blood banks 
that support trauma patients. These include how to correctly identify those patients that are 
in need of a MT, how to minimise temporal delays associated with blood test results, how 
to facilitate effective communication between the blood bank and the clinical team, how to 
rapidly deliver blood products to patient care locations, and finally, how to remain 
organised and well-coordinated in the acute trauma setting (155). A possible solution to 
these issues was the introduction of MTPs.  
 
MT protocols originally evolved from elective (planned) surgery and then translated to the 
trauma setting in conjunction with transfusion services. They included the activation of 
additional personnel, employment of rapid infusion systems, automatic thawing of plasma, 
and changes in the crossmatching policy (159). Numerous studies have supported the 
logical notion that MTPs designed to give RBCs and coagulation factors (i.e. plasma and 
platelets) in pre-specified ratios are associated with increased survival, faster time to 
transfusion (118), reduced incidence of sepsis and MOF, decreased length of stay (162) and 
reduced blood product usage (163).  
 
In the first instance, it is important how the MTP is initiated. One common approach is that 
only a key point person can initiate the protocol; this is frequently the lead trauma surgeon. 
The inherent disadvantage of this single MTP-triggering personnel is that there may be a 
delay in activating the protocol until the trauma surgeon arrives on the scene. More 
recently, there has been a shift towards a range of individuals who can perform protocol 
activation. This can vary among different select groups, such as emergency room 
physicians or pre-hospital teams whose primary aim is to recognise that the patient is at risk 
of massive haemorrhage.  
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While the terms have been used interchangeably, there are clear differences between a MTP 
and the more recent MHPs. An MHP utilises the principles of DCR to aggressively prevent 
TIC with high ratios of blood products early on in the clinical course of the severely injured 
trauma patient. In contrast, MTPs treat TIC. Goal-directed MHPs aim to simultaneously 
improve blood product administration while decreasing any waste of the precious resource. 
 
The biggest challenge for blood transfusion services is supplying PRBCs, together with 
FFP, PLT and CRYO to the exsanguinating patient within a short time frame. In the trauma 
setting, it is vital that large volumes of blood products reach the patients early in their 
clinical course. Transfusion of high volumes of PRBCs prior to other blood products may 
worsen early coagulopathy, as well as increase mortality and blood product waste. Factors 
that contribute to this are the distance of the transfusion laboratory to the ED, time taken to 
process blood results, and the thawing of blood products. Unlike PRBCs and platelets, 
which can be issued to the patient “off the shelf”, FFP can take anywhere up to 30 min to 
thaw. This can lead to a situation in which the rapidly exsanguinating patient may have 
received 10 U of packed PRBCs. A possible solution is the introduction of MHPs that 
account for an empirically predetermined blood product pack with high ratios of thawed 
FFP:PRBCs. This is used in the ED as part of the initial deployment of blood products. The 
newly thawed FFP can be used for up to 24 hours afterwards and, furthermore, it can be 
designated as “thawed plasma” and stored for four days without any significant loss of 
coagulation factor activity. Once the protocol is activated and the initial haemorrhage packs 
are used, plasma should be rapidly thawed as units are issued by the transfusion service to 
allow them to “keep ahead” of expected use in the rapidly exsanguinating patient (164). 
With a standard operating procedure in place for using thawed plasma, the wastage of 
plasma should be minimal, but there is little evidence to support this.  
  
Currently, data directly comparing older MTPs to newer MHP strategies in the trauma 
setting is limited. Increasingly, FFP:PRBC and PLT:PRBC ratios are being used as 
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surrogate measures of effectiveness for a protocol. However, there is also a need to monitor 
the amount of blood products that are wasted during trauma. Trauma is among the largest 
consumers of blood components (165) and these are scarce resources that need to be 
managed efficiently. “Wasted units” are a crucial parameter to track within trauma (164), as 
little is known about the financial impact of unused and wasted blood components..  
 
1.26 Summary 
 
In conclusion, there is a knowledge gap regarding newer transfusion algorithms when using 
DCR principles to target trauma haemorrhage. Furthermore, little is known about the effect 
of MHPs on blood delivery, blood component waste and patient outcomes when directly 
compared to out-dated MTPs. Moreover, there is insufficient research investigating the 
effectiveness of current DCR strategies in addressing TIC in severely injured, bleeding 
trauma patients. Finally, there is an inadequate understanding regarding how these 
strategies affect the coagulation profile in vivo or how effective they are as a resuscitation 
tool altogether.  
 
 
1.27 Hypotheses and aims  
 
The overall research objective of this thesis is to investigate the effect of a DCR strategy on  
TIC. 
 
The individual hypotheses are detailed below: 
 
1. Major haemorrhage protocols improve blood product administration and 
reduces waste compared to traditional massive transfusion protocols.  
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2. TIC deteriorates during acute trauma haemorrhage.  
 
3. Blood component therapy improves trauma haemorrhage.  
 
4. Blood component therapy maintains coagulation factor concentrations during 
trauma haemorrhage.  
 
Each of the aims will be individually addressed within the experimental Chapters 3-6.  
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CHAPTER TWO 
 
Methods 
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The body of work included in this thesis includes patients and used blood samples that I 
collected as part of the on going prospective study at the Trauma Sciences Group. This 
ACIT II study received its original ethical approval from the East London and City 
Regional Ethics Committee on 13 November 2007 (07/Q0603/29) and I wrote the 
subsequent ethics and protocol amendment that was approved in June 2010. Data that I 
collected was combined with that already available within our group. My research 
complied with the Declaration of Helsinki. The ACIT II study was designed to identify the 
clinically significant mechanisms and pathways by which the inflammatory and 
coagulation pathways are activated immediately after major trauma, how they lead to 
clinical coagulopathy and transfusion requirements, as well as produce organ injury, and 
how they affect outcomes in terms of organ failure and death. 
 
2.1 Study design 
 
This was a prospective cohort observational study of 810 trauma patients admitted to the 
Royal London Hospital (RLH) from June 2008 until June 2013. My study followed the 
clinical course of severely injured trauma patients identified on admission to the ED until 
their discharge, death or day 28. Data was combined with those collected by the previous 
research group. Blood samples drawn were analysed using ROTEM and assayed for 
markers of activation of the coagulation and inflammatory systems. Coagulation proteins 
were assayed and subsequently correlated with study participant injuries, their resulting 
physiological disturbances, and their subsequent clinical course and outcome.  
 
2.2 Study participants 
 
The analysis of the trauma service registry provided information on the rate and volume of 
major trauma patients treated at the RLH. On average, there are 1,500 trauma team 
activations per year at the RLH. I extrapolated data from the RLH trauma registry to show 
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that the expected study population would comprise a convenience sample with an injury 
severity distribution of approximately 35% severe, 55% moderate and 7% minor injury 
over the three-year study period. I aimed to recruit severely injured, actively bleeding 
trauma patients who required on going resuscitation with blood products from June 2010 to 
June 2013. These patients were known as “Code Red” patients and form the basis of the 
body of work presented in this thesis. The specific inclusion criteria for Code Red patients 
are detailed below.  
 
Severely injured trauma patients are a challenge to recruit to studies owing to the unplanned 
nature of care, unpredictable work patterns, the emergent nature of treatment and 
complexities in the consent process. This is further complicated by the high early mortality 
rate. To this end, I was present at the hospital between 08:00 to 22:00, five days a week, in 
order to recruit this cohort of patients. I was also present at the hospital on alternate 
weekends for patient recruitment. My contact details were left within the ED department so 
I could be contacted at any time during the first two years. Based on average trauma calls 
within this time frame, it was predicted that a convenience sample of approximately 100 
severely injured Code Red patients would be recruited during the study period. 
 
2.2.1 Inclusion criteria  
 
The following criteria are used by the ED clinical team to determine the need for trauma 
team activation. In order to access the study participants, I carried a bleeper/pager/alert 
device, which enabled my attendance at the trauma team resuscitation while at hospital. If I 
was not on-site at the hospital, a member of the ED team would contact me by long-range 
pager or telephone.  
 
• GCS<14 or RR<10 or <29 or Systolic BP<90. 
• Chest trauma with altered physiology. 
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• Person hit by train. 
• Amputation proximal to wrist or ankle. 
• Occupant ejected from vehicle. 
• Fatality in same vehicle as occupant. 
• Suspected pelvic fracture. 
• Person trapped under vehicle. 
• Suspected open or depressed skull fracture. 
• Fall from >2 metres. 
• Polytrauma with burns. 
• Penetrating trauma (neck to groin or proximal to elbow/knee). 
• Explosions. 
• Industrial accidents. 
 
2.2.2 Exclusion criteria 
 
• Age <16 years. 
• Patients transferred from other hospitals. 
• Patients presenting more than two h after time of injury. 
• Patients who received more than 2,000 ml of intravenous fluids prior to arrival in 
the ED. 
• Patients with burns >5% of their total body surface area. 
• Patients taking anticoagulant medication other than aspirin (<650mg/day). 
• Patients with a known bleeding diathesis. 
• Patients with moderate to severe liver disease (Child’s classification B or C3). 
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2.2.3 Code Red  
 
The most severely injured trauma patients that required ongoing resuscitation were 
deemed Code Red patients by the TTL. This subset of patients had specific inclusion 
criteria and are the focus of this thesis: 
 
• Systolic blood pressure <90 mmHg. 
• Poor response to initial fluid resuscitation. 
• Suspected active bleeding. 
 
2.3 Consent process 
 
This study focuses on the very early post-injury phase, and thus, the majority of severely 
injured trauma patients are either unconscious from a traumatic brain injury or 
haemorrhagic shock, intubated in the pre-hospital phase of their care, or acutely intubated 
in ED. These patients were the core population of my research study as it is these patients 
with severe traumatic injury who will go on to receive a massive blood transfusion. 
Furthermore, patients who are conscious will have just experienced a major 
psychologically disturbing event, be in unfamiliar surroundings, and in varying degrees of 
pain. It is for the above reasons that patients may not be able to comprehend, or it may be 
inappropriate to discuss the details of a complex research study at this point in time. If the 
aforementioned patients were deemed unable to consent for themselves, a professional 
legally authorised representative (PrLAR) was asked to give permission to enrol the patient 
onto the ACIT II study. This is in line with the Mental Capacity Act of 2005 that outlines 
the hierarchy of consent for recruitment of trauma patients to a study. For the first blood 
draw, as part of the trauma team resuscitation, the PrLAR will be the TTL who is 
independent from the research protocol. These PrLARs were either Emergency Medicine 
Consultants or Specialist Registrars and have attended a full brief of the ACIT II study. 
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Their understanding of the study and the consent process has been documented. They 
attended six monthly reviews to ensure that they were kept informed of the research 
progress. If a family member or close friend was available at this point, they could assume 
the role of personal LAR (PeLAR), but, often in the case of trauma, the patient arrives at 
hospital with no next of kin. 
 
Obtaining consent from a patient in the initial phases of trauma evaluation has inherent 
difficulties, and has the ability to seriously compromise patient care. It was for this reason 
that only when patients were conscious and had relatively minor injuries, such that they 
were able to comprehend the research protocol and its implications, informed consent was 
obtained as soon as possible in the ED. A trauma patient can only give informed consent to 
take part in a clinical study if their decision is given freely after they have been informed of 
the nature, significance, implications and risks of the trial. Details of the consent forms and 
patient information sheets are detailed in Appendices 1–6. 
 
In cases where patients remained unidentified, the police and hospital social workers 
continued to assist me in identifying the patient. Daily attempts to locate family members to 
discuss the patient’s condition and enrolment onto the ACIT II study were made. All of 
these attempts were clearly documented in the patient’s medical record notes and in my 
own research consent log database. When a PeLAR was located, all study procedures 
already performed and yet to be completed were explained, and their informed consent for 
continued participation requested. In addition, the patients were provided with the ACIT II 
Protocol v2.0 13 17.06.2010 (Appendix 2) and informed that they have the right to deny 
continued participation at any point in time. The enrolled patient was examined daily to 
determine if and when he/she was able to consent for himself/herself even if surrogate 
consent had already been obtained.  
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While the duration of unconsciousness for trauma patients is extremely very variable (hours 
to weeks), the majority regained consciousness within two to 10 days. At this time, the trial 
and all study procedures—performed and yet to be completed—were explained to the 
patient in detail. As before, patients were offered the opportunity to give informed consent 
to continue participation or to withdraw from the study entirely. 
 
A quarterly report was sent to the LREC regarding the consent process. This report 
included the number of subjects enrolled in the study, the number of subjects for whom 
consent was obtained prior to entry, the number of subjects for whom consent was waived, 
the number of subjects or PeLARs who later refused or agreed to continue in the study, and 
on going study results available. 
 
2.4 Blood collection 
 
Thirty ml of blood was drawn from either the femoral vein or the antecubital fossa for each 
patient enrolled. This baseline sample was the first sample collected within 20 minutes of 
the patient’s arrival in the ED. Subsequently, further follow-up samples of 30 ml were 
obtained at h 24 and 72: these were successively analysed and then banked for future data 
analysis. A flow chart detailing the standard operating procedure (SOP) was made available 
within the ED for ease of reference (Figure 2.1).  
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Figure 2.1. The ACIT II ED sample SOP. Located within the ED.  
 
Those patients that required a blood transfusion had a further 30 ml of blood collected after 
the 4th, 8th and 12th units of PRBC transfusions. This subset of trauma patients is referred 
to as “bleeding” patients. Figure 2.2 outlines the patient journey. 
 
Patient bleeding /severely injured 
(i.e. likely to require ≥4 units within 
next 12 hours) ) 0, 4,8,12U PRBC 
1. Request standard bloods as part of trauma call (FBC, Clotting 
screen, Fibrinogen, U&E, G&S/Crossmatch) 
2. Draw separate 30ml blood for ACIT II research sample 
3. Document time of ACIT II blood sample draw 
Transfer 30ml blood into 5 pre-labelled vacutainers in ACIT II 
trial pack in order (x2 standard/glass blue top, x1 plastic blue 
top (2.7ml), x1 PAXgene, x1 P100) 
ACIT II packs located in ED resus bay 4 
Contact ACIT II researcher (24 hrs) 
 
1. Send off ACIT II vacutainers EXCEPT PLASTIC BLUE 
TOP in ACIT II pack with paperwork to haematology lab ASAP 
2. ROTEM sample to be analysed within 20 minutes 
Patient not bleeding 
1. Request standard bloods as part of trauma call (FBC, Clotting 
screen, Fibrinogen, U&E, G&S/Crossmatch) 
2. Draw separate 20ml blood for ACIT II research sample 
3. Document time of ACIT II blood sample draw 
Transfer 20ml blood into 5 pre-labelled vacutainers in ACIT II 
trial pack in order (x2 standard/glass blue top, x1 plastic blue  
top (2.7ml), x1 PAXgene, x1 P100) 
ACIT II packs located in ED resus bay 4 
1. Send off ACIT II vacutainers EXCEPT PLASTIC BLUE 
TOP in ACIT II pack with paperwork to haematology lab ASAP 
2. Place plastic blue top  pre-labelled vacutainer in rack next to 
RoTEM machine in ED lab 
Trauma team leader to complete 
reverse of red trauma trial 
document and sign informed consent 
section 
ACIT II ED sample standard operating procedure 
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Figure 2.2. Summary of patient experience through the ACIT II study process. Patient 
1: no active bleeding. Patient 2: active bleeding. 
 
At the baseline, all patients had an arterial sample taken for blood gas analysis, including 
the measurement of BD and lactate. A standard trauma panel of blood tests were obtained 
at each point of time for routine clinical use. These included: FBC, PT, aPTT and 
fibrinogen, and U&E. The blood samples required specifically for research use were 
collected in specific vacutainers (Becton Dickinson, Plymouth, UK) (Table 2.1). After 
collection, all samples were processed in the Trauma Clinical Academic Unit (TCAU) 
laboratory and frozen at -80°C within two hours of the blood being drawn.  
 
 
 
 
Patient experience flowchart  
Patient 1 
Conscious on arrival, not actively bleeding 
0* 
 
PLR  
Time from ED arrival 
60-72 
hr* 
  
 
subject 
consent  
24 hr* 
  
Patient 2 
Actively bleeding, ongoing haemorrhage 
0* 
PLR  
60-72 
hr* 
  
24 hr* 
  
4U* 
  
8U* 
  
12U
* 
  
 
subject 
consent 
  
 
LAR 
consent 
  
Clinical course to day 28 
Clinical course to day 28 
*  : Blood sample 
 
? LAR 
consent 
  
ACIT II: Patient flowchart v1.0 10.07.2011 
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Type 
 
Blood volume 
 
Preservative 
 
Intended use 
 
Coagulation 
 
2.7 ml 
 
0.109 M buffered 
sodium citrate 
(3.2%) 
 
ROTEM 
 
Coagulation 
 
2.7 ml 
 
0.109 M buffered 
sodium citrate 
(3.2%) 
Research 
coagulation marker 
assays. 
Inflammatory 
marker assays. 
Genomics. 
 
Proteomics 
(P100) 
 
6.5 ml 
 
Protease Inhibitor 
 
Activated Protein C 
assay. Assays of 
unstable proteases. 
 
RNA (PAXgene) 
 
2.5 ml 
 
RNA stabiliser 
 
RNA analysis. 
 
Table 2.1. Blood sample collection tubes. 
 
Near patient testing was carried out using facilities in the Trauma Sciences Group 
laboratory at the TCAU (Figure 2.3). This laboratory is located within the hospital in close 
proximity to the ED to ensure quick processing of blood samples for patients that need 
ongoing resuscitation with blood component therapy. A research assistant provided help 
with blood sample processing and data capture. During the study period, two other research 
fellows were recruited to increase patient enrolment. To ensure quality control throughout 
the study period, all researchers and assistants performing ROTEM analyses and blood 
processing undertook a period of training with ongoing supervision. During the study 
period, the ACIT II protocol was introduced to two other sites and involved utilising the 
identical inclusion criteria and blood processing techniques as detailed below. These 
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external sites were the John Radcliffe Hospital, Oxford, United Kingdom and Oslo 
University Hospital Ullevaal, Oslo, Norway.  Along side the clinical trials coordinator I 
was responsible for implementation of the ACIT II protocol and auditing the adherence to 
the ACIT II inclusion criteria.  Both of these recruitment sites were equivalent Level 1 
Trauma centres. All study patients across the sites were treated with 24/7 access to damage-
control surgery with anatomic control of hemorrhage and therefore completion of 
transfusion was rapid and typically occurred within the first 2 hours to 3 hours following 
admission.  However due to the lack of permanent, full time research staff resulting in 
recruitment time constraints these sites only contributed to 5% of the total study 
participants (for more details, see Chapters Four Five and Six).  
 
 
 
Figure 2.3. TCAU blood sample processing facilities at the Trauma Sciences Group 
laboratory. 
 
2.4.1 Samplings materials 
 
Throughout the study period, sample tubes and documentation were included in the ACIT 
II trial packs and available in ED clinical trials area. Each study trial pack contained: 
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• Eight sets of vacutainer tubes (hours: 0, 24 and 60–72), labelled with the ACIT II barcode. 
• Sample processing instructions. 
• The flow chart shown in Figure 2.1. 
• Cryotubes for aliquoting of samples, labelled with the ACIT II barcode. 
 
 
 
2.4.2 Coagulation biomarkers 
 
At each time point, the citrated 4.5 ml tubes were centrifuged at 1760g for 10 min in a 
Clinispin horizon 853VES laboratory centrifuge (Woodley Equipment Company Ltd, 
Bolton, UK), located within our TCAU laboratory. The top two thirds of single-spun 
plasma was removed and centrifuged again at 1,760 g for a further 10 min. A 0.5 ml aliquot 
of single-spun plasma was removed after the first centrifugation (i.e. the bottom one third 
of the plasma) and stored in a 0.6 ml Cliklok microcentrifuge tube (Simport, Jencons, UK). 
The remaining single-spun plasma, also known as the “buffy coat”, and the top layer of red 
cells were removed and stored in a 1.5 ml Fisherbrand microcentrifuge tube (Fisher 
Scientific, UK). The top two thirds of double-spun plasma was stored in three 0.5 ml 
aliquots in separate 0.6 ml Cliklok microcentrifuge tubes (Simport, Jencons, UK). All of 
the blood sample aliquots were individually barcoded and stored in grid-labelled cardboard 
cryoboxes at -80°C. Each of the samples were catalogued on an Excel spreadsheet. Figure 
2.4 outlines the blood collection process. 
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Figure 2.4. ACIT II sample processing SOP chart. 
 
2.5 Blood sample analysis 
 
2.5.1 ROTEM analysis 
 
The ROTEM parameters analysed are those detailed in Table 1.2. All of the pipetting steps 
and the mixing of reagents with blood were standardised as per the ROTEM automated 
electronic pipette program. ROTEM analysis was performed at 37°C on three channels 
(INTEM, EXTEM, FIBTEM). The ROTEM Delta machines were located in the TCAU 
laboratory. It was possible to run three samples simultaneously.  
 
The vacutainer containing blood is placed in the heating well for 10 min prior to analysis in 
order to incubate sample at 37°C (Figure 2.5). After 10 mins, four plastic cups and pins 
!
ACIT II sample processing SOP – RLH Trauma Lab 
20ml ACIT II sample (Hour 0, 12, 72) 
(A) Standard citrate sample 
(4.5ml) – process sample 
within 2hr 
Spin sample at 
3400rpm for 10 
mins 
Transfer top 
2/3 (>1.5ml) 
to LP4 tube 
and spin at 
3400rpm for 
10 mins 
Aliquot top 
1.5 ml into 
x3 BLUE 
Eppendorf* 
(top 1ml into 
A1/A2/A3) 
Transfer 
0.5ml of 
remaining 
plasma  to 
YELLOW 
Eppendorf* 
Transfer buffy 
coat and top 
layer of red 
cells to 
GREEN 
Eppendorf* 
(B) Standard citrate 
sample (4.5ml) – process 
sample within 2hr 
Spin sample at 
3400rpm for 10 
mins 
Transfer top 
2/3 (>1.5ml) 
to LP4 tube 
and spin at 
3400rpm for 
10 mins 
Aliquot  top 
1.5ml into x3 
BLUE 
Eppedorf* 
(top 1ml into 
B1/B2/B3) 
Transfer 
0.5ml of 
remaining 
plasma  to 
YELLOW 
Eppendorf* 
Transfer buffy 
coat and top 
layer of red 
cells to 
GREEN 
Eppendorf* 
(C) P100 proteomics 
tube (6.5-8.5ml) – 
process within 2hr 
Spin sample at 
4300rpm for 5 
mins 
Aliquot 0.5ml into 
x5-7 CLEAR 
Eppendorf* 
(D) 
PAXgene 
RNA tube – 
process 
immediatel
y 
Place into 
test tube rack         
(-20°C 
freezer) 
*All samples (Eppendorfs) to be stored in 
cryoboxes at -80°C in trauma lab.   
Hour 0, 24, 72) 
30ml%ACIT%Samples:%0,%24,%72%hr%&%
4,8,12U%PRBC%
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were positioned onto each of the test blocks and rotating pins. The individual ROTEM 
reagents were removed from the fridge for 10 mins prior to use: STAR-TEM (recalcitrant); 
EXTEM (thromboplastin); and INTEM (ellagic acid). The following reagent combinations 
were inserted into the appropriate well followed by 300µl blood for each individual test, 
and were analysed for 60 mins. EXTEM test: 20ng reagent combination; and INTEM test: 
20ng reagent combinations . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. ROTEM detection. A whole blood sample is placed into a cuvette and a 
cylindrical pin is immersed. Between the pin and cuvette, there is a gap of one mm, bridged 
by the blood. The pin is rotated by a spring, moving to the right and the left. As long as the 
blood is liquid, the movement is unrestricted. When blood starts clotting, the clot 
increasingly restricts the rotation of the pin with rising clot firmness. This kinetic is 
mechanically detected and calculated by an integrated computer to the typical curves 
(TEMogram) and numerical parameters. (Taken with permission from ROTEM© 2014 Tem 
International, GmbH.) 
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Precision CT CFT Alpha angle CA5 MCF 
Intra-assay 6 8 1 2 3 
Inter-
instrument 7–13 5–8 2–3 2–3 1–3 
 
Table 2.2. ROTEM repeatability and reproducibility. (Coefficient of variation %. 
Provided by ROTEM GB.) 
 
2.5.2 Definition of coagulopathy 
 
Throughout this thesis, I have defined coagulopathy on the ROTEM as a five-min EXTEM 
clot amplitude (CA) of ≤35 mm (75, 124). It has been previously shown that this definition 
can accurately identify ATC and predicts the need for MT (MT is defined as ≥ 10 units 
PRBC in 24 h) (124). Unless otherwise stated, this definition of ATC has been used.  
 
2.5.3 Sysmex – an automated coagulation analyser 
 
Factors II, V, VII, VIII, IX, X, XI von Willebrand Factor (vWF) antigen 
 
Fresh blood samples were prepared to extract double-spun plasma for analysis (Figure 2.3) 
and PT, PTT and fibrinogen levels (Clauss method) were measured by the laboratory staff 
at the RLH’s central laboratory. The frozen aliquots were thawed using a water bath a 37ºC 
prior to analysis. Normal reference ranges for clotting times and coagulation proteases are 
detailed in Table 2.3. PTr was calculated as observed: PT divided by mean control PT. 
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Parameter Normal range Assay method Intra-assay 
variability 
Inter-assay 
variability 
PT 9.4–12.4 s Clotting 1.3% 2.0% 
INR 0.9–1.1 Clotting 1.3% 2.0% 
aPTT 21–31 s Clotting 4% 4% 
Fibrinogen 1.50–4.5g/L Clauss 5.9% 2.3% 
Factor II 58–155 Clotting by 
multi-dilution 
analysis 
2% 7% 
Factor V 60–150 Clotting by 
multi-dilution 
analysis 
2% 7% 
Factor VII 50–150 Clotting by 
multi-dilution 
analysis 
2% 7% 
Factor VIII 52–153 Clotting by 
multi-dilution 
analysis 
2% 7% 
Factor IX 52–156 Clotting by 
multi-dilution 
analysis 
2% 7% 
Factor X 50–150 Clotting by 
multi-dilution 
analysis 
2% 7% 
Factor XI 50–150 Clotting by 
multi-dilution 
analysis 
2% 7% 
vW:Ag 50–155 Clotting by 
multi-dilution 
analysis 
1.4% 0.9% 
 
Table 2.3. Method of coagulation assays and coagulation laboratory reference ranges. 
 
2.5.4 Procedure for vW:Ag assay 
 
The blood samples are deemed stable for four hours if left undisturbed at room temperature. 
Prior to testing, each of the blood is double-spun (centrifuged at 2500g for 10 min) and the 
plasma removed into a plastic tube and recentrifuged at 2,500g for 10 minutes, to generate 
platelet-poor plasma (<5,000/µl). In instances where testing was delayed for longer than 
four hours from time of collection, centrifuged samples had the plasma layer transferred to 
a plastic tube and flash-frozen at <-80oC. Just prior to testing, the frozen aliquot is rapidly 
	   80	  
thawed at 37oC and testing performed within two hours of thawing. The equipment required 
for analysis is detailed below. 
 
Equipment required: 
 
- Sysmex CS2100i analyser. 
- Sysmex sample racks. 
- Cuvettes. 
- Two ml sample cups 
- Finnpipette 200–1,000µl. 
- Finnpipette tips 200–1,000µl. 
 
Reagents and preparation 
 
Pre-prepared Siemens vWF:Ag kits were available (reference number OPAB03). Each of 
the kits contained: 
 
• Buffer: 4x5 ml bottle of Glycine buffer. Ready for use. Stable for 15 days at 
2–8°C. 
• Reagent diluent: 4x4 ml Glycine diluent.  
• Reagent: 4x2 ml bottles of a suspension of polystyrene micro-particles coated 
with anti-human vWF antibodies.  
 
Procedure 
 
The reagents and control were reconstituted at the same time. The buffer was placed in a 
free position within the reagent ring in the analyser. In this position, the barcode can be 
read and the reagent recognised by the analyser. Next, the contents of one vial of the 
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reagent were added and the sequence started. When the analysis cycle was complete, the 
results of the QC run were checked. If the results were within the acceptable range, the 
patient’s samples were run. However, if the QC was out of range, the assay had to be 
recalibrated.  
 
The test for any patient whose result was less than 15 iu/dl was automatically repeated. The 
sample for any patient whose result was greater than 180 iu/dl was automatically rediluted 
to give a more accurate result. 
 
2.5.5 Procedure for coagulation factors 
 
The blood sample was collected as outlined above. Prior to testing, blood was centrifuged 
at 2000g for 10 min to generate platelet-poor plasma (<10,000/µl). Again, if testing was to 
be delayed for longer than four hours from the time of collection, it was necessary to freeze 
the plasma by transferring the plasma layer to a plastic tube and storing it at <-80oC. Just 
prior to testing, the frozen aliquot is rapidly thawed at 37oC and testing performed within 
two h of thawing. 
 
Equipment required: 
- Sysmex CS2100i analyser. 
- Sysmex sample racks. 
- Sysmex reagent inserts. 
- Two ml sample cups. 
-  Four ml sample cups. 
- Finnpipette 200–1,000µl. 
- Finnpipette tips 200–1,000µl. 
- Finnpipette 1–5 ml. 
- Finnpipette tips 1–5 ml. 
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The reagents and controls were respectively reconstituted as detailed above. Once the 
reagents and control were reconstituted, the required factor deficient plasma was decanted 
into a two ml sample cup (if one reagent bottle was reconstituted) or a four ml sample cup 
(if two reagent bottles were reconstituted). The sample cups were then loaded into analyser 
in four ml reagent inserts with their assigned barcode labels. From the main menu, it was 
possible to select ‘Order’, then ‘Switch Order’ and then ‘Holder QC Order’, depending 
on the order of the samples. Next, the required factor deficient assay for each QC was 
requested and then ‘Start’ and ‘Start Measurement’ was pressed. When the analysis was 
complete, the results of the QC run were rechecked. As stated above, if the results were 
within the acceptable range, the patient’s samples could be run.  
 
2.6 Data collection 
 
At each blood sample time point, heart rate, SBP, respiratory rate, Glasgow coma scale 
(GCS), temperature and the time the blood was drawn were recorded. Patient 
demographics, mechanisms of injury, injury type and severity (ISS) were collated from the 
RLH trauma registry. Each injury was scored and classified according to the AIS to provide 
a composite anatomical ISS (Baker et al., 1974). 
 
Specific outcomes include hospital length of stay (LOS), critical care days and ventilator-
free days. Total intravenous fluid and transfusion requirements from injury to 12 h and 
from 12 h to 24 h were collated. Times of all transfusions (crystalloid fluids, colloids, 
PRBCs, FFP, CRYO, platelet concentrates) in the first 24 h were recorded to calculate ratio 
of blood product replacement.  
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2.7 Statistical analysis 
 
Statistical analysis was performed with GraphPad Prism 4.0 (GraphPad Software Inc., La 
Jolla CA, US) and Microsoft Excel 2010 (Microsoft Inc., Redmond WA, US). Normal 
quantile-quantile plots were used to test for normal distribution. Parametric data are 
expressed as mean ± standard deviation (SD) or 95% confidence intervals. Non-parametric 
data are reported as median (interquartile range). A two-group analysis was performed with 
a two-tailed unequal variance Student’s t test for parametric data and Mann–Whitney U test 
for non-parametric data. ROTEM changes over time were analysed using a two-way 
analysis of variance (ANOVA). Proportions were assessed using Fisher’s exact test and the 
chi-squared test for trend. A p value of 0.05 was chosen to represent statistical significance. 
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CHAPTER THREE 
 
The effect of a major haemorrhage 
protocol at a level 1 trauma centre  
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3.1 Introduction 
 
A growing body of literature points to a paradigm shift from reactionary trauma protocols 
towards more focused, goal-directed MHP.  
 
Death due to traumatic injury is the leading cause of lost life years throughout the world 
(166). Severe haemorrhage accounts for almost 50% of deaths and the majority of these 
occur within the first 24 h of injury (123). MT among severely injured trauma patients is 
not uncommon. Studies have shown that 15% of patients in major trauma centres receive a 
MT and over 25% of these will die, most within six hours of injury (167). Furthermore, 
patients who survive a MT have an increased incidence of sepsis, multi-organ failure, 
longer hospital stays and higher healthcare costs (162, 163).  
 
The concept of MT was originally introduced to highlight the complications that result 
from large volume PRBC infusion—principally, late dilutional coagulopathy (168). 
Traditionally, resuscitation has been initiated with large volumes of crystalloid (ATLS), 
then accompanied by PRBC therapy based on laboratory values and at the discretion of the 
TTL, ED physicians and surgical teams. MTPs, therefore, initially delivered PRBCs and 
provided relatively small volumes of blood component therapy (FFP, PLTs and CRYO) 
only after sufficient units of PRBCs had been transfused to cause a dilutional coagulation 
dysfunction (167, 169). It is for this reason that MTPs may therefore be considered more 
reactionary to large volume blood product replacement and crystalloid therapy (101) in 
comparison to MHPs. The discovery of ATC (34) suggests that this coagulopathy is rapidly 
established after injury and is best treated much earlier in the clinical course (167, 170). 
There is no absolute consensus in the definition of MT, although the general clinical 
population have assigned an arbitrary value of >10 U PRBCs within 24 h. Furthermore, the 
clinical identification of patients who require more than a set number of PRBC units is 
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difficult (167). Additionally, traditional MTPs have been shown to be ineffective in treating 
ATC and reducing blood transfusion requirements (47), as this treatment strategy tackles 
coagulopathy late in the clinical setting, after the patient is stabilised and the acute 
resuscitation complete. It is for these reasons that MT may therefore be an outdated concept 
in the management of trauma haemorrhage. In recent times, newer strategies that directly 
target ATC, such as DCR (39), require protocols that rapidly identify bleeding patients and 
deliver high-dose coagulation therapy. These MHPs must also avoid over-provision, over-
transfusion or waste of blood products, a significant issue with existing transfusion therapy 
in trauma (162, 163).  
 
3.2 Aims  
 
The hypothesis of this study is MHPs improve blood product administration and reduces 
waste compared to traditional MTPs.  
 
Firstly, I aimed to ascertain if an MHP could appropriately identify patients who were 
bleeding and would need a >10 U PRBC transfusion. Second, I wished to determine 
whether the MHP activation criteria could be correctly initiated by the TTL. Third, I 
wanted to ascertain whether there was any improvement in the administration of blood 
components and fourth, if there was a reduction in the waste of blood components. Finally, 
I wished to determine whether there was an improvement in patient outcomes with an 
MHP. I conducted a retrospective one-year before and after the cohort study of all adult 
trauma patients after implementation of an MHP at the RLH. 
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3.3 Methods 
 
3.3.1 Study design  
 
In September 2008, the RLH, a major trauma centre, switched from a standard MTP to a 
newer MHP. The previous MTP was broadly based on the British Committee for Standards 
in Haematology guidelines (Figure 3.1) (81, 84, 171). There were no predefined triggering 
criteria and the MT Clotting Pack (standard MTP) of products could only be requested on 
the instructions of a senior doctor (ED registrar or consultant) who was directly in charge of 
the patient (not the pre-hospital team). Conversely, the new MHP was developed and 
driven by a multidisciplinary team from the RLH that included pre-hospital and emergency 
physicians, trauma surgeons, haematologists and the blood transfusion laboratory (Figure 
3.2). This newer MHP has strict activation criteria and can be initiated by pre-hospital 
teams, by the ED or by the operating room staff. When activated, transfusion begins with 
PRBCs that are held in a blood fridge within the ED, close to the trauma patient. The first 
major haemorrhage pack from the blood bank (Pack A) contains six PRBCs and four FFP 
units. If bleeding persists, a Pack B—containing six PRBCs, four FFP, one pool of platelets 
and two pools of CRYO—is ordered from the blood bank that is located adjacent to the ED. 
Pack B is issued repeatedly until the bleeding is controlled. Antifibrinolytics, recombinant 
factor VIIa, or other procoagulants were not routinely used during the period of study. 
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Figure 3.1. The RLH’s massive transfusion protocol. (Pre-September, 2008.) 
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Figure 3.2. The RLH’s major haemorrhage protocol. (Code Red Policy.) 
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3.3.2 Participants 
 
Two consecutive 12-month time periods before (MTP: September 2007–August 2008) and 
after (MHP: September 2008–August 2009) the new protocol implementation were 
analysed. In order to include all the patients that would potentially receive a MT, patients 
that were transfused greater than 4 U of PRBCs pre- and post implementation of an MHP 
were initially included in this study. Although this chapter is primarily interested in the 
efficacy of the protocols for patients receiving a MT (10 or more units of PRBCs) (101), 
this study included the larger cohort to allow analyses of any effect of the MHP on the 
reduction of PRBC transfusions. 
 
3.3.3 Data collection 
 
Patient information was collected using the RLH trauma registry. Demographic and clinical 
data were collected prospectively, including mechanism of injury, physiological 
observations, ISS, ICU admission and length of stay. Injury severity was defined using the 
ISS (8).  
 
The volume of blood components (PRBCs, PLTs, CRYO and FFP) issued, transfused, 
returned to stock and wasted within the first 24 hours was gathered retrospectively from the 
hospital transfusion database, ED and ICU charts. Wasted blood products were defined as 
those that were issued by the transfusion laboratory and not transfused nor returned to 
stock. MT was defined as receiving 10 or more units of PRBCs in the first 24 h (45). Shock 
was defined as a SBP<90 mmHg. Clinical outcomes were recorded in hospital death, ICU 
and hospital stays.  
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3.3.4 Data analysis 
 
Statistical analysis was performed using GraphPad PRISM v5 (GraphPad Software Inc, San 
Diego, CA, US) and Microsoft Excel 2007 (Microsoft, Inc., Redmond, WA, US). The 
groups were tested for normality using normal quantile–quantile plots. Proportions were 
analysed using the chi-squared test and Students t test for continuous variables. 
 
3.4 Results 
 
In the two-year study period, there were a total of 2,986 adult trauma team activations and 
an 8% increase in overall activity in the second year (Table 3.1). Patients in the MHP group 
were more severely injured, but a similar proportion arrived in shock and received four or 
more units of PRBC transfusions. Overall, 3% (n=) of adult trauma calls received >10 units 
PRBCs in the MTP group and 4% received the same in the MHP group. Patients arriving in 
shock were more likely to receive a MT in the MHP group compared to the MTP group 
(74% vs 43%, p<0.001). Clinical characteristics of the MT patients are detailed in Table 
3.1.  
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September 2007–2008 
 
September 2008–2009 
 
 
P value 
 
Number 1,438 1,548  
Median age 32 (23–45) 30 (22–44) 0.651 
Male 1,183 (82%) 1,290 (83%) 0.852 
Admitted 945 (66%) 1,079 (69%) 0.652 
ISS>15 353 (25%) 430 (30%) 0.432 
SBP<90 mmHg 93 (6%) 80 (5%) 0.762 
    
Transfused>4 U PRBC 100 (8%) 145 (9%) 0.802 
ISS>15 82 (82%) 119 (82%) 1.002 
SBP<90 mmHg 32 (32%) 41 (28%) 0.542 
Median PTr 1.2 (1.1–1.4) 1.2 (1.1–1.3) 0.432 
PTr>1.2 52 (52) 83 (57) 0.482 
Hospital LOS 17 (38–64) 7 (16–29)*** 0.00061 
ICU LOS 9 (1–19) 5 (1–15) 0.601 
% Admitted to ICU 67 (67%) 84 (58%) 0.192 
 
Table 3.1. Clinical characteristics of all trauma patients. 
Clinical characteristics of all trauma patients from September 2007 to September 2009. 
Values are given as numbers (%) or medians (interquartile range). SBP: Systolic Blood 
Pressure; ISS: Injury Severity Score; PTr: Prothrombin ratio; PRBCs: Packed Red Cells; 
FFP: Fresh Frozen Plasma; PLT: Platelets; CRYO: Cryoprecipitate; LOS: Length of Stay; 
* p<0.05. ** p<0.01, ***p<0.001. 1:Students T Test. 2:Chi-squared test/Fisher’s exact test. 
 
Next, I examined the efficiency of the activation criteria in identifying those patients who 
would receive a MT (Table 3.2). When analysing the number of the patients who were 
transfused four or more units of PRBCs, 50 patients (54%) met the MHP activation criteria 
and went on to received ≥10 U PRBCs. Twenty-five patients who, in spite of not meeting 
the MHP criteria (48% of 52), went on to receive a MT. On average, patients that met the 
activation criteria went on to receive nine PRBC units vs five PRBC units for those that did 
not fulfil the criteria for activation (p<0.01). The MHP criteria had 67% sensitivity and 
33% specificity for predicting the need for ≥10 units PRBCs. 
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  Transfused 4–9 U PRBC  Transfused 10+ U PRBC 
 
Met MHP criteria 43 50 
Did not meet the MHP 
criteria 27 25 
 
Table 3.2. Sensitivity and specificity of MHPs. 
 
I next examined whether the MHP was correctly initiated by the TTLs according to the 
activation criteria (Table 3.3). Seventy-five patients (81%) who met the criteria had the 
MHP correctly activated. On average, these 75 patients were transfused nine PRBCs and 
the18 that were not activated (but met MHP criteria) received an average of eight PRBCs. 
The team leaders correctly identified 47 (90%) of the patients that did not meet the MHP 
criteria. In five patients (10%), the MHP was activated despite not fulfilling the criteria and 
none of these went on to require a MT (Table 3.4). 
  
 
 Met MHP criteria 
Did not meet MHP 
criteria 
Activated by TTL 75 5 
Not activated by TTL 18 47 
 
Table 3.3. TTL’s ability to correctly initiate MHP. 
 
 
To determine whether there was an improvement in blood product administration, the 
volume of blood components transfused per person was analysed (Figure 3.3). After 
implementation, there was a two-unit average reduction in PRBC transfusion per patient. 
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MHP patients received an improved ratio of both FFP:PRBC and CRYO:PRBC (Table 
3.4). There was a significant increase in FFP transfused for the MHP cohort with an 
average ratio of 1:2 vs 1:3 for MTP patients (p<0.01). Similarly, the CRYO:PRBC ratio 
increased from 1:10 to 1:7 (p<0.05) in the MHP cohort. Fewer patients received inadequate 
doses of FFP, with the number of patients that were transfused with an FFP:PRBC ratio of 
1:4 was reduced from 20% to 3% (Figure 3.4, p<0.01). The delivery of platelets also 
improved, with a 14% increase from 72% to 86% in transfusion after the implementation of 
the MHP. 
 
 
 
 
 
Figure 3.3. The effect of a MHP on blood component delivery. Values are mean ± SEM. 
Although the transfusion of blood components was similar between the two groups, there 
was a reduction of 2.2 units of PRBCs and 1.2 pools of FFP transfused. 
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Figure 3.4. Effect of a MHP on FFP delivery. The change in the percentage of patients 
receiving differing ratios of FFP:PRBCs. The proportion of patients that received 
FFP:PRBCs of 1:4 was reduced by 17% (p<0.01). There is a trend towards transfusing 
higher ratios of FFP:PRBCs post introduction of the MHP, with over 50% of patients 
receiving a ratio greater than 1:2. 
 
 
I analysed the difference in the waste of blood products after the implementation of an 
MHP. This data showed a 1% decrease in the total waste of FFP (Figure 3.4). Total PLT 
waste reduced (Figure 3.5) was from 16 to 3 pools (p<0.01), with no real change in FFP 
wastage. The greatest reduction in waste per person was evident in PLT transfusion 
(Figure 3.6). The waste of PLT decreased from 0.4 pools per person to 0.05 pools per 
person (p<0.01). Although CRYO waste increased from 0.45 pools to 0.66 per person 
(p=0.44), this only represented 19 pools out of a total of 199 issued (9.5%). 
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Figure 3.5. Effect of a MHP on blood component waste. This refers to the total amount 
of blood component wasted as a percentage of that which is issued by the laboratory. Post 
implementation, there was a 1% reduction in FFP waste and a 12% reduction (p<0.01) in 
PLT waste.  
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Figure 3.6. Effect of a MHP on blood component waste per person. Values are mean ± 
SEM showing blood component waste per person. Platelets showed the greatest reduction 
in waste (0.4 pools pp to 0.05 pools pp, p<0.01). 
 
 
Finally, I wished to determine if there was a difference in outcomes between these two 
groups. Although there was a similar mortality between the two groups, there was a 
significant decrease in the median length of stay of survivors from 54 days to 26 days 
(p<0.05). 
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Patients MTP MHP P-value 
n 40 (3%) 56 (4%) 0.70042 
Median age 37 34 0.32991 
Male 30 (75%) 44 (79%) 0.61452 
    
Injuries    
Median ISS 32 (9–54) 29 (22–41) 0.72112 
ISS>15 38 (95%) 51 (91%) 0.26762 
Blunt injury 30 (75%) 44 (79%) 0.50152 
Median SBP mmHg 103 (81–122) 101.5 (78–120) 0.89111 
Per cent with SBP<90 mmHg 48% 55% 0.98092 
Median PTr 1.3 (1.2–1.5) 1.3(1.2–1.5) 0.29261 
% PTr>1.2 74% 80% 0.31342 
    
Blood components    
Total PRBCs issued 1119 1371  
Total PRBCs transfused 802 (72%) 999 (73%) 0.50722 
Total PRBCs RTS 309 (27%) 358 (26%) 0.40002 
Total PRBCs wasted 8 (1%) 14 (1%) 0.41662 
PRBC transfused per patient 20.1 17.8  
Total FFP issued 404 628  
Total FFP transfused 325 (80%) 520 (83%) 0.17612 
Total FFP RTS 25 (6%) 31 (5%) 0.38632 
Total FFP wasted 54 (14%) 77 (12%) 0.60272 
FFP transfused per patient 8 9  
FFP:PRBCs 1:3 1:2** 0.0031 
Total PLT issued 116 128  
Total PLT transfused 84 (72%) 111 (87%)** 0.00532 
Total PLT RTS 16 (14%) 14 (11%) 0.49752 
Total PLT wasted 16 (14%) 3 (2%)*** 0.00092 
PLT transfused per patient 2 2  
PLTs:PRBCs 1:12 1:10 0.14271 
Total CRYO issued 118 199  
Total CRYO transfused 96 (82%) 156 (78%) 0.58272 
Total CRYO RTS 4 (3%) 6 (4%) 0.70042 
Total CRYO wasted 18 (15%) 37 (18%) 0.44802 
CRYO transfused per patient 2.4 2.8  
CRYO:PRBCs 1:10 1:7* 0.01331 
    
Outcomes    
Admission to the ICU 25 (63%) 37 (66%) 0.65752 
Median hospital LOS 54 (33–98) 26 (6–74)* 0.03882 
Mortality 22 (55%) 32 (57%) 0.6687 
 
Table 3.4. Demographics, injury characteristics and 24-h transfusion requirements in patients 
receiving >10 PRBCs. Values are given as number (%) or median (interquartile range). SBP: 
Systolic Blood Pressure; ISS: Injury Severity Score; PTr: Prothrombin ratio; PRBCs: Packed Red 
Blood Cells; FFP: Fresh Frozen Plasma; PLT: Platelets; Cryo: Cryoprecipitate; LOS: Length of 
Stay; RTS: Returned to Stock; Blood component transfused or wasted given as a percentage of that 
which is issued. *p<0.05, **p<0.01, ***p<0.001. 1:Students T Test. 2:Chi-squared Test. Ratios of 
blood products are based on averages transfused per patient. 
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3.5 Discussion 
 
This chapter researched the effect of the implementation of an MHP at a major trauma 
centre. The introduction of the MHP resulted in an improvement in blood product delivery, 
transfusion practice, reduction in waste and an improvement in outcomes compared to the 
previous traditional dilution-targeted MTP.  
 
The priorities of shock resuscitation in the past were primarily to support the circulating 
volume and to reverse metabolic derangements associated with hypovolemic shock (39). 
Traditionally, this form of resuscitation was initiated with copious volumes of crystalloid 
that was administered early, later accompanied by PRBC transfusions. Other blood 
products such as FFP, platelets and CRYO were supplemented based on arbitrary 
laboratory values and at the discretion of the trauma teams. Coagulopathy was viewed as a 
secondary by-product of this volume resuscitation, haemodilution, and concurrent 
hypothermia. In traditional MTPs, clotting therapy was therefore delivered late in the 
clinical course and treatment further delayed by laboratory-based diagnostics (75) and 
blood banking logistics. However, evidence shows that these MTPs have minimally effect 
in trauma haemorrhage (123, 167). DCR addresses the entire lethal triad and, in particular, 
targets ATC (39). In response, transfusion and trauma services have designed MHPs along 
the principles of early identification of bleeding patients, anticipation of coagulopathy and 
the immediate empiric treatment with high-dose blood component therapy.  
 
Trauma patients who met the MHP activation criteria received almost twice as many PRBC 
units than those that did not (nine vs five units, in this study of all patients who received 
four or more PRBCs). The sensitivity of the MHP to correctly identify those patients that 
would go on to require a MT was above 60% and similar to other published series (172, 
173). Our group has previously shown that MT cannot be reliably predicted from the 
clinical variables available on admission (167). However, the goal of the MHP is not to 
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predict MT but rather to predict patients who are actively bleeding so that coagulopathy 
treatment can be initiated. Severely injured patients who receive four to nine PRBC units 
still have over twice the mortality of those receiving less (167), and over 30% of these were 
coagulopathic on arrival (124). Protocols that aim to identify only those patients who will 
require a MT will result in delays in identifying life-threatening bleeding, delayed 
intervention, and worse outcomes (25). 
 
The MHP anticipates coagulopathy and does not require coagulation tests for the provision 
of blood component therapy. Ideally, FFP, platelets and CRYO should only be given to 
patients who are coagulopathic and should be specifically guided by the nature of the 
clotting derangement. Traditional laboratory tests of coagulation take around 60 min to be 
available to clinicians and point-of-care INR devices may under-read in trauma 
haemorrhage (75). Thromboelastometry can identify coagulopathic patients within five 
min, but still requires a blood sample and subsequent provision of blood components (75). 
It is likely, therefore, that all MHPs will require empiric unguided component therapy in 
the immediate phases of care, regardless of the availability of newer point-of-care 
diagnostics.  
 
The MHP provided higher ratios of both FFP and CRYO to the trauma patients. The 
previous MTP also delivered a relatively high average FFP:PRBC ratio. However, 20% of 
MTP patients received a FFP:PRBC ratio of 1:4 in the previous MTP, whereas this low 
ratio provision was almost eliminated by the current MHP. This much narrower dose-range 
for FFP provision is important in assuring that patients receive the correct therapy. A 
contemporary aphorism is that protocols should aim for 1:1 FFP:PRBC ratios so that the 
patients will receive at least a 1:2 ratio. Despite the complexities of the trauma resuscitation 
environment, trauma pathways should deliver the correct dose of a therapeutic agent to 
patients. Over a 10 PRBC unit “window”, the MHP aimed to deliver a FFP:PRBC ratio of 
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1:2. Over 50% of patients received this ratio and there was a narrow range, with 96% of 
patients receiving between 1:3 and 1:1 ratios. 
 
The MHP reduced waste despite the increased provision of blood products. There is little 
research in terms of blood component waste in the current literature and very few studies of 
MTPs address the issue of waste. The most significant reduction in waste was in the 
transfusion of platelets, with only three pools wasted in the 12 months of the MHP being 
implemented. Slightly fewer FFP were wasted despite nearly 200 additional units being 
transfused in the MHP year. There was a modest 3% increase in CRYO waste, which may 
reflect the increased doses of CRYO administered by the MHP, but correcting this only 
requires scrutiny and team education. Reduction in waste of blood products rests with team 
training and highlighting the importance of preservation of blood stocks. MHPs that aim to 
deliver high volumes of these products to patients must ensure the responsible use of these 
precious resources. 
  
Massively transfused patients in the MHP group had a 50% reduction in their total hospital 
stay compared to the MTP patients. Although this is a historic comparison and there were 
other improvements in service delivery over this time, this is still a dramatic reduction in 
overall hospital stay. It is possible that improved management of trauma haemorrhage with 
DCR and the MHP resulted in lower morbidity for these patients, although this data was 
not collected in this study. I did not see any significant difference in mortality between the 
two cohorts. The original MTP already delivered a relatively high FFP:PRBC ratio and so 
would not reflect the benefit of changing to these doses of FFP, as seen in previous studies 
(160). I also did not see a reduction in the proportion of patients who received a MT or in 
the average amount of blood products transfused per patient. This finding is consistent with 
previous studies and it is not entirely clear how increasing FFP or other blood product 
transfusions lead to improvements in outcomes in these patients. Overall, the MHP was 
associated with equivalent or improved outcomes for these severely injured patients.  
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3.6 Limitations 
 
There are a number of limitations to my study. Firstly, it is a retrospective review of trauma 
registry data and compares the MHP with historic controls. Certain assumptions were made 
when retrospectively ascertaining if the MHP was appropriately activated, especially 
pertaining to the criterion ‘poor response to fluid therapy’, which often had to be abstracted 
from the observation charts. Second, the time of first blood product administration was not 
recorded in the MTP group and therefore I was unable to determine if the blood 
components were provided in a more timely fashion compared to the MTP. I also did not 
notice any reported changes in the coagulation parameters between the two protocols. 
Although admission coagulation tests were available on all patients, there was no standard 
time point at which a coagulation test was ordered at the end of the transfusion and thus any 
improvements in the speed or effectiveness of normalisation of the clotting function could 
not be analysed. Furthermore, the MHP presented in Figure 3.1 has since been updated to 
include other developments, such as the use of tranexamic acid (151, 174).  Further studies 
are planned to assess the impact of this on blood product utilisation and the outcomes.   
Finally definition of Massive Transfusion was set as those receiving greater than 10u PRBC 
transfusion within 24hrs (101) at the time of the study this was the conventional definition 
for MT. However this criteria has subsequently been revised to a more acute definition of at 
least 5 units in 4 hours (175).  
 
3.7 Conclusion 
 
Major haemorrhage protocols are more suited to the current DCR paradigm and offer a 
number of benefits over tradition protocols targeting MT. MHPs can effectively identify 
bleeding patients who are likely to develop coagulopathy and benefit from blood 
component therapy. In conclusion, when combined with a broad staff education 
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programme, they can significantly improve blood product administration, patient outcomes 
and reduce waste in trauma haemorrhage. Further work on the effect of MHPs on the 
coagulation profile during trauma haemorrhage is warranted. 
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CHAPTER FOUR 
 
Characterisation of damage control 
resuscitation use in trauma 
haemorrhage 
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4.1 Introduction 
 
Uncontrolled haemorrhage remains a leading cause of death in trauma. These severely 
injured, bleeding trauma patients are delivered to the ED in hypovolaemic shock and 
suffering from life-threatening TIC. Despite improvements in our understanding of TIC and 
the adoption of the principles of DCR (39, 130, 176), the mortality in such patients remains 
high. These strategies aim to improve outcome by promoting haemostasis through the early 
correction of coagulopathy (134). Numerous civilian and military retrospective studies have 
shown that the presence of coagulopathy on presentation is associated with worse outcomes 
in trauma patients with severe blood loss (101, 149). Permissive hypotension and blood 
component therapy is the mainstay of DCR, with high-dose plasma and platelet 
transfusions recommended alongside red cell transfusions during the acute haemorrhagic 
phase. However, the true incidence and evolution of coagulopathy in the acute bleeding 
phase remains unknown.  
 
Blood components therapy such as platelets (PLT), FFP and CRYO were combined in 
MHPs (149). These MHPs were designed to identify patients who are actively bleeding, in 
need of a massive blood transfusion and improve blood component delivery (100), but 
there is little evidence showing their effect on the coagulation profile during acute active 
haemorrhage (166). Coagulopathy and hypoperfusion have been shown to correct with 
DCR, but only at the end of damage control surgery or after admission to critical care, 
presumably after haemorrhage control has been achieved (177).  
 
4.2 Aims  
 
The overall hypothesis of this study proposes that TIC deteriorates during acute trauma 
haemorrhage.  
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The objective of this study is to describe the effect of DCR in the acute phase of trauma 
haemorrhage.  
 
Specific aims are to characterise the incidence and severity of TIC during the acute phase 
of DCR; determine whether DCR achieved its stated aims of correction of coagulopathy 
and restoration of perfusion during trauma haemorrhage; and characterise lactate clearance 
during haemorrhage. 
 
I conducted a prospective cohort study of bleeding trauma patients presenting directly to 
three major trauma centres. 
 
4.3 Methods 
 
4.3.1 Study design  
 
All adult trauma patients who met the local criteria for trauma team activation were eligible 
for enrolment to the prospective ACIT II observational study (outlined in Chapter Two).  
 
The ACIT II study was being conducted at three trauma centres that are members of the 
International Trauma Research Network (INTRN). These study centres are the RLH, 
Oxford and Oslo. Subjects were enrolled between June 2008 and June 2013. At this time, 
the three active study sites had data-sharing protocols and recruitment was limited to times 
when research personnel were present (08:00 to 22:00). I was the PhD Centre Lead for the 
ACIT II study and was responsible for ethical approval, data collection, analysis and 
presentation of the findings, and updating the protocol. Nine-five per cent of the data 
collected was from the RLH. 
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The ACIT II protocol blood samples were drawn immediately as the patient arrived at the 
ED and processed within 20 minutes. Patients that continued to bleed had further samples 
drawn after four, eight and 12 PRBC units are administered during the acute bleeding 
phase.  
 
4.3.2 Patient selection 
 
All adult trauma patients requiring trauma team activation were eligible for inclusion. 
Criteria for trauma team activation were similar across all three sites and included: 
abnormal physiology (Glasgow Coma Score<14, respiratory rate<10 or <29, SBP<90); 
anatomical injury (chest trauma with any altered physiology, suspected pelvic fracture, 
suspected open or depressed skull fracture, amputation proximal to the wrist or ankle, 
penetrating trauma); and high-energy mechanism of injury (person hit by train, person 
ejected from vehicle or fatality in same vehicle as occupant, person trapped under vehicle, 
fall from less than two metres, explosions, industrial accidents). 
 
Exclusion criteria included arrival in the ED more than two h following injury; transfer 
from another hospital, pregnancy and burns greater than 5% of total body surface area. 
Patients were retrospectively excluded if they declined to give consent for the research 
study at any point in time; if they were receiving anticoagulant medications (not including 
aspirin); and if they had moderate or severe hepatic impairment or a known bleeding 
diathesis.  
 
This study reports on the subset of ACIT II patients that were bleeding and received four or 
more units of PRBCs during the acute haemorrhage phase.  
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The majority of included patients were unable to provide informed consent at the time of 
enrolment, and consent was therefore obtained from the TTL (a senior ED physician 
independent to the ACIT II research study) who acted as the patient’s legally authorised 
representative (PrLAR). Written consent from the patient or next of kin (PeLAR) was 
obtained as soon after enrolment as appropriate. The study was reviewed and approved by 
the respective National Research Ethics Committees.  
 
4.3.3 MHPs 
 
All hospitals adhered to the principles of DCR: early damage-control surgery and  
haemostatic resuscitation. We have defined haemostatic resuscitation as: permissive 
hypotension; limited crystalloid or colloid administration; avoidance of hypothermia, 
targeting TIC through high-dose blood product administration in the form of FFP, PLTs 
and CRYO and administration of anti-fibrinolytic agent. (101) 
 
The strict activation criteria for the MHP included signs such as when a patient presented 
with a SBP of less than 90 mmHg, demonstrated a poor response to initial fluid 
resuscitation and/or had suspected active haemorrhage (Chapter 3, Figure 3.2). The MHP 
was initiated by pre-hospital teams, or by ED staff. The majority of MHP activations are 
initiated in the pre-hospital phase by emergency physicians on scene prior to the arrival of 
the patient in the ED. When activated, transfusion begins with PRBCs that are held in a 
blood fridge within the ED (immediate availability). For London and Oxford, target ratios 
for FFP:PRBCs are 2:3 with platelets and CRYO provided after every six units of PRBCs 
transfused. Delivery is in cooler boxes: pack A contains four units of FFP, while pack B 
and all subsequent packs contain six units of PRBCs, two pools of CRYO and one pool of 
platelets. In Oslo, FFP:PRBCs is provided in a 1:1 ratio (Octaplas) with platelets issued 
with every five units of PRBCs, and monitored according to conventional coagulation tests.  
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In all centres, resuscitation continues with these multi-component packs until bleeding is 
controlled.  
 
4.3.4 Sampling technique 
 
An initial 30 mm research blood sample was drawn along with the standard trauma 
laboratory blood tests (peripheral blood count, clotting screen, and arterial blood gas) 
within 20 minutes of the patient’s arrival at the ED.  
 
For those patients with acute active bleeding, which required immediate transfusion as part 
of DCR, further blood samples were drawn after the 4th, 8th and 12th unit of PRBCs were 
transfused and on days one and three of admission. A summary of the SOP for ACIT II 
study is shown in Flowchart 1, Chapter Two. 
 
4.3.5 Sample analysis 
 
ROTEM samples were processed using a ROTEM delta instrument (TEM International 
GmbH, Munich, Germany) at 37°C. The methodology and the parameters of ROTEM have 
been described previously in Chapter Two (178). Two separate ROTEM assays were 
performed for each trauma patient. The first, EXTEM, measured tissue factor-initiated 
clotting and the second is FIBTEM with the addition of cytochalasin D, a platelet inhibitor. 
All pipetting steps and mixing of the reagents with samples were performed with an 
automated electronic pipette program. Clotting time, clot amplitude at five minutes (CA5), 
alpha angle were reported for each sample analysed. 
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4.3.6 Fibrinogen level analysis 
 
Fresh blood samples were prepared to extract double-spun plasma for analysis, and PT, 
PTT and fibrinogen levels (Clauss method) were measured by the laboratory staff in the 
central laboratory. Frozen aliquots were thawed using a water bath at 37˚C prior to analysis, 
which used the Sysmex CS2100i automated coagulation analyser. PTr was calculated as 
observed: PT divided by mean control PT.  
 
4.3.7 Definitions  
 
Coagulopathy has been defined on the ROTEM as a five-min EXTEM clot amplitude (CA) 
less than or equal to 35 ml (14). This has been shown to identify ATC and predicts 
transfusion requirements (75). From the original 300 patient cohort, I classified abnormal 
ROTEM parameters as +/- 1 SD from normal (PTr<1.2): CT>94 seconds, CFT>171 
seconds, MCF<54mm, alpha angle<65 degrees. Samples with a prolonged PT ratio (>1.2) 
were also analysed, as this has previously been shown to be a clinically relevant diagnostic 
threshold for this measure (65).  
 
Minor injury was defined as any patient who had an ISS (8) less than or equal to four. This 
cohort of the ACIT II study were used as a baseline comparator, as previously described 
(154). A lactate level of ≥5.0 mmol/l was selected to indicate patients with severe 
haemorrhage (179). I defined normalisation of lactate as levels dropping below an upper 
limit of normal, i.e. 2.0 mEq/l (179, 180). Completion of PRBC transfusions was used as a 
surrogate for haemorrhage control.  
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 4.3.8 Data collection 
 
Data were based prospectively on patient demographics, time of injury, mechanism (blunt 
or penetrating), pre-hospital fluid administration, time of arrival at the ED, baseline vital 
signs and total transfusion requirements in the first 12 h of admission. The amount of FFP, 
PLT and CRYO was recorded after each four units of PRBCs transfused. Ratios of 
FFP:PRBC, PLT:PRBC and CRYO:PRBC were then calculated for each interval. In 
addition, the total dose of fibrinogen was calculated using the estimated constituent values 
above. Coagulation changes for each interval after four units of PRBCs were calculated as: 
[post-interval sample value - pre-interval sample value].  
 
4.3.9 Statistical analysis 
 
Statistical analysis was performed using GraphPad PRISM v5 (GraphPad Software Inc, San 
Diego, CA, US) and Microsoft Excel 2007 (Microsoft, Inc., Redmond, WA, US). Normal 
quantile–quantile plots were used to test for normal distribution. Parametric data are 
expressed as mean ± 95% confidence intervals (CI). Non-parametric data are given as 
median (interquartile range, IQR). A p value of <0·05 was chosen to represent statistical 
significance throughout. 
 
4.4 Results 
 
There were a total of 810 patients included in the ACIT II study over the study period. 
Forty-nine patients were retrospectively excluded from the analysis, 28 after personal or 
legal representative consent was declined following enrolment, and 21 for retrospective 
exclusion criteria. Of the remaining 761 subjects, 106 were transfused with four or more 
PRBCs. Clinical characteristics, admission physiology, and laboratory parameters are 
detailed in Table 4.1. The majority of the bleeding patients were severely injured (94% 
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ISS>15) and had sustained blunt injury (87%). Over 40% were coagulopathic on admission 
by CA5 or PTr. On average, patients required eight units of PRBCs with 38% requiring a 
MT of 10 or more PRBCs. Early deaths during the bleeding intervals were PRBC 5–8 U: 
10 (10%); PRBC 9–12 U: 6 (6%); PRBC 12 U+ to h 12: 6 (6%). The average FFP:PRBC 
ratio between intervals was PRBCs 0–4 U: 0.5; PRBCs 5–8 U: 0.9, PRBCs 9–12 U: 0.7 and 
at h 12: 0.7.  
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Patients  
 
Minor Injury 
 
Bleeding 
Number 139 106 
Age 33 (22–42) 44 (30–60)* 
Male 116 (83%) 75 (76%) 
 
Injury 
  
ISS 1 (1–4) 34 (25–41)* 
ISS>15 0 99 (94%) 
Blunt injury 100 (72%) 92 (87%)* 
 
Admission parameters 
  
SBP<90 mmHg 5 (4%) 41 (46%)* 
Base deficit>6 mEq/L 7 (5%) 68 (67%)* 
PT (secs) 10.9 (10.5–11.3) 12.9 (11.7–14.6)* 
PTr>1.2 2 (2%) 40 (40%)* 
CA5 ≤35 mm 12 (9%) 41 (43%)* 
 
Fluid requirements (first 12 h) 
  
Pre-hospital PRBCs (units) 0 (0) 0 (1–6)* 
Pre-hospital Crystalloid (ml) 0 (0–100) 500 (100–2000)* 
Crystalloid (ml) 0 (0–800) 2,500 (1300–4000)* 
Colloid (ml) 0 (0) 875 (0–1688)* 
PRBC (units) 0 (0) 8 (5–13)* 
PRBC ≥10units 0 (0) 40 (38%)* 
FFP (units) 0 (0) 6 (4–8)* 
Platelet (units) 0 (0) 1 (1–2)* 
Cryoprecipitate (units) 0 (0) 2 (0–2)* 
 
Damage Control Procedure 
  
Operating Room - 61 (70%) 
Interventional Radiology (IR) - 6 (7%) 
Combined OR/IR - 4 (5%) 
 
Table 4.1. Patient demographics and clinical characteristics. Clinical characteristics of 
patients (n=106). Minor injury refers to those patients with an ISS<4 from the ACIT II 
cohort. Values are given as median (interquartile range, IQR). *p<0.05. 
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Forty-three per cent (n=41) of bleeding patients were coagulopathic upon admission (Table 
4.1). This proportion rose to 58% after four PRBC units and 81% after eight units (Figure 
4.1A). Similarly, more patients developed a prolonged PTr during haemorrhage despite 
DCR and high plasma ratios (average six unit of FFP, two pools of CRYO and one pool of 
PLTs) (Figure 4.1B). The bleeding cohort had a significantly longer CT on admission 
(p<0.01) as compared to the minor injury cohort (mean CT 88s vs 64s) as they continued to 
bleed. Patients who continued to bleed further had a gradual lengthening of their CT. The 
mean rate of clot formation also steadily deteriorated as patients bled and by 12 U, I found 
a 15% reduction in the alpha angle (p<0.01). Clot strength (as measured by MCF EXTEM) 
was also reduced on admission in bleeding patients (p<0.001). MCF continued to fall 
during DCR where, by the 12 U PRBCs, it had deteriorated by a further 19% (p<0.001, 
Figure 4.1E). The fibrinogen contribution to clot strength as measured by MCF FIBTEM 
also worsened in bleeding patients. Clot strength continued to worsen to 9 mm (Figure 
4.1F) by the 12 U PRBCs, although this did not reach statistical significance. All functional 
clotting parameters deteriorated during haemorrhage, with the most significant changes 
seen in clot generation and clot firmness (Figures 4.1C–F). DCR protocols did not correct 
or improve TIC during the acute active haemorrhage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   115	  
Figure 4.1. The evolution of TIC during haemorrhage. 
 
 
Figure 4.1A. 
 
 
Figure 4.1B. 
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Figure 4.1C. 
 
 
 
 
 
 
Figure 4.1D. 
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Figure 4.1E. 
 
 
 
 
Figure 4.1F. 
 
Figure 4.1A–F. The evolution of TIC during haemorrhage. Bars are mean with 95% CI. 
+ Signifies comparison of admission vs minor injury. Minor injury refers to those patients 
with an ISS<4 from the ACIT II cohort. *p<0.05 Signifies a comparison to admission only. 
Minor injury values and upper/lower threshold for normal (---) ROTEM values for 
reference. A: Incidence of coagulopathy (CA5<35) during trauma haemorrhage. B: 
Proportion of patients with PT(r)>1.2 during trauma haemorrhage. C: Mean CT on 
EXTEM. D: Mean alpha angle on EXTEM. E: Mean MCF on EXTEM. F: Mean MCF on 
FIBTEM. 
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The average clot amplitude values remained below the diagnostic threshold for 
coagulopathy (CA5≤35mm) throughout the bleeding episode (Figures 4.2A–C) with only 
partial correction evident on day one. During trauma haemorrhage, there was profound 
variability in individual responses to DCR (Figure 4.2D). Deterioration in maximum clot 
firmness was also observed during ongoing bleeding (Figures 4.3A–C). In the highest 
transfusion group, MCF deteriorated 15% during DCR and only improved on day one 
(PRBC 12+ U: Time 0, MCF 46 mm vs Day one MCF 59mm, p<0.05) (Figure 4.3C). 
Again, there was significant variability to DCR (Figure 4.3D). Prolonged CT (>94 seconds) 
was observed in 33 patients (31%) despite DCR. This parameter also did not correct during 
ongoing bleeding (Figures 4A–D), with correction only observed on day one. A total of 65 
patients (61%) had an abnormally flattened alpha angle <64° (normal range 63–81°) and, 
similar to the clot strength parameters, the angle deteriorated throughout the bleeding 
episode. Time 0: alpha 59°, PRBC 4–12 U: alpha 54°–55°, day one: alpha 70° (p<0.05). 
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Figure 4.2. Change in CA5 (mm) during bleeding episode in coagulopathic patients 
(CA<35 mm) stratified by transfusion requirements. 
 
 
 
 
Figure 4.2A. 
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Figure 4.2C. 
 
 
 
 
 
Figure 4.2D. 
Figure 4.2A–D. Change in CA5 (mm) during bleeding episode in coagulopathic 
patients (CA5 < 35 mm) stratified by transfusion requirements. The dotted line is the 
diagnostic threshold for ATC (CA5 < 35 mm). A: Patients receiving 4 U to 7 U of PRBCs. 
Time 0: CA5, 35 mm vs day one: CA5, 39 mm (p < 0.05). B: Patients receiving 8 U to 11 U 
of PRBCs. Time 0: CA5, 33 mm vs day one: CA5, 32 mm (p = 0.78). C: Patients receiving 
12 U or more PRBCs. Time 0: CA5, 27 mm vs day one: CA5, 39 mm (p < 0.05). D: 
Individual responses in all patients receiving four or more units of PRBCs.   
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Figure 4.3. Change in MCF (mm) during bleeding episode in coagulopathic patients 
(MCF < 54 mm) stratified by transfusion requirements. 
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Figure 4.3A–D. Change in MCF (mm) during bleeding episode in coagulopathic 
patients (MCF < 54 mm) stratified by transfusion requirements. The dotted line is the 
diagnostic threshold for ATC (MCF < 54 mm). A: Patients receiving 4 U to 7 U of PRBCs. 
Time 0: MCF, 55 mm vs day one: MCF, 58 mm (insignificant). B: Patients receiving 8 U to 
11 U of PRBCs. Time 0: MCF, 51 mm vs day one: MCF, 53 mm (insignificant). C: Patients 
receiving 12 U or more PRBCs. Time 0: MCF, 46 mm vs day one: MCF, 59 mm (p < 0.05). 
D: Individual responses in all patients receiving four or more units of PRBCs.  
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Figure 4.4. Change in CT (secs) during bleeding episode in coagulopathic patients (CT 
> 94 secs) stratified by transfusion requirements. 
 
Figure 4.4A. 
 
 
Figure 4.4B. 
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Figure 4.4C. 
 
Figure 4.4D. 
Figure 4.4A–D. Change in CT (secs) during bleeding episode in coagulopathic patients 
(CT > 94 secs) stratified by transfusion requirements. The dotted line is diagnostic 
threshold for ATC (CT  94 seconds). A, Patients receiving 4 U to 7 U of PRBC. Time 0:CT, 
108 seconds versus Day 1: CT, 69 seconds (p G 0.05). B, Patients receiving 8 U to 11 U of 
PRBC. Time 0: CT, 107 seconds versus Day 1: CT, 69 seconds (p = 0.07). C, Patients 
receiving 12 U or more PRBCs. Time 0: CT, 126 seconds versus Day 1: CT, 63 seconds (p 
G 0.05). D, Individual response in all patients receiving four or more PRBC units. 
 
 
Tim
e0
PR
BC
4
PR
BC
8
PR
BC
12
Da
y11
0
50
100
150
200
250
300
CT
1s
ec
s
Tim
e0
PR
BC
4
PR
BC
8
PR
BC
12
Da
y11
0
50
100
150
200
250
CT
1se
cs
	   125	  
The average admission lactate was 6.2 mEq/l. Increased transfusion requirements were 
associated with higher baseline lactates (PRBCs four to seven U: Lactate 3.2 mEq/l vs 
PRBCs 12+ U: Lactate 9.2mEq/l, p<0.05). Lactate levels remained elevated during the 
bleeding episode regardless of overall transfusion (Figures 4.5A–C). Patients who received 
up to seven units of PRBCs did not correct lactate levels until transfusion was complete 
(Figure 4.5A). Similarly, patients requiring eight to 11 units of PRBCs (Figure 4.5B) or 
12+ units of PRBCs (Figure 4.5C) did not clear lactate during haemorrhage. Lactate levels 
were only normal (and significantly lower) on the day one sample (Figure 4.5A–C). 
 
 
 
 
Figure 4.5. Lactate clearance during haemorrhage. 
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      Figure 4.5B 
 
Figure 4.5C. 
Figure 4.5A–C. Lactate clearance during haemorrhage. Lactate clearance during 
haemorrhage. A–C box and whisker plots—median, IQR and adjusted range. *vs Time 0. 
A: Patients receiving PRBCs four to seven U. B: Patients receiving PRBCs eight to 11 U. 
C: Patients receiving PRBCs 12+ U.  
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4.5 Discussion 
 
This study describes the evolution of trauma haemorrhage in the severely injured, actively 
bleeding trauma patient. Large proportions of trauma patients are not only coagulopathic 
upon arrival to the ED, but more develop TIC during haemorrhage despite modern DCR 
practices. I have shown that DCR does not correct hypoperfusion or coagulopathy during 
the acute phase of haemorrhage. Furthermore, transfusion of FFP:PRBC ratios>1:2 
throughout the bleeding episode failed to normalise any ROTEM parameters and lactic 
acidaemia did not clear until day one, after haemorrhage control had been achieved. 
 
The paramount aim in treating exsanguinating trauma patients is immediate surgical control 
of the bleeding. Abdominal and extraperitoneal packing, closure of an open pelvic girdle 
and vascular embolisation are common measures to mechanically stop bleeding (103). 
Recently, there has been a paradigm shift in terms of treatment concepts that take into 
account contributors to TIC, including dilutional coagulopathy, hypovolaemic shock, 
hypothermia, acidaemia and hyperfibrinolysis. This has led to the concept of damage 
control surgery being extended to a more focused DCR, which implied permissive 
hypotension and fast provision of blood components. Severe acidosis, mostly a result of 
shock-related tissue hypoperfusion, impairs clotting factor activity, thrombin generation, 
platelet adhesion and aggregation, and enhances fibrinogen degradation (103, 181). Serum 
lactate measurements are a prognostic marker of tissue hypoperfusion and the severity of 
haemorrhagic shock in trauma (179, 182). Lactate clearance is correlated with survival and 
organ failure (183). Furthermore, correction of lactic acidaemia remains an important 
therapeutic goal of both DCR and surgery. Combining these two strategies in combat 
casualties has shown to correct metabolic derangements in a ‘before and after’ study of 
haemorrhage control (177). The results from this study are consistent with the current 
study’s findings, but has also added to the body of knowledge by showing that restoration 
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of normal tissue perfusion and improvement in TIC does not occur until haemorrhage 
control is achieved. 
 
Clot strength and clotting times deteriorated during ongoing bleeding, and only corrected 
when no further transfusion of PRBC units were required. These findings reinforce those 
from a comparative study of a lab-guided MHP vs empiric 1:1:1 (PRBC:FFP:PLT) protocol 
(94) (13). Fibrinogen, platelets and prothrombin time trends in the acute bleeding episode 
were identical in both transfusion strategies, despite a four-fold increase in patients 
receiving high FFP:PRBC ratio (>1:2). DCR may offer several advantages over historical 
transfusion strategies, such as rapid access to empiric component therapy, but the findings 
from my study show it has limited efficacy in correcting TIC.  
 
The benefits of DCR have been stated to be a reduction in crystalloid (CSL) use. 
Traditionally, in the presence of haemorrhagic shock, intravenous fluid infusion was the 
main treatment to improve tissue perfusion. However, aggressive replacement perpetuates 
the dilution coagulopathy and interstitial oedema, and impairs microcirculation, worsening 
oxygenation. Studies have shown that increased CSL use, in particular, is associated with 
dilutional coagulopathy and worse outcomes (35). Permissive hypotension is a strategy 
used to minimise or withhold fluid therapy or vasopressor support until the active bleeding 
has been controlled either by damage control surgery, or by radiologic or pharmacologic 
interventions. Untreated hypovolemic shock not only promotes tissue hypoperfusion but 
also hypoxia (184). Conversely, over utilisation of intravenous fluid resuscitation can 
increase blood pressure, thereby increasing hydrostatic forces on a newly developed 
thrombi. This could potentially displace the thrombi, resulting in a worsening of the 
haemorrhage. Permissive hypotension was practiced at all study sites, with limited volumes 
of CSL infused prior to baseline blood samples being taken in the ED. More severe changes 
in coagulopathy may have been seen had DCR protocols not been followed by centres in 
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this study. DCR may therefore somewhat protect from the deterioration of these parameters 
during bleeding but, in itself, is unable to correct TIC.  
 
4.6 Limitations 
 
There are several limitations to this study. I was only able to sample up to the 12th PRBC 
unit transfused and therefore could not follow coagulation profile trends up to the point of 
haemorrhage control in some patients. The precise timing of haemorrhage control was 
difficult to ascertain and therefore, I used the completion of the PRBC transfusions as a 
surrogate measure for the control of bleeding. The average FFP:PRBC ratios were greater 
than 1:2 throughout ,and I did not look specifically at the effect of differential ratios on 
coagulation or hypoperfusion. I also did not look at other component therapies (platelets 
and CRYO), although they will clearly influence correction of TIC. However, this is 
addressed, in part within the study reported in Chapter Five. In particular, fibrinogen is 
fundamental to haemostasis and falls to critical levels soon after the onset of major trauma 
haemorrhage (154). Early aggressive fibrinogen replacement may therefore prove 
efficacious in the correction of TIC and merits further investigation.  
 
4.7 Conclusions 
 
The purpose of the study described in this chapter was to address the knowledge gap that 
exists regarding the evolution of TIC during trauma haemorrhage. This study shows that 
severely injured trauma patients are coagulopathic on arrival at the ED and that 
coagulopathy worsens during haemorrhage and DCR. Controlling haemorrhage and the 
cessation of transfusion appear necessary before TIC can be corrected and tissue perfusion 
restored. Following haemorrhage control and the completion of transfusions, ROTEM 
parameters do not immediately return to values seen in normal healthy controls. The 
question for the future design of goal-directed therapy-utilising devices such as ROTEM is 
	   130	  
the identification of target values for coagulation parameters in trauma haemorrhage. 
Significant opportunities exist to tailor management and improve outcomes for bleeding 
trauma patients. A balanced and potentially novel strategy is required to achieve the 
correction of TIC while maintaining organ perfusion. Damage control resuscitative 
strategies as practiced by the institutions in this study may be protective but it is neither 
haemostatic nor resuscitative.  
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CHAPTER FIVE 
 
The effects of blood component 
therapy on coagulopathy during 
trauma haemorrhage  
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 5.1 Introduction 
 
Chapter Four addressed the knowledge gap that exists in the incidence of TIC in an actively 
bleeding trauma patient. The ethos of DCR has been widely introduced among centres 
treating trauma patients with severe bleeding. This model concentrates on the early 
provision of coagulation products (in the form of plasma and platelet transfusions) as part 
of an MHP and addresses important confounders of the coagulation process, such as the 
lethal triad of coagulopathy, hypothermia, and acidosis. However, the efficacy of these 
blood components, as well as DCR overall, to correct TIC during acute bleeding is 
unknown.  
 
The majority of studies supporting the use of high-dose blood components in trauma 
haemorrhage have retrospectively associated their use with survival, with the assumption 
that this is due to improved haemostasis during resuscitation (123, 177). However, 
observed survival benefits may be attributed to other factors, such as differential rates of 
bleeding and delayed provision of products, avoidance of crystalloid dilution or other 
unknown potential biases (46, 54, 124, 185). Our group has shown that physiological and 
haemostatic markers are not maintained during haemorrhage and DCR in the same study 
population (135, 154). A previous pilot study examined the ability of plasma to correct 
functional coagulation tests but did not find conclusive evidence that high-dose plasma 
offered a haemostatic benefit during bleeding (124). This study was small and therefore 
limited to the examination of one blood component only. To date, there have been no 
further prospective studies of the efficacy of type, dose or combinations of blood 
component therapies in correcting TIC during haemorrhage nor its effect on the coagulation 
profile during DCR. 
 
Our research group has studied the bleeding phase following trauma and previously shown 
that fibrinogen, the primary substrate of coagulation, falls during haemorrhage. However, 
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despite DCR, fibrinogen did not correct with standard DCR (154). While high-dose plasma 
and platelets have both been associated with improved outcomes (94, 124), the preliminary 
findings showed that different ratios of FFP:PRBCs had minimal effect on the coagulation 
profile during trauma haemorrhage (124). It therefore remains unclear whether component 
therapy can improve coagulopathy in the acute phase.  
 
5.2 Aims  
 
The hypothesis of this study is that blood component therapy improves trauma 
haemorrhage.  
 
The overall objective is to describe the effect of blood component therapy on trauma 
haemorrhage.  
 
The specific aims of my study are to describe the effect of individual blood components on 
TIC; and to examine the effect of increasing doses of FFP and fibrinogen for the correction 
of TIC.  
 
5.3 Methods 
 
Trauma patients presenting directly to three Level 1 trauma centres between June 2010 and 
June 2013 were eligible for inclusion. Blood samples were collected as part of the ongoing 
prospective ACIT II investigation. All data and samples used in this study were consented 
for and the study was reviewed and approved by the respective National Research Ethics 
Committee of each country involved in the study. 
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5.3.1 Study design 
 
This study is undertaken with the same cohort of patients described in Chapter Four. 
 
5.3.2 Patient selection 
 
This study is undertaken with the same cohort of patients described in Chapter Four. Patient 
selection is also as previously detailed in Chapter Four. 
 
5.3.3 Sampling technique  
 
The sampling technique and analysis has been described in Chapter Four. 
 
5.3.4 Definitions  
 
I defined coagulopathy by ROTEM as a five-min EXTEM Clot Amplitude (CA5) ≤35 mm 
(75). This has been shown to accurately identify ATC and predicts the need for MT (MT is 
defined as ≥ 10 units PRBCs in 24 h). The estimated expected fibrinogen doses transfused 
in each product are: PLT – 0.4g; FFP/Octaplas – 0.9g; and Cryoprecipitate – 2g for each 
pool/unit transfused (128).  
 
5.3.5 Data collection and analysis 
 
Data were collected prospectively on patient demographics, time of injury, mechanism 
(blunt or penetrating), pre-hospital fluid administration, time of arrival at the ED, baseline 
vital signs, and total transfusion requirements in the first 12 h of admission. For each 4 U of 
PRBCs transfused, interval FFP:PRBC ratios were calculated up to the 12th PRBC unit. 
The change in coagulation parameters for each interval after four units of PRBCs was 
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calculated, e.g. time point A (baseline) to time point B (after the 4th, 8th and 12th Unit of 
PRBCs). Statistical analysis was performed using GraphPad PRISM v5 (GraphPad 
Software Inc, San Diego, CA, US) and Microsoft Excel 2007 (Microsoft, Inc., Redmond, 
WA, US). Normal quantile plots were used to test for normal distribution. Parametric data 
are expressed as mean ± 95% confidence intervals (CI). Non-parametric data are given as 
median (interquartile range, IQR). A p value of <0·05 w  as chosen to represent statistical 
significance throughout. 
 
5.4 Results 
 
A total of 810 patients were included in the ACIT II study over study period with 49 
exclusions: consent declined or not possible (21 patients) and retrospective exclusion 
criteria (28 patients). A total of 106 study patients were transfused ≥4 U PRBCs during the 
study period with 27 receiving 8–11 U PRBCs and 31 who received ≥12 U PRBCs. The 
average FFP:PRBC ratio between intervals was PRBCs 0–4 U: 0.5; PRBC 5–8 U: 0.9, 
PRBCs 9–12 U: 0.7 and at h 12: 0.7. Median crystalloid use was 0 ml for all intervals: 
PRBCs 0–4 U (IQR: 0–100 ml), PRBCs 5–8 U (0–500 ml), PRBCs 9–12 U (0–1,000 ml). 
Overall, mortality was 35%. Clinical characteristics, admission physiology, and laboratory 
parameters are detailed in Table 5.1. After the first interval, there were no differences in the 
ratio of any blood product transfused between the 4–8 and 8–12 unit intervals (Table 5.2). 
  
In total there were 181 4-U PRBCs intervals available for analysis in this study (Table 5.2). 
Very few blood components other than PRBCs were delivered in the first 4-U window, as 
emergency blood is delivered from stocks held in EDs. On average, patients received 2 U 
of FFP with the first 4 U of PRBCs. Patients received significantly more of all components 
in subsequent 4-U intervals—on average, 3.4 U of FFP, 0.5 pools of platelets and 0.8 pools 
of CRYO, equivalent to 4.4g of fibrinogen (Table 5.2).  
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Patients n=106 
Age 44 (30–60) 
Male 75 (76%) 
Injury 
ISS 34 (25–41) 
ISS>15 99 (94%) 
Blunt injury 92 (87%) 
Admission parameters 
SBP<90 mmHg 41 (46%) 
Base deficit>6 mEq/L 68 (67%) 
Lactate>5 mEq/L 44 (42%) 
PT (secs) 12.9 (11.7–14.6) 
PTr>1.2 40 (40%) 
CA5≤35 (mm)   41 (43%) 
Fluid requirements (first 12 h) 
Pre-hospital Crystalloid (ml)     500 (100–2,000) 
Crystalloid (ml) 2500 (1,300–4,000) 
Colloid (ml) 875 (0–1688) 
PRBC units 8 (5–13) 
PRBC≥10 U 40 (38%) 
FFP units 6 (4–8) 
Platelet units 1 (1–2) 
Cryoprecipitate units 2 (0–2) 
 
Table 5.1. Clinical characteristics of patients. Values are given as n (%) or median 
(interquartile range). 
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Blood component  0–4 unit interval 5–8 unit interval 9–12 unit interval 
Number 106 49 26 
    
Average FFP units 2.0 3.2* 3.7* 
Average FFP:PRBCs 0.5 0.9* 0.7* 
    
Average PLT units 0.2 0.4* 0.8* 
Average PLT:PRBCs 0.0 0.1* 0.2* 
    
Average CRYO units 0.2 0.6* 1.2* 
Average CRYO:PRBCs 0.0 0.2* 0.3* 
    
Total Fg transfused (g) 2.1 4.3* 4.7* 
 
Table 5.2. Blood components administered during DCR. Transfusion requirements for 
each interval of 4 U of PRBCs. There was no significant difference between the 5–8 U 
window and the 9–12 U window for any product transfused. *p<0.05 when compared to 
the 0–4 U interval +p<0.05 when compared to the 4–8 U interval. 
 
Blood component therapy was compared to the transfusion of PRBCs alone (Figures 5.1A–
D). There was little discernible effect on the clotting function regardless of the type of 
blood component administered. The average dose of FFP administered per interval (3.2 U) 
had no significant effect on clotting time, clot generation nor maximum clot firmness 
(Figures 5.1A–2D). When adding CRYO (an average of 1.6 pools per interval) and 
platelets (an average of 1 pool per interval), this showed some level of protection for the 
clotting function across the interval, but only an improvement in CT time was significant 
(+7.6 s vs. -19.2 s p<0.05). There were very few intervals where platelets or CRYO was 
transfused in isolation; thus I could not identify the individual effect of these products. 
Component therapy in average doses appears to have little effect on functional clotting 
profile during acute haemorrhage. 
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Figure 5.1. Effect of blood component therapy on coagulopathy when administered 
during DCR. 
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Figure 5.1A. 
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Figure 5.1A–D. Effect of blood component therapy on coagulopathy when 
administered during DCR. Bars are mean interval change in ROTEM parameters with 
95% CI. A: Change in CT on EXTEM. B: Change in alpha angle on EXTEM. C: Change in 
MCF on EXTEM. D: Change in MCF on FIBTEM.  
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There was sufficient variation in FFP administered between intervals to allow an analysis 
of the effect of FFP dose on the coagulation function. Overall, less than 10% of 
coagulopathic patients had their coagulopathy corrected at the end of the 4-U interval, 
regardless of the amount of FFP administered (Figure 5.2A). Increasing doses of FFP also 
did not prevent patients from becoming coagulopathic, with 56% of intervals that started 
with CA5>35 mm becoming coagulopathic with 1:1 FFP:PRBC administration, compared 
to 35% with 1:4 ratios (Figure 5.2A). Increasing doses of FFP had a slightly better effect on 
the PTr, with 60% of intervals that started with a PTr>1.2 normalising with a 1:1 ratio, 
compared to less than 20% with a 1:4 ratio (Figure 5.2B). However, on average, all 
parameters of the coagulation function deteriorated in all intervals regardless of the dose of 
FFP administered (Figures 5.2C–F). There were more consistent findings for the effect of 
the total dose of fibrinogen administered within the blood components. Fibrinogen doses of 
six g or more achieved correction of CA5 and PTr in 36% and 29% of patients respectively 
(Figures 5.3A–B). There were statistically significant improvements in functional clotting 
parameters when six g or more of fibrinogen was administered within a 4-U PRBC interval 
(Figures 5.3C–F). However, 57% of intervals that started with normal functional clotting 
developed coagulopathy despite this dose of fibrinogen (Figure 5.3A). Although there was 
a wide variability in the fibrinogen response, higher dose replacement offered the most 
consistent improvements in functional clot measures during haemorrhage. 
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Figure 5.2. The effect of increasing doses of FFP on TIC. 
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Figure 5.2C. 
 
 
 
 
 
 
Figure 5.2D. 
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Figure 5.2E. 
 
 
 
Figure 5.2F. 
 
Figure 5.2A–F. The effect of increasing doses of FFP on TIC. Bars are mean change in 
ROTEM parameters with 95% CI. A: The effect of increasing FFP:PRBCs on the 
proportion of trauma patients with coagulopathy corrected (CA5>35) and coagulopathy 
worsened (CA5<35). B: The effect increasing FFP:PRBCs compared to the proportion of 
patients with corrected PT(r) and worsening PT(r). C: Average CT on EXTEM. D: Average 
alpha angle on EXTEM. E: Average MCF on EXTEM. F: Average MCF on FIBTEM. 
There was no difference between the FFP:PRBC ratio groups in any measurement of the 
coagulation response.   
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Figure 5.3. The effect of increasing interval fibrinogen doses on TIC.  
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Figure 5.3C. 
 
 
 
 
 
 
 
Figure 5.3D. 
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Figure 5.3E. 
 
 
 
Figure 5.3F. 
 
 
Figure 5.3A–F. The effect of increasing interval fibrinogen doses on TIC. Bars are 
mean change in ROTEM parameters with 95% CI. A: Change in CT on EXTEM. B: 
Change in alpha angle on EXTEM. C: Change in MCF on EXTEM. D: Change in MCF on 
FIBTEM. 
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5.5 Discussion 
 
In this prospective study of severely injured, bleeding patients, I have shown that high-dose 
blood component therapy is generally able to maintain coagulation parameters but cannot 
correct TIC. It is only at the highest dose of combinations of products that a consistent, 
although small, effect was observed within this population. 
 
Despite the widespread use of blood components to treat TIC, their effects on the 
coagulation profile when administered during DCR remains unknown. There are many 
clinical studies that emphasise the importance of the identification and treatment of TIC 
early in the clinical course of the bleeding trauma patient (186). However, some studies 
suggest that, even in patients where clinically apparent coagulopathy is addressed with 
blind early administration of blood products, namely FFP, the amount transfused often falls 
significantly below what is required to address the complex coagulopathy related to 
dilution, consumption, and fibrinolysis (46, 187). Previous studies have investigated the 
effect of varying FFP:PRBC on outcomes, but there has been conflicting evidence 
regarding the use of high ratios. High-dose plasma and platelets have both been associated 
with improved outcomes (8), but our previous pilot study found that increasing ratios of 
FFP:PRBCs had a variable effect on the coagulation profile during haemorrhage (124). 
Through this study, I have shown that there was no consistent correction of any measure of 
clot function when FFP was delivered during the acute phase of ongoing bleeding. 
Furthermore, I could not identify a major haemostatic benefit to FFP:PRBC ratios above 
1:2.  
 
Normal haemostasis is critically dependent on fibrinogen as a substrate for clot formation. 
The fibrinogen level is decreased in the severely injured, bleeding patient on admission and 
is associated with poor outcomes (130). Our group has previously shown that fibrinogen 
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depletion occurs in TIC and progresses during trauma haemorrhage (130, 161). Fibrinogen 
levels do not normalise during DCR despite the provision of high ratios of both plasma and 
platelets. There was a small but inconsistent response to high doses of fibrinogen in this 
current study. This may be due to the volume of blood components that have to be 
administered to achieve such high doses in a standard DCR protocol. For example, four 
units of FFP, one pool of platelets and one pool of CRYO would provide six g of 
fibrinogen, but diluted into a volume of approximately three l (when given with four units 
of PRBCs). It is possible that a more concentrated delivery may be more effective, and 
clinical trials of early high-dose CRYO therapy and fibrinogen concentrate are underway. 
 
5.6 Limitations 
 
There are several limitations to this study. Firstly, this was an observational study and thus, 
results can only show the effect of blood components as administered by the MHPs in our 
institutions. Patients received different blood components across different PRBC intervals, 
and were more likely to receive 1:1 FFP:PRBC ratio between PRBC units 8 and 12. These 
interval cohorts may be influenced by our transfusion protocols and practices, rate of blood 
loss, or early haemorrhage control. The effect of immediate balanced transfusion therapy 
with plasma, platelets and RBCs was not evaluated in the present study. Randomised 
control trials of plasma and other blood component therapies in TIC are highly warranted 
(161). While I have excluded survival bias in this study, there may still be differences in 
these parameters that may have influenced the observed efficacy of the component 
therapies. Precise timing of haemorrhage control is difficult to ascertain, and therefore, I 
used the completion of PRBC transfusions as a surrogate measure for the control of 
bleeding. I did not examine the fibrinolytic component of TIC in this study, although from 
2010 and the publication of the CRASH-2 trial, MHPs at all sites specified early 
administration of tranexamic acid. Under-treated or persistent hyperfibrinolysis may 
contribute to poor clot function and is therefore part of a continued investigation within 
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INTRN. Finally, 28 patients were logistically impossible to sample as the rate of 
transfusion meant I was unable to sample every 4 U of PRBCs. As I was not studying 
outcomes, this will not have introduced bias to our results, but this is clearly an important 
group of patients who I was not able to study. 
 
5.7 Conclusion 
 
The purpose of this study is to address the knowledge gap that exists regarding the efficacy 
of blood component therapy on TIC during active bleeding. I have shown that severely 
injured trauma patients were coagulopathic on arrival at the ED and early replacement of 
increasing doses of plasma and average doses of other blood component therapies had little 
effect on the deranged ROTEM coagulation parameters during the acute phase of care. I 
have shown that aggressive high-volume replacement of plasma has little effect on 
deranged ROTEM coagulation parameters. A better understanding of the pathogenesis of 
TIC is required to delineate the limitations of current DCR strategies in the treatment of 
major trauma haemorrhage and in the identification of novel therapeutic targets. There is an 
important opportunity to improve the efficacy of DCR by improved the management of 
TIC during haemorrhage. 
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CHAPTER SIX 
 
The effects of damage control 
resuscitation on coagulation factor 
concentration during trauma 
haemorrhage 
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6.1 Introduction 
 
DCR is the administration of early and aggressive clotting factor transfusions in the form of 
high-dose FFP and CRYO in combination with PRBCs, while simultaneously avoiding 
large volumes of crystalloid transfusion (117, 170, 185, 188). The effect of DCR on 
coagulation-factor activity levels in the acute bleeding phase is an area of continued 
uncertainty but is of obvious importance. In the last two decades, there have been numerous 
studies, albeit all retrospective, that have shown that the early transfusion of plasma, 
containing coagulation factors, improves survival (38, 40, 41, 123, 189, 190). The first of 
these major investigations that examined DCR was carried out by Borgman et al. at a US 
combat hospital in Iraq. This retrospective study examined 252 patients who had been 
given a MT, and found significant differences in mortality between patients who were 
given low, medium or high plasma to red blood cell ratios. The higher the plasma ratio in 
the blood, the lower the risk of death. This was achieved primarily by reducing early 
mortality (less than four h from admission) from haemorrhage (123). This study was 
limited by the lack of standard timing for measuring variables, and the lack of a MT 
protocol that would be consistently applied to patients. Other studies in military trauma 
have also shown a mortality benefit from high plasma to red blood cell ratios (41, 47, 123, 
191). Holcomb described similar results in 466 MT civilians (40). The ideal ratio of PRBC 
to FFP is controversial, with some studies proposing that such high ratios do not have any 
additional benefits over medium ratios (124). A recent large, prospective cohort study 
documenting the timings of transfusions during active resuscitation and patient outcomes 
concluded that, in the first six hours, patients with ratios less than 1:2 were three to four 
times more likely to die than patients with ratios of 1:1 or higher (130). Nonetheless, it is 
clear from the literature that there exists a knowledge gap, as relatively little is known of 
the effect of blood component therapy on coagulation factor concentration during the acute 
phase of bleeding (54, 119, 123, 134). 
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Recent evidence has shown that there is an early clotting factor deficiency on admission 
that is associated with hypoperfusion (190, 192). Studies have reported that up to 20% of 
patients had at least one clotting factor deficiency on arrival, defined as less than 30% 
activity or concentration (192). However, the designation of critical coagulation factor 
activity levels associated with clinically relevant abnormalities is based on the study of 
patients with hereditary single-factor deficiencies. The effects of multiple subcritical 
deficiencies, as seen in trauma patients, are not well understood. Further evidence regarding 
clotting factor deficiency contributing to ATC has come from the PROMMT study (130). In 
addition to DCR, where many proteins are replaced concurrently, isolated factors such as 
recombinant factor VII (rFVII) have been proposed as treatments for injured patients with 
haemorrhagic shock (193). However, transfusing clotting factors in the form of FFP or 
CRYO implicitly refutes the hypothesis that clotting factor deficiency is implicated in early 
TIC (192). It is important to understand what effect the type, dose and combinations of 
blood component therapies have on coagulation factor level in the severely injured, 
bleeding trauma patient. 
 
6.2 Aims 
 
The hypothesis of this study proposes that blood component therapy maintains coagulation 
factor concentrations during trauma haemorrhage.  
 
The overall objective is to characterise the effect of DCR and blood component therapy on 
coagulation factor concentrations during trauma.  
 
The specific aims are to characterise the evolution of coagulation factor concentrations 
during the acute phase of trauma haemorrhage. The second aim is to describe the effect of 
TIC on coagulation factor concentrations. The third aim is to examine the effect of 
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individual blood components on coagulation factor concentrations. Finally, the fourth aim 
is to determine the effect of increasing doses of FFP on coagulation factor concentrations. 
 
6.3 Methods 
 
6.3.1 Study design  
 
This was a multicentre, prospective, cohort study of trauma patients presenting directly to 
level 1 trauma centres between June 2010 and June 2013. The study was reviewed and 
approved by the UK National Research Ethics Committee or equivalent (as described in 
Chapter Two). I analysed baseline laboratory coagulation parameters on arrival for 
comparison with coagulation factors, ROTEM and BD.  
 
6.3.2 Patient selection  
 
All adult trauma patients (>16 years) who met the local criteria for full trauma team 
activation were eligible for enrolment and recruited into the study when research personnel 
were present (08:00 to 22:00 daily). Exclusion criteria included arrival at the ED more than 
two h after injury; the administration of more than 2,000 ml of intravenous fluid prior to 
arrival at the ED; transfer from another hospital; and burns covering more than 5% of the 
total body surface area. Patients were retrospectively excluded if they declined to give 
consent for the study to use research samples collected, were found to be taking 
anticoagulant medications, and had moderate or severe liver disease or a known bleeding 
diathesis. Clinicians actively involved in patient treatment were blinded to ROTEM results. 
Further details of methodology are given in Chapter Two. 
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6.3.3 Sampling technique  
 
A 30 ml research sample of blood was drawn from either the femoral vein or antecubital 
fossa along with the standard trauma laboratory tests within 20 minutes of the patient’s 
arrival in the ED. Samples for PT, fibrinogen and coagulation factor assay were collected 
into 4.5 ml glass vacutainers (0.109 M buffered sodium citrate, 3.2%: Becton Dickinson, 
Plymouth, UK). PT and fibrinogen were processed by the central hospital along with a 
standard FBC. PTr was calculated as observed: PT divided by mean control PT values in 
order to enable direct comparison. Blood for ROTEM analysis was drawn into a 2.7 ml 
citrated vacutainer (0.109 M buffered sodium citrate, 3.2%: Becton Dickinson, Plymouth, 
UK) and 97 were processed in the trauma research laboratory. Arterial blood analysis for 
BD was performed simultaneously with the research sample collection. For those patients 
with acute active bleeding that required immediate transfusion as part of DCR, further 
blood samples were drawn after the 4th, 8th and 12th unit of PRBC were transfused. Only 
patients that were transfused with more than 4 U PRBCs within 12 h were recruited to this 
study.  
  
6.3.4 Sample analysis  
 
The blood samples were analysed in batches at the end of the study period (July 2013). An 
automated analyser (Sysmex CA-1500 System, Siemens AG, Germany) was used to 
measure coagulation factor activity ([normal range]: V [60–150]; VIII [52–153], IX [52–
156]; VII, X, XI [50–150]) and von Willebrand Factor (vWF) ([50–155]).  
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6.3.5 Automated one-stage factor assays 
 
The one-stage clotting factor assay was used to identify patients with a deficiency of one or 
more of their clotting factors. Clinically, this can be demonstrated by prolonged bleeding 
episodes.  
 
The one-stage clotting factor assay relied on the principle of testing various dilutions of the 
plasma by either the PT (used for factors II, V, VII and X) or the aPTT (used to assay 
factors XII, XI, IX and VIII) and comparing the clotting times against a standard curve. A 
standard curve was generated on the Sysmex using five dilutions of standard human plasma 
(SHP) in Owren’s Buffer, added to an equal volume of factor deficient plasma. The SHP 
has a known concentration for each factor and the clotting times for each dilution are 
plotted against the concentration.  
 
The deficient plasma contains all other coagulation factors in normal amounts except the 
one being assayed for. Therefore, the clotting times were dependent on the quantity of the 
factor present. Thus, if a patient sample is assayed that has a low fibrinogen, or has more 
than one factor deficiency, the clotting times will only depend on the factor being assayed. 
Further details regarding the factor analysis are given in Chapter Two. 
 
6.3.6 ROTEM analysis 
 
Blood samples were processed within one hour of being drawn at 37°C on a ROTEM delta 
instrument (Pentapharm GmbH, Munich, Germany). All of the treating medical staff were 
blinded to the ROTEM results. The methodology and the parameters of ROTEM have 
previously been described in detail ((178), Chapter Two). 20µl of recalcitrant (STARTEM) 
and 20µl of tissue factor derived from rabbit brain (EXTEM) were placed into the test 
cuvette, after which 300µl of the blood sample was added. Activation with tissue factor was 
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performed to standardise the in vitro coagulation process and produce a more rapid result. 
All pipetting steps and the mixing of reagents with samples were performed as standard 
using the automated electronic pipette program. Clot amplitude at five min (CA5) was 
reported for each sample analysed in this bleeding subgroup. 
 
6.3.7 Data collection  
 
Data were collected prospectively on patient demographics, time of injury, mechanism 
(blunt or penetrating), pre-hospital fluid administration, time of arrival at the ED, baseline 
vital signs and total transfusion requirements in the first 12 h of admission. Injury was 
classified using the ISS (8). Metabolic acidosis was defined as BD>6mEq/l (194, 195). 
Coagulopathy has previously been defined as a laboratory PTr>1.2 (36, 64, 194). In trauma, 
PTr>1.2 has been shown to be a clinically relevant threshold associated with significant 
increases in mortality and transfusion requirements (64). Normal values for ROTEM clot 
strength parameters were determined from patients without ATC. It has been shown that 
ATC is primarily a deficiency in clot strength, not clotting times, and thus, ATC was 
defined using ROTEM as CA at five min (CA5) ≤35 mm (75, 124). Results from a cohort 
of patients with minor injuries (defined by an ISS of ≤4) were used as a baseline 
comparator as previously described (154). These are referred to as “Minor Injury” in the 
results section. 
 
6.3.8 Outcome measures 
 
Patients were followed until discharged from hospital or death. Specifically, 24-hour 
mortality, 28-day mortality, 12-h PRBC requirements and FFP:PRBC ratio measures were 
recorded. 
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6.3.9 Statistical analysis  
 
Statistical analysis was performed using GraphPad PRISM v5 (GraphPad Software Inc, San 
Diego, CA, US) and Microsoft Excel 2007 (Microsoft, Inc., Redmond, WA, US). Normal 
quartile-quartile plots were used to test for normal distribution. Parametric data are 
expressed as mean ± 95% confidence intervals (CI) and compared using two-tailed unequal 
variance Student’s t test or one-way ANOVA. Non-parametric data are given as median 
(interquartile range, IQR). A p value of 0.05 was chosen to represent statistical 
significance. 
 
6.4 Results 
 
A total of 810 patients were included in the ACIT II study over the 52-month period. Forty-
nine individuals were excluded: in such cases, consent was declined or not possible (n=21 
patients) or the cases adhered to the retrospective exclusion criteria (n=28). A total of 106 
study patients were transfused ≥4 U PRBCs during the study period, with 27 receiving 8–
11 U PRBCs and 31 receiving ≥12 U PRBCs. The mean FFP:PRBC ratio between intervals 
was PRBCs 0–4 U: 0.5; PRBCs 5–8 U: 0.9, PRBCs 9–12 U: 0.7 and at h 12: 0.7. Clinical 
characteristics, admission physiology, and laboratory parameters are detailed in Table 6.1.  
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Patients 
 
Minor Injury 
 
Bleeding 
Number 139 106 
Age 33 (22–42) 44 (30–60)* 
Male 116 (83%) 75 (76%) 
 
Injury 
ISS 1 (1–4) 34 (25–41)* 
ISS>15 0 99 (94%)* 
Blunt injury 100 (72%) 92 (87%)* 
 
Admission parameters 
SBP<90 mmHg 5 (4%) 41(46%)* 
BD>6 mEq/L 7 (5%) 68 (67%)* 
PT (secs) 10.9 (10.5–11.3) 12.9 (11.7–14.6)* 
PTr>1.2 2 (2%) 40 (40%)* 
CA5≤35 mm 12 (9%) 41 (43%)* 
 
Fluid requirements (first 12 h) 
Pre-hospital PRBCs (units) 
0(0) 0 (1–6) * 
Pre-hospital Crystalloid (ml) 0(0–100) 500(100–2,000)* 
Crystalloid (ml) 0 (0–800) 2,500 (1,300–4,000)* 
Colloid (ml) 0 (0) 875 (0–1,688)* 
PRBCs (units) 0 (0) 8 (5–13)* 
PRBCs≥10units 0 (0) 40 (38%)* 
FFP (units) 0 (0) 6 (4–8)* 
Platelet (units) 0 (0) 1 (1–2)* 
Cryoprecipitate (units) 0 (0) 2 (0–2)* 
 
Table 6.1. Patient demographics and clinical characteristics. Values are given as n (%) 
or median (interquartile range). 
 
 
	   159	  
The evolution of coagulation factor concentration during haemorrhage was evaluated 
(Figure 6.1A–J). On admission, the 106 bleeding trauma patients had an almost universal 
deterioration in coagulation factor concentration when compared to the minor injury group 
(p<0.05). By far the greatest reduction was seen in factor V activity (reduction of 45%, 
p<0.001, Figure 6.2C). However, vW:Ag showed a 46% increase in circulating 
concentration (p<0.001) and factor VIII concentration remained virtually unchanged. On 
admission to the ED, 16% of bleeding patients had at least one critically low factor level 
when compared to standard ranges (<50lu/dl). This increased to 19%, 26% and 33% for 4 
U, 8 U and 12 U PRBCs respectively.  
 
As trauma patients continued to bleed, there was a gradual deterioration in coagulation 
factor concentration as compared to the minor injury group. By the end of the 4th U 
PRBCs, all the coagulation factor levels were below 70% of the minor injury cohort, with 
the exceptions of vW:ag and VII. At 4 U PRBCs, the average factor activity was 70% when 
compared to standard ranges (excluding VIII and vW:Ag). As bleeding persisted, by the 8th 
U PRBCs, the average factor activity fell to 56%. At the point of the 12th PRBC 
transfusion, there was a further reduction with an average factor concentration of 50% as 
compared to standard ranges. Patients who required 12 U PRBCs showed the greatest 
reduction in factors II, V, VIII, IX and X when compared to admission levels (p<0.05). 
Again, the greatest fall in activity was seen in factors V (35%) and VIII (36%) as compared 
to the minor injury cohort. However, fibrinogen concentration showed a significant trend 
towards admission concentration. Overall, a deterioration in coagulation factor 
concentrations as the patients bled could be observed. Nevertheless, while the reduction of 
coagulation factor concentrations reached statistical significance, only factor V fell to a 
clinically significant level. The remainder were mostly within laboratory-reference ranges 
(0.5–1.5 U/mL). In summary, DCR was able to maintain coagulation factor levels when 
compared to admission, but did not return levels to minor injury levels. 
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Figure 6.1A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1B.  
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Figure 6.1C. 
 
 
 
 
 
 
Figure 6.1D.  
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Figure 6.1E. 
 
 
 
 
 
 
Figure 6.1F.  
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Figure 6.1H. 
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Figure 6.1I. 
 
 
 
 
 
 
Figure 6.1A–J. The effect of DCR on coagulation factor concentration in actively 
bleeding trauma patients. Coagulopathic, PTr>1.2 and admission were compared to 
ISS<4 (+ p<0.05). 4 U, 8 U and 12 U are compared to admission (*p<0.05). 
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Next, the effect of TIC on coagulation factor concentrations was examined (Figure 6.1). 
When comparing coagulopathic patients to the minor injury group, it was noticed that there 
was a statistically significant deterioration in all coagulation proteases (p<0.05). Those 
patients with an admission of PTr>1.2 were still worse (p<0.05). However, although there 
was a statistically significant deterioration in concentration, none of the coagulation 
proteases reached values that were clotting factor activity level ≤30% of normal reference 
ranges. Patients who corrected their TIC were compared against those who became 
coagulopathic after DCR (Figure 6.2). Among those patients that corrected their TIC, there 
was an almost universal decrease in absolute values of coagulation factor levels. The 
greatest difference seen was in factors II, V, IX, and XIII. In both groups, however, none of 
the coagulation factors reached clinically critical levels of 30% below normal laboratory 
values. 
 
 
Figure 6.2. Coagulation factor concentration in those patients who had their TIC 
corrected compared to those patients who worsened during the bleeding phase (* 
p<0.05). Overall, the majority of coagulation proteases were found to be in lower 
concentrations in patients who corrected their TIC. Factors II, V, IX and XIII had 
statistically significant lower concentrations in those patients who corrected their TIC 
(p<0.05).  
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I examined the effect of FFP transfusion on coagulation factor concentration. On average, 
transfusion of FFP had little effect on coagulation factor concentration (Figure 6.3A–J). 
When broadly examining those patients who received FFP with those who did not receive 
any, we did not find any statistically significant improvement in the interval change in 
coagulation factor concentration. On average, there were minor improvements in interval 
change in all coagulation proteases apart from factor VIII and vW:Ag, although none 
reached statistical significance. Next, I investigated the effect of increasing doses of FFP on 
coagulation factor interval change (Table 6.2). On average, FFP in PRBC ratios of 1:2 or 
higher generally preserved levels procoagulant coagulation factors II, V, IX, X, XI and 
XIII. However, the difference in these factor levels between low and high FFP ratios was 
small, varying by only 5–10% of the baseline (Table 6.2). Transfusing higher ratios of FFP 
did not confer any additional benefit over lower ratios in correcting coagulation factor 
concentration.  
 
There was a varied effect on coagulation factor concentration regardless of type of blood 
component administered. I examined the effect of blood component use on the interval 
change in coagulation factor concentrations in bleeding patients (Table 6.2). The greatest 
deterioration in overall coagulation factor concentration was seen when transfusing PLT in 
addition to CRYO and FFP. A moderate improvement in interval change in coagulation 
factor levels was seen in V, IX and X when transfusing FFP and CRYO. Overall, however, 
there was little change seen in coagulation factor concentration regardless of the blood 
component used.  
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 Figure 6.3. The effect of a FFP transfusion on coagulation factor concentration in 
bleeding patients.  
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Figure 6.4C. 
 
 
 
Figure 6.4D. 
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Figure 6.4E. 
 
 
 
 
 
 
Figure 6.4F. 
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Figure 6.4G. 
 
 
 
 
 
Figure 6.4H. 
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Figure 6.4I. 
 
 
 
 
Figure 6.4J. 
 
 
Figure 6.3A–J. The effect of FFP transfusion on coagulation factor concentration in 
bleeding patients. Values show interval change in coagulation factor concentration. In 
general, there was a decreased interval change in coagulation actor concentration in 
those patients that did not receive FFP, but this did not reach statistical significance. 
(*p<0.05). 
 
 
No#FFP FFP
&30
&20
&10
0
10
20
30
In
te
rv
al
#c
h
an
ge
#
(l
u
/d
l)
Factor#XIII
No#FFP FFP
&100
&50
0
50
100
In
te
rv
al
#c
h
an
ge
#
(l
u
/d
l)
Von#Willebrand#Factor#An?gen
	   173	  
 
6.5 Discussion 
 
In this study, the effects of DCR on coagulation factor concentrations in severely injured 
trauma patients were prospectively examined. The majority of bleeding trauma patients 
had a statistically significant deterioration in coagulation factor concentration on 
admission. These levels continued to fall as patients bled, although by the 12th U, only 
factor V activity decreased to clinically relevant concentrations. Patients who 
successfully corrected their TIC by DCR techniques had, on average, lower coagulation 
factor levels than those that went on to develop TIC, although no single coagulation 
protease fell below critical threshold for normal functional activity. Furthermore, this 
work revealed that transfusions of FFP in average doses had little effect on coagulation 
factor concentration and transfusing higher ratios of FFP did not confer any additional 
benefit over lower ratios in correcting coagulation factor levels. Overall, blood 
component therapy had little discernable effect on coagulation factor concentration. 
 
In the severely injured trauma patient, TIC represents a significant contribution to death. 
It is vital that prompt and appropriate haemostatic intervention is implemented to 
prevent and correct life-threatening bleeding. One approach proposed for preventing 
exsanguination and promoting haemostatic control is to transfuse patients with a fixed 
FFP:PRBC ratio, in addition to CRYO and platelets, in order to provide optimal 
concentrations of coagulation factors (88, 103, 176). However, little research has been 
undertaken in either understanding the evolution of coagulation factor concentration in 
actively bleeding trauma patients or the effect of these blood components on coagulation 
factor activity.  
 
Historically, it is thought that coagulopathy was the result of an ongoing cycle of 
dilution and consumption of coagulation factors, hypothermia and acidosis (121). A 
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previous small case-control study of trauma patients with (n=38) and without (n=53) 
TIC, conducted by Shaz et al., reported that following injury, TIC is associated with 
decreased factor activities (196). However, in contrast with findings reported in this 
chapter, Shaz et al.’s TIC group were less severely injured (mean ISS 14 vs 34) and 
infused with greater volumes of pre-hospital crystalloid (852 ml vs 500 ml). 
Furthermore, only a single time point of coagulation factor level (admission) was 
analysed. In contrast, this study’s multiple time point analysis demonstrated that the 
majority of coagulation factors do not deteriorate to below critical levels. Previous 
studies have investigated the relationship between FFP:PRBCs and mortality proposed 
through increased coagulation factor concentration (121).  
 
The results reported in this chapter show that, on average, patients who present with TIC 
do not have critical levels of coagulation factor activity. Furthermore, transfused higher 
ratios of FFP:PRBCs do not, on the whole, improve coagulation factor concentrations. 
Therefore, the combination’s haemostatic benefits may be through alternative 
mechanisms other than solely improving coagulation factor concentration. Moreover, 
the greatest benefit in product transfusion was seen in the combination of FFP and 
CRYO and, in contrast to current opinion, there was no significant improvement of 
interval coagulation factor activity when adding platelets.  
 
The clinical significance of minor derangements in coagulation factor activity is 
uncertain. Jansen et al. performed a post hoc analysis of the effect of hypoperfusion (by 
measuring lactic acidosis) on the activity of coagulation factors (190, 197, 198). This 
analysis concluded that hypoperfusion in trauma patients was associated with a 
moderate, dose-dependent reduction in the activity of coagulation factors II, VII, IX, X, 
and XI, and a more marked reduction in factor V activity, which is relatively 
independent of the severity of shock. Moreover, they found preservation of coagulation 
factor activity in the majority of normally and moderately hypoperfused patients. This 
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suggests that aggressive administration of plasma is probably only indicated in severely 
hypoperfused patients. The results presented in this chapter support these findings and 
also that of Rizoli et al. with the greatest deterioration seen in factor V as patients 
continue to bleed (192). Despite this, the majority of patients in both studies had 
coagulation factor activity levels within the normal range, implying that either the 
reference ranges for trauma patients may need to be adjusted to represent the injured 
population or, alternatively, minor alterations in coagulation factor activity have 
possibly resulted in a combined added effect, resulting in altered haemostasis (192). 
Their study, like others (192), was limited to using critical coagulation factor activity 
levels associated with clinically relevant abnormalities. These thresholds are based on 
the study of patients with hereditary single-factor deficiencies which may not be 
applicable to the trauma setting. Furthermore, it is classically accepted that the loss of 
70% of coagulation factor concentration is not generally associated with a bleeding 
diathesis (199). It is below this level, with approximately 30% residual coagulation 
factors, that the PTr is approximately 1.5 times the midpoint of the normal reference 
range, levels that should provide sufficient functional clotting factor activity (199). This 
is broadly accepted as indicative of a major haemostatic defect and has been used by 
haematologists as the threshold for normal blood clotting in congenital coagulopathies. 
However, TIC is an acquired coagulopathy and previously published work has shown 
that clinically relevant coagulopathy is as prevalent at PTr values of greater than 1.2. 
Therefore, while in non-trauma patients, normal haemostasis requires only 30% of 
activity from each individual clotting factor, the levels needed after injury or when 
multiple deficiencies coexist are not known. Furthermore, it is possible that they are 
significantly higher than the critical thresholds used in this study. Therefore, the critical 
threshold for coagulation factor activity is perhaps greater than 30% and should be re-
evaluate using minor severity injured trauma patients as a comparator.  
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6.6 Limitations 
 
This study has several limitations. As described above, there are inherent problems with 
using a threshold value of 30% for defining a critical clotting factor deficiency—this 
definition has not previously been used in the trauma context. It was impossible to 
perform coagulation factor assays in all bleeding patients, mostly due to difficulties in 
obtaining sufficient blood samples in all patients. This issue was predominantly seen in 
patients that exsanguinated at a high rate and therefore sequential blood draws were 
logistically impossible. Another limitation was the lack of standardised definitions for 
early trauma-associated coagulopathy. There is no universally acknowledged threshold 
value of INR or aPTT that defines coagulopathy, potentially affecting the translation of 
these findings.  
 
6.7 Conclusions 
 
The findings of this study have important clinical implications. The pillars of DCR are 
aggressive clotting factor replacement with permissive hypotension. Early high-dose 
FFP elicits a variable response in the coagulation system. It is long believed that blood 
component therapy exerts its haemostatic benefits via increased concentrations of active 
coagulation factors. The present study shows that, on the whole, critical clotting factor 
deficiencies do not occur immediately after injury, prior to substantial fluid 
resuscitation. 
  
	   177	  
 
 
 
CHAPTER SEVEN 
 
Conclusions 
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7.1 Summary of the findings 
 
This thesis has tested the hypotheses described in Chapter One, and has led to significant 
and novel contributions to the body of knowledge regarding the role of blood component 
use in DCR.  
 
Chapter Three successfully described the effect of the implementation of an MHP on 
outcome and blood product administration. Major haemorrhage protocols are required as 
part of DCR regimens in modern trauma care, and the hypothesis tested in this study 
stated that major haemorrhage protocols improve blood product administration and 
reduce waste compared to traditional MTPs.  
 
Fundamentally, outdated MTPs targeted dilutional coagulopathy that occurs after a 
massive transfusion, while MHPs target ATC. This approach fundamentally supports a 
new way of thinking, moving from identifying patients who will, at some point, require 
10 or more units of blood, to identifying those who, on arrival, are bleeding and already 
coagulopathic. I believe that a MHP is therefore conceptually more suited to the DCR 
paradigm. 
 
In this study, the administration of blood component therapy significantly improved post 
MHP implementation, with specific enhancements to both FFP and CRYO to PRBC 
ratios. Platelet transfusion improved by 15%, and there was a significant reduction in the 
wastage of platelets from 14% to 2%. The introduction of an MHP also correlated with 
improved clinical outcomes, where median hospital LOS was reduced by half. In 
conclusion, implementation of a MHP results in improved delivery of blood components 
and a reduction in the wastage of blood products compared to the older model of a MTP. 
Furthermore, in combination with educational programmes, MHPs can significantly 
	   179	  
improve blood product administration and patient outcomes in trauma haemorrhage as 
well as reduce cost. 
 
Chapter Four hypothesised that TIC deteriorates during acute trauma haemorrhage. 
Within this study, I have successfully described the effects of DCR in the acute phase of 
trauma haemorrhage. The evolution of coagulopathy and the effect of DCR in correcting 
TIC and restoring tissue perfusion during acute haemorrhage had not been previously 
studied in the context of severely injured trauma patients. The specific aims of the 
chapter were to characterise the incidence and severity of TIC during the acute phase of 
DCR, characterise lactate clearance during haemorrhage, and determine whether DCR 
achieves its stated aims of correcting coagulopathy and restoring perfusion during 
trauma haemorrhage. 
 
I conducted a prospective cohort study of ROTEM and lactate measurements taken from 
trauma patients. On admission, 40% of patients were coagulopathic and this number 
increased to 58% after 4 U of PRBCs and to 81% after 8 U of PRBCs. On average, all 
functional coagulation parameters deteriorated during haemorrhage. Clot strength and 
clotting times only corrected when no further PRBCs were needed. The average 
admission lactate was 6.2 mEq/L. Trauma patients with hyperlactatemia on admission 
did not clear lactate until haemorrhage control was achieved and no further transfusion 
of PRBC units was required. I concluded that DCR offers several advantages over 
traditional strategies; however, it still does not achieve the correction of hypoperfusion 
or coagulopathy during the acute phase of trauma haemorrhage.  
 
Chapter Five succeeded in determining the efficacy of blood component therapy in the 
correction of TIC during haemorrhage. DCR strategies target TIC with the early delivery 
of high-dose blood components such as FFP and platelet transfusions. However, the 
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ability of these products to correct TIC during haemorrhage and their effect on the 
coagulation profile was unknown. 
 
Within this study, I demonstrated that there was no clear benefit observed with high-
dose FFP therapy in any coagulation parameter, contrary to current belief. Only 
combined high-dose FFP, CRYO and platelet therapy, along with a high total fibrinogen 
load, appeared to produce a consistent improvement in coagulation. This chapter 
concluded that DCR with standard or average doses of blood components does not 
consistently correct TIC during haemorrhage.  
 
The importance of the findings of both Chapter Four and Chapter Five are particularly 
relevant in light of the recent publication of the Pragmatic Randomized Optimal Platelet 
and Plasma Ratios (PROPPR) trial (138). This multicentre, randomised and controlled 
trial suggests better outcomes from a 1:1:1 ratio in secondary analyses. In contrast to the 
data presented in this current thesis, the authors of the PROPPR trial did not present any 
data on the effect of the different ratios on coagulation or resuscitative parameters. At 
present, it is therefore unclear how a higher dose of plasma might exert its effect on 
haemostasis.  
 
In Chapter Five, I was able to expand on the relationship between blood component 
delivery during the acute phase of trauma haemorrhage and the viscoelastic measures of 
coagulation. In both Chapter Four and Chapter Five, the majority of major haemorrhage 
protocols were activated in the field by physician-led medical teams. Consequently, the 
first products transfused on arrival were PRBCs and FFP in high empiric ratios with 
pooled platelets (equivalent to 6 U) administered in the second and subsequent packs or 
coolers. All of the study patients were treated at Level 1 trauma centres with 24-hour 
access to damage control surgery with anatomic control of haemorrhaging. Completing 
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transfusions was therefore rapid and typically occurred within the first two to three 
hours following admission, thus allowing the analysis of the acute bleeding phase.  
 
The PROMMTT study has also provided valuable observational data on trauma-induced 
coagulation, transfusion, and outcome (56, 200). Restricted crystalloid use remains a key 
component of hemostatic resuscitation; however, neither the PROMMTT publication 
nor the PROPPR study presents any data on crystalloid use (138, 200). Cotton et al. 
(185) have shown, in a contemporary retrospective study of DCR versus pre-DCR, that 
crystalloid use, although reduced in DCR, remains not insignificant, with equivalent 
volumes (pre-hospital, 300–900 mL; emergency department, 200–2,000 mL; and 
operating room, 1,800–4,100 mL) to those reported in this thesis. Moreover, another 
publication from the PROMMTT study has actually demonstrated that pre-hospital 
crystalloid use is associated with improved survival (201). In both of my studies, none of 
the patients received colloid during active haemorrhage. The question of optimal 
intravenous fluid administration in the early phase that follows the control of major 
haemorrhage remains unanswered, particularly in patients who continue to be 
intravascularly depleted without signs of ongoing bleeding and adequate haemoglobin.  
 
The primary focus of these two chapters was to examine whether hemostatic 
resuscitation is able to correct coagulation, restore tissue oxygenation, and repay oxygen 
debt in trauma haemorrhage. I have shown that DCR with standard doses of blood 
components does not consistently correct TIC during ongoing bleeding.  
 
In this body of work, I have shown that the mean dose of FFP administered (3.2 U) per 4 
U of PRBCs has no effect on clotting time, clot generation, or maximum clot firmness 
on ROTEM. Adding cryoprecipitate (an average of 1.6 pools per interval) and platelets 
(an average of 1 pool per interval) showed some protection of the clotting function 
across the interval, but only an improvement in the clotting time was statistically 
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significant. Moreover, there was no clear benefit connected to high-dose FFP therapy in 
any coagulation parameter. It seems that the magnitude of coagulopathy is so large that, 
in trauma patients with uncontrolled haemorrhage, restoration of normal clotting factor 
levels may not be possible with current transfusion algorithms that use products less 
concentrated than whole blood. Further research is required on the efficacy of the early, 
concentrated, and targeted replacement of key clotting substrates—for example, 
fibrinogen in not only reversal of coagulopathy but also for controlling haemorrhage and 
in terms of patient outcomes.  
 
Finally, Chapter Six successfully described the effect of blood component therapy on 
coagulation factor concentration during trauma haemorrhage.    
 
Given that a mainstay of trauma management is the replacement of lost and consumed 
coagulation factors, the very fact that coagulopathy is commonly seen during trauma 
resuscitation points to a possible hypothesis that we are not giving enough coagulation 
factors during this phase of care. Many classical accounts of TIC describe it as a 
relatively late event resulting from consumption and loss of clotting elements and their 
iatrogenic dilution by resuscitation (32). Consequently, aggressive transfusion therapy 
with FFP and platelets could prevent or correct clotting deficiencies by providing higher 
concentrations of coagulation factors, and may improve the coagulation profile and 
survival.  
 
As stated above, the pillars of DCR include aggressive clotting factor replacement with 
permissive hypotension. However, the principle findings of Chapter Six showed that not 
only were coagulation factor concentrations, on the whole, maintained on admission, but 
they also did not fall to clinically critical levels in severely injured and bleeding trauma 
patients. Interestingly, investigators from the PROMMTT study also conducted a subset 
analysis of 165 trauma patients, where plasma was prospectively assayed for coagulation 
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factor concentration (202). In this subset analysis of TIC vs non-TIC patients, TIC was 
shown to be characterised by reductions of coagulation proteases and fibrinogen; 
however, none of these coagulation proteases reached clinically significant 
concentrations. This data, in addition to the work presented in Chapter Six, gives weight 
to the argument that TIC may be mediated by the activation of the protein C system 
(75).  
 
Activated protein C is a serine protease, which, once activated in a mechanism that 
involves thrombin, thrombomodulin, and the endothelial protein C receptor, mediates its 
anticoagulant effects through direct proteolytic cleavage of factors V and VIII. The data 
presented here—in addition to the data generated by the PROMMTT study—showed 
decreased factor V to a point of clinically relevant concentrations and a trend towards 
significance in factor VIII levels, which lends support to the aPC hypothesis that ATC is 
mediated through the proteolytic inactivation of factors V and VIII. In a separate study, 
Rizoli et al. also reported that 20% of all severely injured patients had critical clotting 
factor deficiency on admission, particularly of factor V, which indicates a broad 
depletion of factor levels after injury (192) and is suggestive of coagulopathy after 
trauma. However, the majority of patients in this study still had coagulation factor 
activity higher than critical concentration reference ranges.  
 
Furthermore, findings from Chapter Six revealed that transfusions of blood components 
in the form of FFP in average doses had little effect on coagulation factor 
concentrations. Moreover, transfusing higher ratios of FFP did not confer any additional 
benefit over lower ratios in terms of correcting coagulation factor levels. It remains 
unclear whether reduced factor levels in general represent enhanced but nonpathologic 
functional protease activation toward fibrin production, or whether these reduced levels 
seen here and in studies published by others is evidence of dilution or pathologic 
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depletion. Nonetheless, blood component therapy had little discernable effect on 
coagulation factor concentration. 
 
7.2 Strengths and limitations of this thesis 
 
A significant achievement of this project is to have set up and conducted the UK’s single 
largest ongoing prospective evaluation of blood component therapy in trauma patients to 
date. Although it is notoriously difficult to undertake and traditionally prohibitive to 
conduct research in trauma, a further key strength of my study is the successful use of 
emergency consenting procedures. Specifically, the use of a PrLAR was able to provide 
consent for inclusion in the ACIT II study. Patient consent was successful in over 95% 
of cases, thus demonstrating that large-scale research can be performed in the 
emergency clinical scenario through the application of a well-designed and executed 
protocol. The enrolment of all patients requiring trauma team activation provided a 
control population of trauma patients with only minor injuries (ISS<5) and normal 
admission physiology. The large number of patients enrolled enabled normal reference 
ranges for all parameters to be established for this uninjured cohort. This robust system 
remains in place, and thus enables ongoing data collection. This is the first prospective 
study to show evidence that aggressive transfusions of plasma have very little effect in 
reversing the coagulopathy caused by severe trauma bleeding.   
 
There are, however, notable limitations to the work presented in this dissertation. In the 
first instance, the study described in Chapter Three could have been subject to inaccurate 
documentation of patient characteristics and their outcomes due to the study’s 
retrospective nature. However, despite historic controls, there is a relatively tight time 
frame between the two studied periods and the clinical characteristics of the two cohorts, 
and presenting physiology was very similar.   
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Furthermore, the triggering criteria for the MHP had not been validated, although 
clinically relevant and based on expert consensus. The clinical assessment of fluid 
response is, of course, vital to the assessment of ongoing haemorrhage, as opposed to a 
single blood pressure reading. The clinician must also suspect haemorrhage rather than 
tamponade or other shock physiology. Unfortunately, the exact timing of plasma 
administration was not available to me in this retrospective study, and it is now the 
subject of my ongoing prospective work. Consequently, without continuous assessment 
of coagulation, it is difficult to know when coagulopathy was actually resolved; 
therefore, it was not possible to examine this in Chapter Three, but, again, I explored 
this prospectively in later chapters. 
 
The trauma population studied in this thesis are a heterogeneous group. I enrolled 
patients known to have, or who have had, a high index of suspicion for bleeding based 
on abnormal primary survey findings at admission, as, at this stage, one is unable to 
detect the exact nature of their injuries in order to match injury cohorts. While this 
resulted in a heterogeneous cohort, my study does reflect the clinical presentation of 
polytrauma patients as seen in MTCs and for whom MHPs and targeted component 
therapy may have the most utility. 
 
I found a large variability in the coagulation response to FFP transfusion among the 
different study participants. In order to adequately account for this heterogeneity in 
future studies, I will need to use data mining techniques and exploratory data analysis to 
understand the relevance of each variable, and to dimensionally reduce the complexity. 
Techniques that could be used include clustering, principal component analysis and 
network analysis. These techniques would help to understand the patterns in larger data 
sets, to reduce the variables to those that are mathematically most relevant, and to 
explore the data in ways that are not limited to traditional scrutiny.    
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Collecting samples from bleeding patients was, in some cases, particularly challenging, 
especially across three international centres. In order to deal with the complexities of an 
international observational study, regular site visits to audit data entry were carried out. 
This not only ensured that the strict inclusion criteria for the ACIT II study was adhered 
to, but also enhanced the accuracy of the data analysed.  
 
Missing data for blood samples were, unfortunately, frequent, due in part to the practical 
difficulties involved in taking blood from patients with such critical injuries. This 
occurred over all three sites. Reliance on pre-hospital data was kept to a minimum, 
however, as all three centres collected prospective data via their respective pre-hospital 
medical emergency services. Clinical needs understandably took priority in patients with 
life-threatening injuries and, thus, serial blood sampling was not always possible, 
rendering some data sets incomplete. This was frequently the case with patients who 
were extremely injured and required the largest volume of blood component transfusion.  
 
An important limitation in this body of work was the extreme difficulty in ascertaining 
the precise timing of haemorrhage control in severely injured and acutely bleeding 
patients. This was further compounded by the fact that microvascular bleeding may 
continue after haemorrhage control or the repair of major vascular injury. Throughout 
this thesis, I have taken a pragmatic approach and used a surrogate marker of the 
cessation of blood product administration as a possible alternative. Furthermore, to 
ensure I capture the acute phase of the bleeding response, all of these patients would 
have had control of haemorrhage within the first one to two hours of their arrival in the 
emergency department. Clearly, the more shocked a patient is, or the longer they remain 
shocked, the worse the coagulopathy is likely to be and will further drive the bleeding, 
shock and coagulopathic process.  
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While bleeding is important, there is building evidence that suggests that coagulopathy 
actually represents a perturbed inflammatory milieu and is associated with endothelial, 
epithelial, and organ dysfunction. Hence, whether haemostatic resuscitation prevents 
mortality by the attenuation of bleeding or the attenuation of an ‘endotheliopathy’ 
remains a crucial question. This will only be addressed by a comprehensive 
characterisation of coagulation and inflammation after injury, coupled with animal and 
in vitro based studies.  
 
I prospectively captured PRBC interval data on coagulation response to reduce the 
biases present in previous retrospective studies. However, certain temporal limiting 
effects do remain, and cannot be examined in this study due to the relatively small 
patient numbers. In a rapidly exsanguinating trauma patient, a lack of immediately 
available FFP will prohibit the transfusion of higher FFP:PRBC ratios, such that patients 
who bleed more briskly tend to receive lower ratios as do patients who die of 
exsanguination (54). When blood component therapy is considered as a time-dependent 
covariate, the survival advantage becomes less clear. I have shown that patients are more 
likely to receive higher ratios between PRBC 8 and 12. However, the interval cohorts 
may be influenced by confounding due to the institution’s transfusion practice, rate of 
blood loss, or early haemorrhage control. Patients with rapid bleeding are more likely to 
require 8 U of PRBCs and enter the 8 U to 12 U interval, by which time FFP is 
available, thereby increasing the FFP:PRBC ratio. Similarly, patients who have brisk 
haemorrhage control or for whom bleeding stops spontaneously may not require 8 U 
and, therefore, are unlikely to have received a high dose of plasma as a result of our 
transfusion protocol. Thus, some patients died not because they did not receive 
treatment; they did not receive treatment because they died.  
 
In order to reduce survivor bias, I have purposefully excluded mortality data and 
concentrated on the coagulation profile as a primary outcome. If anything, non-survivors 
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would possibly have a higher bleeding rate and are likely to have worse coagulation 
profiles during resuscitation. However, I do not believe their exclusion materially affects 
any of the results I am presenting, as I am not reporting survival or other outcome 
effects, only coagulation profile response during haemorrhage. Furthermore, for the 
overall increasing coagulopathy across groups, ‘survivor bias’ would lead to an 
underestimation of effect. Patients with a sample at PRBC 12 are alive. Patients at 
PRBC 8 who then die from haemorrhage would likely have had a worse coagulopathy 
and, therefore, my results would, if anything, underestimate the trend if this effect were 
real. In this small study, it is difficult to precisely quantify the influence these factors 
could have on my data. A future study that incorporates a larger number of patients and 
that should allow these temporal effects to be fully analysed is currently ongoing.  
 
The confidence intervals were very wide in places, and suggested this investigation 
lacks a sufficient number of patients to achieve statistical significance. Indeed, although 
there was a large overall study population, certain categories, such as deceased patients 
≥65 years with an ISS<5, have few or no patients; this will have led to incomplete data 
analyses. As a result of all these, the statistical validity of the results may have been 
undermined, and thus the strength of the study’s overall conclusions weakened. 
Furthermore, as a relatively inexperienced researcher at the start of my studies, I 
acknowledge the limitations of my statistical analysis. Throughout the experimental 
chapters, I used simple yet appropriate statistical tests to compare pairs or groups. In 
Chapter Three, I measured the effect of implementing a MHP on clinical outcomes such 
as length of stay. However, the introduction of a MHP may not be the only factor 
associated with a change in outcome, and confounders such as age, gender and 
admission shock could also play a role. While patients analysed in this chapter and in 
subsequent studies received standardised transfusion protocols, surgical interventions 
and comparable ICU management, confounders might have been accounted for using 
multivariate logistic regression modeling. In the future, I will seek further statistical 
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advice that will allow me to account for confounders and identify strong associations 
between blood component therapy and outcomes.  
 
Finally, many of the conclusions in this thesis are based on associations made in 
relatively small study populations. Although larger than many previous investigations, 
the existing data would benefit from substantiation in future studies using greater 
statistical power. 
  
7.3 Clinical importance and future work 
 
The devastating effect of ATC on the morbidity and mortality of trauma patients 
underlines both the social and scientific imperative for a better understanding of the 
treatment of this condition. There is an engaging and important debate about the 
optimum treatment or prevention strategy required to target ATC. Ultimately, the aim of 
the research generated and presented in this thesis will be to identify opportunities to 
reduce the mortality and morbidity associated with trauma. Little was known about the 
effect of DCR on the coagulation profile during trauma haemorrhage. This work has 
shown that DCR, in the form of MHPs, is beneficial in the trauma setting but, in average 
doses, blood component therapy (while maintaining coagulopathy) has little effect on 
reversing TIC. Of all the blood components, high-dose fibrinogen (in the form of FFP or 
CRYO) exerted the greatest benefit. The body of knowledge generated by this thesis has 
directly changed the management of the severely injured and bleeding trauma patient. 
The new revised Code Red protocol incorporating goal-directed ROTEM parameters at 
the RLH is detailed in Figure 7.1.  
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Figure 7.1. The RLH’s revised major haemorrhage protocol. (2014) 
  
Cryoprecipitate is the standard method of fibrinogen supplementation in the UK. 
Fibrinogen concentrate (FgC) is also available, and is increasingly being used as therapy 
for major haemorrhages. A Cochrane Review of six small trials, none in a trauma 
setting, evaluated the effectiveness of FgC for patients with bleeding. It found limited 
data and reported no effect on overall mortality, but did find a reduction in allogeneic 
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•TXA 1g bolus + start 1g infusion 
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•POC FBC 
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•TEMP >34C 
•CALCIUM >1mmol/L 
DCS 
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THROMBIN 
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blood transfusion (203). The evidence relating to the clinical effectiveness of CRYO is 
more limited, with no randomised controlled trials completed to date (204). Randomised 
controlled trials evaluating transfusion therapy in trauma are further complicated by 
virtue of the emergent clinical situation, availability of research personnel outside 
normal working hours, and time pressure with regard to administering the thawed blood 
product within a clinically relevant time frame. The body of work within this thesis 
supports the need for larger studies to determine the clinical benefits of early fibrinogen 
supplementation.  
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Appendix 1. ACIT II patient information sheet 
  
10.09.2010 Info Sheet A – Subject. V2 Page 1 
Date: _ _ / _ _ / _ _ Researcher Initials: ____ 
   
Patient information sheet   
 
DIRECTORATE OF SURGERY AND ANAESTHESIA 
ROYAL LONDON HOSPITAL, WHITECHAPEL, LONDON E1 1BB 
 
Information Sheet A: Subject  
Version 2, 10.09.2010 
 
East London and the City Research Ethics Committee 1 
REC number: 07/Q0603/29 
 
Title: Activation of Coagulation & Inflammation in Trauma II   
Principal Investigator: Professor Karim Brohi, FRCS FRCA    
 
Date: ___/___/_____ 
 
Subject Name: _______________________.   NHS Ref: ________________ Study Ref: ________ 
 
 
Introduction 
You are being invited to take part in a research study. This research will help us to improve the care 
of patients who suffer severe injuries in the future. Before you decide, it is important for you to 
understand why the research is being done and what it will involve.  Please take time to read the 
following information carefully. Talk to others about the study if you wish. Ask us if there is anything 
that is not clear or if you would like more information. Take time to decide whether or not you wish 
to take part. 
 
Why is this research being carried out? 
Trauma (serious injury) is the leading cause of death and disability in children and young adults 
worldwide. Over half of all trauma deaths are due to bleeding or the complications resulting from it.  
Injury, shock and blood loss all contribute to a failure of the body’s normal blood clotting 
mechanisms (coagulation), which then leads to more bleeding.  The mechanisms of these disorders 
in blood clotting and how they affect the body are not well understood, and we hope that this 
research will help us to determine why, when and how the blood clotting mechanisms fail, and what 
the consequences of this are. 
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Date: _ _ / _ _ / _ _ Researcher Initials: ____ 
 
Why have I been chosen? 
On ___ - ___ - ______ (date), you were injured and admitted to the Royal London Hospital.  At the 
time, you were unable to give informed consent. When you arrived in the emergency department, a 
full trauma team of doctors and nurses attended to you.  The trauma team leader, who is not part of 
this research study, gave consent as your representative for you to be enrolled in this study. As part 
of the immediate management blood is taken and sent to the laboratory for analysis. A small 
amount of extra blood (approximately six teaspoonfuls) was drawn and saved for research 
purposes.  We are now asking for your consent to allow us to use the samples we have collected 
and to continue to participate in the study, since all the procedures have not yet been completed.  
Should you not wish to continue your involvement in the trial we may ask for your consent to place 
the samples already collected in a registered research tissue bank for use in future research. 
 
Do I have to take part? 
No, participation is completely voluntary. It is up to you to decide whether or not to take part. If you 
do, you will be given this information sheet to keep and be asked to sign a consent form. You are 
still free to withdraw at any time and without giving a reason. A decision to withdraw at any time, or 
a decision not to take part, will not affect the standard of care you receive. 
 
What will happen to me if I take part? 
If you agree to continue with the study the following will happen:  
1. We will store and process the samples we have already collected.  
 
2. We will continue to collect blood samples until the third day in hospital.  We will draw ___ blood 
samples in total. ___ (number) of these have already been obtained.  Each blood sample is 
equivalent to six teaspoonfuls, and the total amount of blood drawn over three days is less than 
six fluid ounces.  Wherever possible we will draw the blood out of a line already in a blood 
vessel, or coincide the blood draw with tests required for your care, in order to minimize any 
discomfort from the procedure.  
 
3. At day 28 or on your day of discharge (whichever is sooner) and again at one year following your 
injury and admission to hospital we will provide you with a short questionnaire to complete.  Each 
questionnaire should take approximately five minutes to complete.  The answers to the questions 
will provide us with valuable information about how you perceive your quality of life after the 
injury as well how many times you have had to visit healthcare professionals (doctors, 
physiotherapists, specialist nurses etc).  All answers to the questions will remain confidential. 
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What do I have to do? 
If you agree to continue with the study the following will happen: 
1. We will collect ___ (number) of further blood samples from you, on ______________________  
                   (date/times) 
2. We will ask you to complete a short questionnaire at day 28 or on your day discharge (whichever 
is sooner) and again at one year following your injury and admission to hospital. 
 
What are the possible disadvantages and risks of taking part in the study? 
There are no long-term risks to you from participating in this study.  The specific risks associated 
with each sample are as follows: 
• Blood samples - the risks of drawing blood include temporary discomfort from the needle stick 
and bruising.  
 
What are the possible benefits of taking part in the study? 
There will be no direct benefit to you from participating in this study, but we hope that the 
information we get will help to improve the care of trauma patients in the future. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible harm you 
might suffer will be addressed. The detailed information on this is given in Part 2. 
 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. The details are included in Part 2. 
  
This Completes Part I. 
If the information in Part 1 has satisfied you and you are considering continuing in the study,  
please read the additional information in Part 2 before making any decision. 
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PART 2 
What will happen if I don’t want to carry on with the study? 
If you decide, at any time, to withdraw from the study all study procedures will be stopped 
immediately.  Any information and samples that have already been collected will be processed as 
part of the study unless you wish to have your samples withdrawn from the study, in which case we 
will destroy them.  Your decision will in no way result in a change in the type or quality of care you 
subsequently receive.  Should you not wish to remain in the trial we may ask for your consent to 
place the samples already collected in a registered research tissue bank for use in future research. 
 
What if I am not happy about the study? 
We will only make very minor changes to the way we look after you. It is extremely unlikely that this 
small change to normal practice would cause any problems. However, if you are harmed by taking 
part in this study, there is no special compensation arrangement. If you are harmed due to 
someone’s negligence, then you may have grounds for legal action but you may have to pay your 
legal costs. Regardless of this, if you wish to complain or have any concerns about any aspect of 
the way you have been approached or treated during the course of this study, the normal National 
Health Service complaints mechanisms should be available to you.  Please contact Patient Advisory 
Liaison Service (PALS) if you have any concerns regarding the care you have received, or as an 
initial point of contact if you have a complaint.  Please telephone 020 3594 2040, or email 
pals@bartshealth.nhs.uk . You can also visit PALS by asking at any hospital reception. 
 
Will my taking part in the study be kept confidential? 
All information which is collected about you during the course of the research will be kept strictly 
confidential and will be stored securely in coded form. Information about you and your samples will 
be identifiable only in a coded format, separate from your personal information. Only authorised 
personnel such as researchers and research auditors will have access to the data.  
 
What will happen to your study data and samples? 
Your study data and samples (i.e. materials) will always be collected, stored, transferred and used 
in a secure and ethical manner that ensures protection of your fundamental rights and privacy. All 
materials will initially be processed at the research centre where you were enrolled and linked to 
you by a unique study identifier (i.e. coded). As part of this research study, we would also like to add 
some of the materials that have been collected to an international trauma database and tissue bank. 
These centralised collections will be used by trauma investigators across the world, to increase the 
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Who has reviewed the study?  
All research in the NHS is looked at by independent group of people, called a Research Ethics 
Committee to protect your safety, rights, wellbeing and dignity. This study has been reviewed and 
given favourable opinion by East London & City Research Ethics Committee 1. 
 
Who can I contact for further information? 
1. If you require further information about the study, please contact the ACIT researchers by 
telephone: 020 3594 0731  or by email: Claire.rourke@bartshealth.nhs.uk or 
sirat.khan@qmul.ac.uk  
 
2. If you require impartial, local advice, please contact the Patient Advice and Liaison Service, 
telephone: 020 3594 2040  or e-mail: pals@bartshealth.nhs.uk.  
 
Thank you for taking the time to read this information.  
 
Date: ___/___/_____         Researcher Signature: ______________ _____ 
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Personal Consultee (PC) information sheet  
 
DIRECTORATE OF SURGERY AND ANAESTHESIA 
ROYAL LONDON HOSPITAL, WHITECHAPEL, LONDON E1 1BB 
 
Information Sheet E: PC 
Version 2, 10.09.2010 
 
East London and the City Research Ethics Committee 1 
REC number: 07/Q0603/29 
 
Title: Activation of Coagulation & Inflammation in Trauma II   
Principal Investigator: Professor Karim Brohi, FRCS FRCA    
 
Date: ___/___/_____ 
 
Subject Name: _______________________.   NHS Ref: ________________ Study Ref: ________ 
 
 
Introduction 
We would like to invite you to agree to your relative/significant other taking part in a research study, 
while they are unable to give consent for themselves. This research will help us to improve the care 
of patients who suffer severe injuries in the future. Before you decide, it is important for you to 
understand why the research is being done and what it will involve.  Please take time to read the 
following information carefully. Talk to others about the study if you wish. Ask us if there is anything 
that is not clear or if you would like more information. Take time to decide whether or not you agree 
to your relative/significant other taking part. 
 
Why is this research being carried out? 
Trauma (serious injury) is the leading cause of death and disability in children and young adults 
worldwide. Over half of all trauma deaths are due to bleeding or the complications resulting from it.  
Injury, shock and blood loss all contribute to a failure of the body’s normal blood clotting 
mechanisms (coagulation), which then leads to more bleeding.  The mechanisms of these disorders 
in blood clotting and how they affect the body are not well understood, and we hope that this 
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research will help us to determine why, when and how the blood clotting mechanisms fail, and what 
the consequences of this are. 
 
Why has my relative/significant other been chosen? 
On ___ - ___ - ______ (date), your relative/significant other was injured and admitted to the Royal 
London Hospital.  They were unable to give informed consent. When they arrived in the emergency 
department, a full trauma team of doctors and nurses attended to them.  The trauma team leader, 
who is not part of this research study, gave consent as a representative for your relative/significant 
other to be enrolled in this study.  As part of the immediate management blood is taken and sent to 
the laboratory for analysis.  A small amount small amount of extra blood (approximately six 
teaspoonfuls) was drawn and saved for research purposes.  We are now asking for your consent to 
allow us to use the samples we have collected and to allow your relative/significant other to 
continue in the study, since all the procedures have not yet been completed.  Should you not wish  
your relative/significant other to remain in the trial we may ask for your consent to place the samples 
already collected in a registered research tissue bank for use in future research. 
 
Do I have to agree? 
No, participation is completely voluntary. It is up to you to decide whether or not your 
relative/significant other should take part. If you do, you will be given this information sheet to keep 
and be asked to sign a consent form. You are still free to withdraw at any time and without giving a 
reason. A decision to withdraw at any time, or a decision not to take part, will not affect the standard 
of care your relative/significant other receives. 
 
What will happen to my relative/significant other if they take part? 
If you agree to continue with the study the following will happen: 
 
1. We will store and process the samples we have already collected. 
2. At day 28 or on the day of discharge (whichever is sooner) and again at one year following your 
injury and admission to hospital we will provide your relative/significant other with a short 
questionnaire to complete.  Each questionnaire should take approximately five minutes to 
complete.  If your relative/significant other is unable to complete the questions we may ask you to 
assist in the process and/or answer some of the questions on their behalf.  The answers to the 
questions will provide us with valuable information about how they perceive their quality of life 
after the injury as well how many times they have had to visit healthcare professionals (doctors, 
physiotherapists, specialist nurses etc).  All answers to the questions will remain confidential. 
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We will continue to collect blood samples until the third day in hospital.  We will draw ___ blood 
samples in total. ___ (number) of these have already been obtained.  Each blood sample is 
equivalent to six teaspoonfuls, and the total amount of blood drawn over three days is less than six 
fluid ounces.  Wherever possible we will draw the blood out of a line already in a blood vessel, or 
coincide the blood draw with tests required for care, in order to minimize any discomfort. 
 
What do I have to do? 
If you agree for your relative/significant other to continue with the study the following will happen: 
1. We will collect ___ (number) of further blood samples on ______________________ 
(date/times) 
 
2. We will ask your relative/significant other to complete a short questionnaire at day 28 or on their 
day discharge (whichever is sooner) and again at one year following their injury and admission to 
hospital.  Completion of the questionnaire may require your assistance if your relative/significant 
other is unable answer the questions themselves. 
 
What are the possible disadvantages and risks of taking part in the study? 
There are no long-term risks from participating in this study.  The specific risks associated with each 
sample are as follows: 
1. Blood samples  
The risks of drawing blood include temporary discomfort from the needle stick and bruising. 
 
What are the possible benefits of taking part in the study? 
There will be no direct benefit to your relative/significant other from participating in this study, but we 
hope that the information we get will help to improve the care of trauma patients in the future. 
 
What if there is a problem? 
Any complaint about the way you or your relative have been dealt with during the study or any 
possible harm they might suffer will be addressed. The detailed information on this is in Part 2. 
 
Will taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about your relative/significant other 
will be handled in confidence. The details are included in Part 2. 
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This Completes Part I 
If the information in Part 1 has satisfied you and you are considering continuing in the study,  
please read the additional information in Part 2 before making any decision. 
 
 
Date: ___/___/_____         Researcher Initial: _____ 
 
 
 
 
PART 2 
What will happen if I don’t want to carry on with the study? 
If you or your relative/significant other decides, at any time, to withdraw from the study all study 
procedures will be stopped immediately.  Any information and samples that have already been 
collected will be processed as part of the study unless you wish to have your samples withdrawn 
from the study, in which case we will destroy them.  Your decision will in no way result in a change 
in the type or quality of care you subsequently receive. Should you not wish for your 
relative/significant other to remain in the trial we may ask for your consent to place the samples 
already collected in a registered research tissue bank for use in future research. 
 
 
What if I am not happy about the study? 
We will only make very minor changes to the way we look after your relative/significant other. It is 
extremely unlikely that this small change to normal practice would cause any problems. However, if 
they are harmed by taking part in this study, there is no special compensation arrangement. If they 
are harmed due to someone’s negligence, then you may have grounds for legal action but you may 
have to pay your legal costs. Regardless of this, if you wish to complain or have any concerns about 
any aspect of the way you or your relative have been approached or treated during the course of 
this study, the normal National Health Service complaints mechanisms should be available to you.  
Please contact Patient Advisory Liaison Service (PALS) if you have any concerns regarding the 
care you have received, or as an initial point of contact if you have a complaint.  Please telephone 
020 3594 2040, or email pals@bartshealth.nhs.uk. You can also visit PALS by asking at any 
hospital reception. 
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Will my taking part in the study be kept confidential? 
All information which is collected about you during the course of the research will be kept strictly 
confidential and will be stored securely in coded form. Information about you and your samples will 
be identifiable only in a coded format, separate from your personal information. Only authorised 
personnel such as researchers and research auditors will have access to the data.  
 
What will happen to your study data and samples? 
Your study data and samples (i.e. materials) will always be collected, stored, transferred and used 
in a secure and ethical manner that ensures protection of your fundamental rights and privacy. All 
materials will initially be processed at the research centre where you were enrolled and linked to 
you by a unique study identifier (i.e. coded). As part of this research study, we would also like to add 
some of the materials that have been collected to an international trauma database and tissue bank. 
These centralised collections will be used by trauma investigators across the world, to increase the 
scale and impact of injury research projects. This will reduce the time taken to bring benefit to future 
trauma patients. 
Some materials will be transferred to a central data registry (in the UK) and tissue bank (in 
Denmark). Materials may then be provided to external researchers for approved injury research. 
The design and secure usage of both of these coordinating research facilities is according to 
national safety and governance standards (e.g. UK Data Protection Act 1998, Directive 95/46/EC, 
Oviedo Convention Rec (2006)4). Study materials will not be able to be linked back you, other than 
by responsible personnel at the site of your original enrolment. The coded data and samples will 
only be accessed by authorised personnel (e.g. research fellows, study auditors).  
We will not share your personal details (e.g. name, address). Research conducted may contain key 
personal information of necessity for research (e.g. age, gender, clinical and treatment data) but all 
study information will be anonymised at the end of any research project, when results are published 
and you will not receive the results of any future research project. All future research projects will 
have been approved by a Research Ethics Committee. We hope that this will allow us to identify 
new areas of investigation and potentially allow future trauma care to be specifically tailored to the 
characteristics of each individual patient. 
 
Will any genetic tests be done? 
Your study data and samples will be used for more than one study, including studies aimed at 
identifying genetic differences in patients that makes them more or less susceptible to the effects of 
traumatic injury. We will store a sample of your DNA, obtained from the blood sample for future 
testing.  This is performed to see if there are genetic differences between patients that make them 
	   221	  
 
10.09.2010 Info Sheet E – PC.  V2 Page 6  
Date: _ _ / _ _ / _ _ Researcher Initials: ____ 
more or less susceptible to the effects of injury.  We will not be testing for genetic diseases or 
named inheritable conditions and therefore this test will be of no individual significance to yourself in 
terms of inherited risk, insurance issues or to your children.   
The DNA will be stored in a coded form in a special DNA bank, with the same data protection 
safeguards that apply to your other blood samples.  Any future studies outside the scope of this 
study that would use your DNA will have to be independently authorised by a research ethics 
committee.  If you wish not to have your DNA stored, please sign to this effect in the appropriate 
part of the consent form.    
 
What will happen to the results of the research study? 
We hope to publish the results in a scientific journal. It will not be possible to identify any individual 
who has taken part from this scientific report. Copies of the report will be available on request. 
 
Who has reviewed the study?  
All research in the NHS is looked at by independent group of people, called a Research Ethics 
Committee to protect your safety, rights, wellbeing and dignity. This study has been reviewed and 
given favourable opinion by East London & City Research Ethics Committee 1. 
 
Who can I contact for further information? 
1. If you require further information about the study, please contact the ACIT researchers by 
telephone: 020 3594 0731  or by email: Claire.rourke@bartshealth.nhs.uk or 
sirat.khan@qmul.ac.uk   
 
2. If you require impartial, local advice, please contact the Patient Advice and Liaison Service, 
telephone: 020 3594 2040  or e-mail: pals@bartshealth.nhs.uk  
 
Thank you for taking the time to read this information.  
 
Date: ___/___/_____         Researcher Signature: ______________ _____ 
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Consent Form A – Subject.  V3.2 1 10.09.2010 
   
Consent form   
DIRECTORATE OF SURGERY AND ANAESTHESIA 
ROYAL LONDON HOSPITAL, WHITECHAPEL, LONDON E1 1BB 
 
Consent Form A – Subject 
Version 2, 10.09.2010          
 
East London and the City Research Ethics Committee 1   REC number: 07/Q0603/29 
 
Title: Activation of Coagulation & Inflammation in Trauma   
Principal Investigator: Professor Karim Brohi, FRCS FRCA   Please initial box to 
   Indicate agreement 
 
1. I confirm that I have read and understood the information sheet dated 10.09.2013  [ ] 
(version 3.2) for the above study and have had the opportunity to ask questions.  
I have been given a copy of the patient’s information sheet to keep. 
 
2. I understand that my participation in this study is voluntary and that I am free to withdraw [ ] 
at any time, without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked at by professional [ ] 
individuals involved in this study or by regulatory authorities where it is relevant to my taking  
part in research. I give permission for these individuals to have access to my records. 
 
4. I understand that I have given my consent voluntarily to the international transfer, storage  [ ] 
and use of my study data and tissue for future medical research and that I am free to  
withdraw my consent at any time. 
 
5. I agree that the tissue may be used for future genetic research but not for research that [ ] 
involves reproductive cloning or testing for inherited diseases without my express consent.  
                                        
6. I agree to take part in the above study.       [ ] 
        
 
 
 
                   
Name of patient    Date    Signature 
 
I have explained this in terms which, in my judgement, are suited to the understanding of the patient. 
 
 
 
                                
Name of person taking consent  Date    Signature 
(if different from Investigator) 
 
 
 
                      
Investigator    Date                          Signature 
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Consultee declaration form   
DIRECTORATE OF SURGERY AND ANAESTHESIA 
ROYAL LONDON HOSPITAL, WHITECHAPEL, LONDON E1 1BB 
 
Consent Form B – Personal Consultee (PC) Declaration Form 
Version 2.0, 10.12.2010            
 
East London and the City Research Ethics Committee 1   REC number: 07/Q0603/29 
 
Title: Activation of Coagulation & Inflammation in Trauma   
Principal Investigator: Professor Karim Brohi, FRCS FRCA   Please initial box to 
   Indicate agreement 
 
1. I confirm that I have read and understood the information sheet dated 10.09.2013  [ ] 
(version 3.2) for the above study and have had the opportunity to ask questions.  
I have been given a copy of the patient’s information sheet to keep. 
 
2. In my opinion the patient would have no objection to taking part in the above study  [ ] 
 
3. I understand that I can request the patient’s withdrawal from the study at any time, without 
giving any reason and without the patient’s medical care or legal rights being affected.  [ ] 
 
4. I understand that relevant sections of the patient’s medical notes and data may be looked at 
by responsible individuals involved in this study or by regulatory authorities where it is relevant 
to their taking part in research.          [ ] 
 
5. In my opinion, the patient would have no objection to the international transfer, storage   
and use of their study data and tissue for future medical research.    [ ] 
 
6. I agree that the patient’s tissue may be used for future genetic research but not for research 
that involves reproductive cloning or testing for inherited diseases without express consent.  [ ] 
                                        
7. I agree to allow my relative/significant other to take part in the above study.   [ ] 
        
 
 
 
                   
Name of Consultee   Date    Signature 
 
I have explained this in terms which, in my judgement, are suited to the understanding of the Consultee. 
 
 
 
                                
Person undertaking consultation  Date    Signature 
(if different from Investigator) 
 
 
 
                      
Investigator    Date                          Signature 
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Appendix 5. Consent to donation and storage of blood samples 
 
 
 
 
1 copy for Patient, 1 for medical notes  
original to be kept in research file and sent with any sample to the HTRC when applicable 
 
Consent Form C – Tissue.  v1.3 1 20.09.2007 
           
 
CONSENT TO DONATION AND STORAGE OF RESIDUAL TISSUE FOR MEDICAL 
RESEARCH 
 
Study Title: Activation of Coagulation & Inflammation in Trauma II    
  
 
 
 
 
Research Ethics Committee Reference: 
Following the present research project any residual (left-over) tissue, may be collected, stored and used 
by the Barts and the London NHS Trust and / or Queen Mary’s School of Medicine and Dentistry, for 
medical research in the future.  Research conducted on these samples may contain personal 
information but all such information will be anonymised at the end of any project, when the results are 
published, and you will not receive the results of any future research project.  All staff undertaking 
future studies will abide by the Data Protection Act 1998 with any medical information relating to you 
being kept confidential.  The tissue may be given to external research organisations for approved 
medical research but tissue will not be sold, although costs will be recovered without any financial 
benefit to either you or to the researcher.  Any residual tissue will be disposed of lawfully when it is no 
longer required. 
                        Patient Initials 
      
 
I understand that I have given my consent voluntarily to the storage of tissue for future medical 
research and that I am free to withdraw my consent at any time 
 
I agree that the tissue may be used for future genetic research but not for research that  
involves reproductive cloning, or be tested for inherited diseases without my express consent 
 
If you have any preferences or exclusions for use of the donated tissue, or any other comments, please include 
them here: 
 
 
 
 
 
 
 
 
 
________________________ ________________                __________________ 
Name of Patient Date Signature 
 
_________________________ ________________                __________________ 
Name of Person taking consent Date Signature 
(Researcher) 
 
 
     
